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QUILL ON SCALPEL

Intramedullary Rod Fixation of Femoral
Shaft Fractures: Comment
J.P. Waddell, MD, FRCSC
Member, Editorial Board. Canadian Journal o f Si
Hospital, University o f Toronto, Toronto, Ont.

n this issue of the Journal (pages
286 to 290) McLaren and associ
ates have demonstrated through
analysis of a small group of patients
treated at their institution that
closed intramedullary nailing of dia
physeal fractures of the femur gives
results that are preferable to those
of similar fractures treated by the
open technique. Presumably both
groups of patients were managed by
the same surgeons, since, as the au
thors state, the better results were
achieved even while the operators
were learning the closed technique.

I
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mon to both types of nailing and
have suggested methods by which
these may be avoided.
I concur with their conclusion
that closed nailing offers a superior
outcome, but I would caution that a
well-done open nailing is infinitely
preferable to a poorly done closed
nailing. Therefore, surgeons who
set out to perform closed nailing
and find themselves in difficulty
should not hesitate to open the
extremity at the fracture site and
proceed with a properly done open
nailing. ■
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Q U ILL O N SCALPEL

Iatrogenic Injuries to Popliteal Vessels
J.E. Mullens, MD, MS, FACS, FRCSC
Assistant Secretary-Treasurer, The Canadian Medical Protective Association, Toronto, Ont.

n this issue of the Journal (pages
294 to 297), Rubens and col
leagues report their experience o f
two iatrogenic injuries to the popli
teal artery that occurred during
high tibial osteotomy.
During any operation in or near
the knee the popliteal vessels are at
risk. In the last 5 years the Canadi
an Medical Protective Association
(C M P A ) has opened five files on
iatrogenic injuries to these vessels;
two injuries occurred during osteot
omy o f the tibia and three during
arthroscopic surgery. Iatrogenic in
juries to vessels can occur during
elective or emergency operations in
any discipline of surgery and, al
though the CMPA hears o f some o f
them, it is likely that there are
others that are not reported. Every
surgeon is trained to operate safely
near vital structures, but even the
most skilled can injure a normal
structure accidentally while operat
ing competently and carefully. Such
misadventures are inherent risks o f
operations.
It is w ell established in Canadian
law that the risks o f each operation
must be discussed with the patient
as part o f informed consent. Injury
to the popliteal vessels, although
rare, may have devastating effects
on the patient. Hence, here, if the
patient has not been warned o f such
possibilities, the surgeon may be
found negligent should damage to
these structures occur. In obtaining

I
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the patient’s consent for operation,
the surgeon must be satisfied that
the risk is, or is not, one that would
be regarded by a reasonable patient
in similar circumstances as being
substantial. That means asking spe
cifically about professional and rec
reational activities. For example, a
professional dancer should be made
aware that an operation on the knee
presents special risks if the nerves
or vessels adjacent to the knee are
injured. Every conceivable risk need
not be discussed. In addition, each
surgeon must take personal experi
ence into consideration; the risk of
the procedure in the individual sur
geon’s hands may be higher or
lower than that generally reported
in the literature. It is important for
the surgeon to record that such a
discussion has taken place.
Surgeons are sometimes loathe
to admit, even to themselves, that
they have caused a complication,
and this often exacerbates an al
ready serious situation which can
be repaired easily if dealt with im
mediately. All surgeons must learn
early to acknowledge when a seri
ous complication has occurred and
be prepared to accept the most
likely explanation even if it is the
worst possible one. This requires
the honesty and humility to discuss
the problem with the patient and
return the patient to the operating
room with dispatch if necessary.
W hen in doubt, the surgeon should

not hesitate to seek the advice and
assistance o f an experienced col
league. Although it is by no means
easy, surgeons must bring to their
own professional work the objectivi
ty and decisiveness that they would
expect to find in the w ork o f others.
It is delay and denial that some
times make legal defence difficult.
What of the legal defensibility o f
iatrogenic injuries? Does iatrogenic
injury automatically signify negli
gence or carelessness? N ot neces
sarily. The answer in each case will
depend upon the opinion o f expert
consultants asked to consider the
question o f whether such an event
could occur in the hands of a
reasonably competent practitioner
o f like skill and experience. The
matters open to detailed review in
clude the training and expertise o f
the surgeon, the indications for and
choice o f operation, the manner of
its performance and the attentive
ness and quality o f the postopera
tive care.
When the surgeon is faced with
an iatrogenic complication, he
should be honest with the patient
and next o f kin, while not admitting
fault. The operative notes should be
clear and explicit, and the progress
notes should be timely and precise
because they will be important to
the defence if a law suit results. A
telephone call to the C M PA for ad
vice at this time also makes good
sense. ■

QUILL ON SCALPEL

Management of Inguinal Sarcomas
W.J. Temple, MD, FACS, FRCSC
Member. Editorial Board, Canadian Journal o f Surgery. Director o f Surgery, Tom Baker Cancer
Centre, Calgary, Alta.

(pages 309 to 312)
I nBellthisandissuecolleagues
present an
interesting and valuable report on
inguinal sarcomas as a distinct enti
ty. They highlight the important
issues, which are similar for most
histologic types of sarcoma in this
area — obtaining local control, pri
mary wound healing and the team
approach for the management of
sarcomas.
Curing a local sarcoma in the
inguinal region while maintaining a
functional extremity is often diffi
cult because the vascular and neu
ral supplies to the leg are located
within a few millimetres of the
tumour. The management principle
in these patients includes preopera
tive treatment to sterilize the tu
mour margins so that a marginal
resection is sufficient. In general,
the only consistent, useful tech
nique is preoperative radiotherapy
of 5000 to 6000 cGy. Alternatively,
our experience1 with preoperative
treatment indicates that a modified
Eilber regimen of intra-arterial ad
ministration of Adriamycin, 30

m g/d continuous perfusion for 3
days and 300 cGy/d of radiothera
py for 10 days is highly effective in
multiple sites, including the ingui
nal area. If the vessels and nerves
are still involved after preoperative
treatment, one must still resect
them and carry out arterial recon
struction. Similarly, if en bloc resec
tion requires sacrifice of the femoral
nerve, one may expect a reasonably
functioning leg, so that a young
patient may be able to walk without
a brace or other device. In our
experience1 at the Tom Baker Can
cer Centre in four patients who
had inguinal sarcoma, neoadjuvant
local treatment also resulted in
long-term control at 3 to 5 years’
follow-up.
The second challenge in manag
ing inguinal sarcomas is to provide
primary wound healing. This ana
tomical area is known for its poor
wound healing in surgery of similar
magnitude, even when there has
been no preoperative radiotherapy.
The consequence of wound break
down and infection when vascular

reconstruction is required is often
amputation. The use of nonirradiated tissue flaps, such as the
rectus myocutaneous or tensor fas
cia lata-myocutaneous flaps, pro
vides safe and dependable cover. A
wide defect can also be closed safely
and dependably with prosthetic
mesh covered by omentum and a
skin graft.
Finally, Bell and colleagues illus
trate that a key component in han
dling a sarcoma successfully is the
team approach. In their series an
experienced oncologic surgeon, a
medical oncologist, a radiation on
cologist, a vascular surgeon and a
plastic surgeon were all involved.
This not only minimizes major po
tential morbidity but maximizes the
chances of local and regional con
trol.
Reference
1. T emple WJ, Russell JA, A rthur K, et al:
Neoadjuvant treatment in conservative
surgery of peripheral sarcomas. Can J
Surg 1989; 32: 361-365
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HOW I DO IT

Intraoperative Angiography: a Simplified
Technique
Carlos Del Campo, MD, FRCSC
ntraoperative angiography is a
valuable technique when a preop
erative percutaneous approach is
not adequate or desirable and when
the technical aspects of the proce
dure are to be visualized.
Traditionally, intraoperative angi
ography has been performed by
needle stick into the artery or the
graft itself.12 Mavor, Walker and
Dhall3 have recommended the use
of a Portex nylon intravenous can
nula, and embolectomy catheters
with a second lumen have been
marketed for this purpose.
The technique I describe is inex
pensive, uses materials readily avail
able in all operating rooms and has
several advantages over other tech
niques.
Most peripheral vascular inter
ventions involve the lower extremi
ty. Emergency embolectomies must
often be done with insufficient angi
ographic information. Although the
technique described applies to the
lower extremity, it is also applicable
to the upper extremity and other
sites.

I

Technique
The femoral vessels are exposed
through a standard groin incision.
The patient is systemically hepari

nized, and the common femoral,
superficial femoral and deep femoral
arteries are clamped. A longitudinal
arteriotomy is made in the common
femoral artery extending into the
superficial femoral artery. Proximal
flow is checked by momentarily
releasing the proximal clamp. Prox
imal and distal clots are removed
with a balloon embolectomy cathe
ter of the appropriate size.
The arteriotomy is closed primar
ily or patched with a segment of an
adjacent superficial vein or fabric as
indicated. A continuous 5-0 mono
filament stitch is used. Both ends of
the suture are left untied. The plas
tic cannula of a no. 14 Jelco intra
venous catheter (Critikon Canada
Inc., Markham, Ont.) is cut from its
hub. Both suture ends are threaded
into the cannula using a straight
needle, and a rubber shod clamp is
used to tighten it as a tourniquet
(Fig. 1). A pediatric feeding tube of
the preferred size is selected. The
guide wire of the previously used
embolectomy catheter is utilized to
stent the pediatric feeding tube so it
can be manipulated proximally and
distally. This step provides enough
rigidity to allow easy retrograde
advancement of the feeding tube to
the aortic bifurcation. Blood is not
lost because the tourniquet is easily
snugged around the feeding tube.

From the Department o f Surgery, Halifax Infirmary H ospital Dalhousie University, Halifax. NS
Accepted for publication Aug. 29. 1989
Reprint requests to: Dr. C. Del Campo, Assistant Professor o f Surgery, Rm. 412, Gerard Hall,
5303 Morris St., Halifax, NS B 3 J1 B 6

The guide wire also allows easy
visualization of the catheter under
fluoroscopic control if desired. The
guide wire is removed, and angiog
raphy is carried out using a 60-ml
syringe containing the perferred
contrast medium.
A radiographic plate is placed
inside a sterile bag and centred
under the area to be visualized. The
contrast is injected as fast as possi
ble, the speed depending on the size
of the pediatric feeding tube used.
When the distal run-off is to be
visualized, a better-quality picture
can be obtained by directing the
feeding tube downstream and

FIG. I. Diagram showing final stage of
intraoperative angiogram. Note proxi
mal location of pediatric feeding tube
with guide wire in its lumen. Rubber
shod clamp prevents fracture of mono
filament suture.
CJS, VOL. 33, NO. 4, AUGUST 1990
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clamping the common femoral ar
tery or applying digital pressure at
the time of injection. This step
allows a higher concentration of
dye and prevents the washout ef
fect. The feeding tube is then re
moved and the two sutures are tied
together.

Discussion
Intraoperative angiography in
vascular surgery is or may be indi
cated in the following situations:
• When limb ischemia, due to
an embolus, has been present for
several hours and surgical interven
tion must not be delayed.
• In patients with poor run-off,
which is not clearly visualized preoperatively in spite of added digital
subtraction techniques, due to poor
flow.
• When postoperative flow is
poor after arterioplasty (i.e., intimal
flap, distal embolization) and endar
terectomy.
• When there is unexpected
poor inflow (i.e., proximal stenosis).
In cases of thrombosis of the
vascular repair in the immediate
postoperative period, angiography
is rarely indicated. Intraoperative
angiography saves time and pro
vides information that cannot be
obtained when the graft is occlud
ed.
All materials required are inex
pensive and readily available in the
operating room. A single-lumen embolectomy catheter sells for $32.97
versus $47.00 for the double-lumen
catheter. The no. 5 pediatric feed
ing tube costs only $1.01. Thus,
embolectomy and angiography per
formed by the above method will
save $13.02 per patient. If embolec
tomy is not needed, the cost can be
reduced to $1.01. In centres per
forming several hundred operations
a year the saving could be substan
tial. A portable x-ray machine usu
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ally suffices. Fluoroscopy with an
image intensifier may be desirable
in some cases but is not indispensa
ble.
The pediatric feeding tube has a
soft, rounded tip, so vessel damage
is unlikely; it provides better dye
flow than a double-lumen embolec
tomy catheter because of its larger
lumen and multiple side holes.
Stenting of the pediatric feeding
tube with the guide wire from the
embolectomy catheter provides
more rigidity for manipulation
against flow and is accomplished at
no extra cost.
The small size of the Jelco cathe
ter for tourniquet control makes all
subsequent steps easier.
Patch angioplasty is recommend
ed in most cases. In patients who
have a large artery, this procedure
can be done directly through the

suture line of a direct closure if
desired.
This technique of angiography
offers two important advantages:
the iliac vessels proximal to the
graft can be visualized and direct
puncture of the patch or graft,
which may lead to increased turbu
lence and stricture when closing the
needle hole, is avoided.
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SESAP VI Question
Item 130
Which of the following statements about carcinoid syndrome is TRUE?

(A) It is more frequently seen in association with tumors originat
ing in the hindgut than in the foregut
(B) It is rarely associated with diarrhea as a major complaint
(C) It is manifest by cutaneous flushing, which is directly related to
the effect of serotonin
(D) Symptoms may be reproduced by the pentagastrin provocative
test, especially in patients whose tumors originate in the
midgut
(E) Symptoms are rarely improved by less-than-total resection of
hepatic metastases
For the answer to and critique of Item 130 see page 270.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa
tion and Self-Assessment Program No. 6. For enrolment in the Surgical
Education and Self-Assessment No. 6, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Palliative Treatment of Advanced
Colorectal Carcinoma With the YAG Laser
A.G. Nagy, MD, FRCSC
The Nd-YAG laser was used to provide palliative treatment for eight patients (two
women and six men), ranging in age from 53 to 76 years, who had locally advanced
colorectal cancer. The main indications for treatment were obstruction, bleeding and
copious rectal mucus discharge. Only one complication, a Staphylococcus aureus
infection, followed the treatment; the infection was easily controlled. The laser
treatment was considered to ease the symptoms in five patients, but survival was not
influenced by the treatment. This form of palliation must be evaluated in larger
numbers of patients to assess its real value in advanced colorectal cancer.
Le laser Nd-YAG a ete utilise comme traitement palliatif d’un cancer colorectal
localement avance chez huit patients (deux femmes et six hommes) dont l’age variait
de 53 a 76 ans. Les indications principales du traitement furent l’obstruction, les
saignements ou un ecoulement muqueux abondant. On a enregistre une seule
complication au traitement, soit une infection a Staphylococcus aureus qui fut
facilement maitrisee. On a juge que le traitement au laser avait ameliore les
symptomes de cinq patients mais il n’eut aucune influence sur la survie. Cette forme
de traitement palliatif doit etre evaluee chez un plus grand nombre de malades afin
d'etablir son interet reel dans les cancers colorectaux avances.

urgical resection is the treat
ment of choice for both cure
and palliation of colorectal carcino
ma. However, resection is associat
ed with substantial morbidity and
mortality in cases of locally ad
vanced or metastatic disease. Proxi
mal diverting colostomy does not
always control symptoms such as
bleeding or excessive mucus dis
charge. Some patients are simply
too ill medically to undergo surgery
or refuse surgery. For them, treat
ment options include radiotherapy,
chemotherapy, electrocoagulation
or cryotherapy. If radiotherapy fails
to control local disease it cannot be
repeated, so other treatments must
be considered. Successful applica
tion of laser therapy in obstructing

S

carcinoma of the esophagus led to
attempts to apply the same therapy
for palliation in patients with ad
vanced colorectal cancer.
The application of Nd:YAG laser
treatment in eight patients who had
advanced colorectal carcinoma is
reported in this paper.

Patients and Methods
Patients

Eight patients (six men, two
women) with advanced or recurrent
rectal adenocarcinoma were referred
for palliative endoscopic laser
coagulation by the gastrointestinal
follow-up clinic of the Cancer Con
trol Agency of British Columbia.
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Seven patients had documented,
advanced, recurrent, local pelvic
disease or metastases. They had
received previous pelvic irradiation
and prolonged courses of chemo
therapy with 5-fluorouracil. The re
maining patient initially refused
conventional surgical treatment for
an obstructing carcinoma of the
rectosigmoid and received Nd:YAG
laser treatment as primary therapy.
The patients ranged in age from
53 to 76 years (mean 65 years).
Preoperative preparation included
saline enemas and irrigations.
The patients were subjected to a
maximum of three treatment ses
sions (total of 14 sessions for all
patients). Treatment was carried out
under general anesthesia (three ses
sions), spinal anesthesia (six) or
intravenous sedation (five). As expe
rience with the technique improved,
only intravenous sedation was used.
Equipment and Technique

The procedure was carried out
through a flexible colonoscope
(Olympus CF Type 20M; Carsen
Medical & Scientific Co. Ltd., Mark
ham, Ont.) with the patient in the
lithotomy position. A Medi-Las
2YAG model 621 laser source (Uni
tec Medical Lasers Inc., Oakville,
Ont.) was employed. Safety goggles
were worn throughout the proce
dure. The flexible laser fibre was
introduced through the biopsy
channel of the colonoscope. A coax
ial flow of carbon dioxide was used
to cool the laser tip. Following
passage of the delivering fibre the
tip was held approximately 1 cm
distal to the target tissue and the
laser beam was directed with the
CJS. VOL. 33. NO. 4. A U G U S T 1990
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red aiming beam. Laser coagulation
was directed at the most accessible
and protruding tumour or the most
obvious bleeding site on the surface
of the tumour. Each laser shot was
limited to 1 second duration and the
power ranged from 30 to 90 W.
Treatment was terminated when a
whitish grey coagulum covered the
tumour surface. As experience was
gained more total energy (joules)
was applied at each session.
Selection, Criteria and Treatment
Policy
Patients were selected for this
treatment approach when, in the
oncologists’ opinion, there was no
further adjuvant therapy to offer.
One patient steadfastly refused con
ventional primary surgical treat
ment but accepted laser treatment
to his obstructing rectosigmoid car
cinoma. Strangely, following im
provement of his symptoms he con
sented to conventional surgical re
section.
In all cases, patients were in
formed before the treatment that no
definite benefit could be guaranteed
from this experimental approach.
However, it was gratifying to note
that after symptomatic improve
ment some patients sought further
treatment when symptoms im
proved. Others refused further at
tempts at laser treatment and no
undue pressure was brought upon
them to continue with this form of
palliation.

Results
The details of treatment with the
YAG laser in these eight patients
are summarized in Table I. Treat
ment failed in two patients. In one
the rectal lumen could not be dis
tended, so the laser beam could not
be focused at the tumor. In the
second patient treatment had to be
abandoned when copious semiliq
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uid feces entered the rectal segment
following distension with carbon di
oxide and after only 500 J had been
applied. Feces interfere with visual
ization and the delivery fibre tip
cannot be adequately cleaned.
In one woman who had extensive
pelvic disease and pelvic discomfort,
only the invading intraluminal tu
mour mound was vaporized, leaving
a posterior rectal ulcer, and her
symptoms did not improve much.
Her surgeon elected to cauterize
the tumour invading her rectum
with electrocautery from time to
time.
In the remaining five patients the
goals of treatment were achieved,
thus the results of treatment were
considered satisfactory.
Severe bloody mucus discharge
was satisfactorily treated in two
patients for the remainder of their
lives. One of these patients required
three treatment sessions — two
several days apart and a third
session at 6 months after the first.
Six months later he died of the
disease but remained free of mas
sive mucopurulent discharge. The
other patient also had satisfactory
palliation though he refused further
treatment sessions offered to him to
try to debulk his rectal mass. In a
third patient, bloody diarrhea (more
than 10 movements daily) was suc
cessfully controlled with two treat
ments, 3 months apart.
In two other patients, initial ob
struction was relieved, allowing an
antegrade bowel preparation; one
refused conventional surgical treat
ment for his rectosigmoid carcino
ma, diagnosed 18 months earlier.
He had bloody diarrhea, every 30
minutes, with crampy abdominal
pain and abdominal distension when
he consented to laser treatment. His
symptoms were markedly improved
(four to six bowel movements daily)
and he elected to undergo rectosig
moid resection, in one stage, follow
ing adequate bowel preparation. He

remains well at 18 months. The last
patient had his obstruction relieved
by laser treatment and then under
went laparotomy aimed at resecting
the suture line recurrence of his
cancer. At laparotomy, however, he
was found to have extensive meta
static disease with peritoneal im
plants and he was treated by proxi
mal colostomy only. He died of his
disease 5 weeks after the initial
laser treatment. No complication of
laser treatment was noted at lapa
rotomy.

Complications
Only one complication was en
countered — a Staphylococcus au
reus septicemia which occurred im
mediately after laser treatment. This
episode of sepsis was quickly con
trolled with intravenously adminis
tered antibiotics. The patient under
went further laser treatment with
no undesirable side effects.

Discussion
In this preliminary report of laser
coagulation of advanced rectosig
moid adenocarcinoma eight patients
were so treated between January
1987 and July 1988. During this
same period numerous reports of a
similar treatment protocol have ap
peared in the literature.’"‘Although
Fleischer5 described laser treatment
of gastrointestinal neoplasms with
good results as early as 1984, prog
ress in the application of this mode
of therapy has been slow. Over the
last 4 or 5 years it has become
apparent that this modality of palli
ation for advanced colorectal malig
nancy is feasible and desirable in
selected patients.
Radiotherapy has been found ef
fective in local control of small
rectal tumours and in preventing
local recurrence after surgery for
rectal carcinoma.6 However, in
cases of advanced local disease,

YAG LASER AND COLORECTAL CANCER
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no.

A ge,
yr

S ex

Tum our
location,
cm

Extent of
d is e a se

.

1 Patient Data and Results of Treatment

M a in
sym p to m s

P re v io u s
tre a tm e n t

1 attempt

70

12

Advanced
pelvic
disease,
liver
metastases

Mucus,
bleeding

Anterior resection,
divided proximal
colostomy, pelvic
irradiation with
5-FU

65

10

Ascites,
widespread
metastases,
suture line
recurrence

Incomplete
obstruction

Rectosigmoid
resection. 5-FU

1

Pelvic
recurrence,
invading
rectum

Constipation,
pelvic
discomfort

1

Liver/lung
metastases,
pelvic
recurrence

Bloody
diarrhea
(10/d),
tenesmus

Transverse
colostomy,
resection of
rectosigmoid,
closure of
colostomy, pelvic
irradiation with
5-FU
Resection of
rectosigmoid,
pelvic irradiation
with 5-FU

Extensive
pelvic
disease

Mucus + + +
Blood + +
Pain +

Colostomy for
unresectable
cancer, pelvic
irradiation with
5-FU

2

Suture line
recurrence

Obstruction,
crampy
abdominal
pain and
distension

Sigmoid resection.
5-FU

2

Extensive
pelvic
disease

Mucopurulent Palliative Flartmann
resection, pelvic
discharge (8
irradiation with
diapers/d)
5-FU

3

Locally
advanced
disease

Bloody
diarrhea
(every
30-60 min)
(incomplete
obstruction)

75

59

12

5

53

M

5

6

53

M

16

7

76

M

8

66

M

15

None

T o ta l
la s e r
e n e rg y , J

N o. ot
la s e r
s e s sio n s

2

3

0

C o m m e n ts

Rectal stump
encased with
tumour, not
distensible.
Technical
failure
500 Inadequate
luminal
preparation.
Technical
failure.
Refused
further
treatment
1380 No measurable
relief of
symptoms,
but invading
tumour
vaporized,
leaving rectal
ulcer
2292 3 bowel
movements/d
after 1st
treatment.
Recurrent
symptoms
after 3 mo.
Improved on
further
treatment
3965 Mucus and
blood loss
improved but
pt refused
more
treatment
2860 Obstruction
relieved,
bowel prep,
reoperation.
Extensive
disease found.
Colostomy
only. No com
plication of
laser therapy
9600 Minimal
discharge post
treatment.
Septicemia
after 2nd
session
22 834 Obstruction
relieved (4-6
bowel
movements/d)
Finally
consented to
anterior
resection

P o s t-tr e a t
m ent
c o u rs e

Alive 21 mo

Died 7 mo

Alive 2 yr.
Further
conventional
cauterization
of rectal
tumour
Died 9 mo

Died 11 mo

Died 4 wk
post-op (5
wk after
laser
treatment)

Died 10 mo
after last
treatment.
Renal failure
Well 18 mo.
No evidence
of disease

5-FU = 5-fluorouracil.
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bleeding and mucus discharge often
persist despite completion of adju
vant radiotherapy. In these patients,
therapy with the YAG laser may
provide palliation for obstruction,
troublesome discharge of mucus
and bleeding.7
The Nd:YAG laser is ideally suit
ed for application in general sur
gery. At low powers (10 to 15 W)
and comparatively long exposure (2
seconds) it can shrink and coagu
late tissue, and at high powers (90
to 100 W) and shorter exposure
(0.5 to 1 second) it can vaporize
tissue. The YAG wavelength of
1064 nm is absorbed best by the
colour black.
When carbonization of the tissue
has taken place the beam of the
YAG laser will act as a cutting and
vaporizing instrument. With the
non-contact quartz fibres used in
the present series, there are disad
vantages. The quartz tip, for in
stance, may be damaged should it
come in contact with blood, feces or
tissue, and this was a problem. The
introduction of contact sapphire
probes may improve our ability to
vaporize endoscopically or cut tu
mours more efficiently, that is, at
lower energy levels and more pre
cise delivery to the offending tu
mour.8
There are no series at present to
compare the applications of YAG
laser therapy, radiotherapy and
electrocautery. Often, YAG laser
therapy is applied only after radiatotherapy has been tried and trou
blesome local symptoms persist.
Electrocautery is applicable only in
low lesions, whereas YAG laser en
ergy can be delivered at high loca
tions through the colonoscope. As
with electrocautery, YAG laser ther
apy is usually applied during several
treatment sessions and the total
amount of energy applied should be
dictated by the extent of local dis
ease being treated. The ameliora
tion of the patients’ symptoms will
264
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dictate how often laser coagulation
should be employed. At repeat en
doscopic evaluation, previously
treated areas appear as whitish,
fibrotic, avascular areas with areas
of necrotic coagulum visible, de
pending on the time elapsed since
previous treatment.
In this series there was only one
case in which a resected specimen
was available for pathological exam
ination. The pathologist reviewing
the slides commented: “ ...the sur
face tumour was basically in the
muscle, implying that the mucosa
and submucosa had been lost.
Whether this loss was due to tu
mour or to laser is unknowable.” It
is evident from clinical reports,
however, that the endoluminal ob
structing tumour mound seems per
manently destroyed and luminal
patency is maintained on long-term
follow-up.8 One can only speculate
that the necrosis of the mucosal
lesion and the subsequently noted
whitish fibrous avascular luminal
surface prevents endoluminal re
growth of the tumour. It is clear
that tumour continues to grow lat
erally, however, and progression of
the disease is not halted by laser
treatment in these advanced lesions.
Our patients experienced sub
stantial improvement after laser
therapy for troublesome bloody di
arrhea and discharge of mucus.
Survival was likely not influenced,
but palliation of these annoying
symptoms was gratifying. In addi
tion, obstruction was relieved by
recanalization of the lesion in two
patients. The implication of recanal
ization is that a one-stage proce
dure may become possible after the
recanalization and antegrade bowel
preparation. It is not clear how
many laser treatments or laser
“shots” should be applied in indi
vidual patients. These answers will
only become clearer following ex
tensive applications of laser cauteri
zation in larger numbers of pa

tients. Palliative laser coagulation
of advanced colorectal cancer is
here to stay and should be em
ployed in larger centres associated
with regional cancer agencies. Fur
ther developments in this form of
therapy may occur with the advent
of sapphire-tipped laser probes,
which will allow application of the
laser energy through direct contact
with the tumour. Any gastrointesti
nal surgeon trained in endoscopy
and familiar with the use of the
laser can use this modality. Laser
training courses are widely available
in the United States and should
soon become more accessible in
Canada.
I thank the oncologists at the Cancer
Control Agency of British Columbia
who referred their patients for this
modality of treatment. I also gratefully
acknowledge the assistance of Dr. R.
Miller, who kindly reviewed and com
mented on the pathological material of
one of the patients in this series.
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Preoperative Radiotherapy for
Adenocarcinoma of the Rectum
E.M. Webber, MD; J.K. MacFarlane, MD, FRCSC, FACS
Curative surgery remains the principal treatment for rectal carcinoma.
Unfortunately failure following surgery, particularly through local recurrence, is an
all too common event. Among the potential adjuvant therapies, preoperative
radiotherapy holds clear promise. A review of the clinical trials evaluating this
treatment modality shows that it can decrease the rate of local recurrence and may
even improve the overall 5-year survival. Preoperative radiotherapy is consistently
well tolerated up to doses as high as 60 Gy; it does not complicate the surgical
resection or increase the perioperative morbidity and mortality. Preoperative
radiotherapy warrants further investigation to select those patients who are most
likely to benefit from it.

La chirurgie a visees curatives demeure le principal traitement du cancer du rectum.
Malheureusement, les echecs de chirurgie, particulierement dus a des recidives
locales, sont frequents. Parmi les therapies adjuvantes possibles, la radiotherapie
preoperatoire est nettement prometteuse. Une revue des essais cliniques qui ont
evalue cette modalite therapeutique, montre qu’elle peut reduire le taux des
recidives locales et ameliorer la survie a 5 ans. La radiotherapie preoperatoire est
regulierement bien supportee jusqu’a concurrence d’une dose de 60 Gy; elle ne
complique pas la resection chirurgicale et elle n’augmente pas la morbidity et la
mortality peroperatoires. La radiotherapie preoperatoire vaut d’etre davantage
etudiee afin de choisir les patients les plus susceptibles d’en beneficier.

he results of surgical treatment
of rectal carcinoma have
changed little over the past 25
years despite efforts to increase
early detection of the disease. The
overall 5-year survival is 30% and is
50% for those who undergo cura
tive resection.12 Between 25% and
50% of failures after surgery are
attributed to local recurrence,

T

which occurs in up to 65% of
patients with Dukes’ stage C dis
ease.3
When performing surgery for
rectal carcinoma the surgeon en
counters problems not seen in sur
gery of other colonic carcinomas.
The rectum is confined within a
small bony cavity, adjacent to im
portant genitourinary structures; it
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possesses no peritoneal covering or
mesentery. These factors prevent
the establishment of wide excision
margins and increase the risk of
tumour spillage at surgery. Because
of the survival and recurrence sta
tistics, other therapeutic modalities,
including combinations of radio
therapy and chemotherapy, are
being investigated. The role of adju
vant radiotherapy in improving the
outcome of the disease has attract
ed considerable interest.

History
The preoperative use of radio
therapy dates back 75 years, with
more intensive work being done
during the past 30 years. In 1914
Symonds4 described the case of a
73-year-old man who was found to
have an annular rectal carcinoma
3.75 cm above the anus. Radium
bromide (100 mg) was applied to
the tumour for 6 hours on each of
5 consecutive days. One week after
completion of this treatment no
tumour was visible or palpable. Be
cause of local stricturing 3 months
later a diverting colostomy was cre
ated. Two months after that the
tumour site was excised and the
bowel ends were reanastomosed by
a transperineal route. The postoper
ative course was uncomplicated; the
colostomy was closed 1 month lat
er.
During the 1930s radiation treat
ment alone was attempted using
high voltage x-rays or interstitial
CJS, VOL. 33, NO. 4, A U G U S T 1990
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radium; results were not favoura
ble.5 The first major report of pre
operative radiotherapy was that by
Stearns, Deddish and Quan6 at the
Memorial Center for Cancer in New
York who presented a retrospective
analysis of 1786 patients with carci
noma of the rectum and rectosig
moid colon seen between 1939 and
1951. Of these, 1276 underwent
surgical exploration; the tumour
was resected in 971. Of the 1276
patients, 727 had received preoper
ative radiotherapy (an average of
less than 20 Gy). The group receiv
ing preoperative radiotherapy had a
higher resectability rate than the
control group (86% versus 69%).
The only groups showing a differ
ence in survival were those who had
Dukes’ stage C tumours: the 5-year
survival rate was 37% in the irradi
ated group compared with 23% in
the controls. Local recurrence was
not analysed. Despite the inherent
limitations of this type of study it
spurred further investigations.

Clinical Trials
The group at Memorial Hospital
then embarked on a prospective
randomized control trial comparing
surgery alone to radiotherapy (20
Gy over 2 weeks) followed by sur
gery7 (Table I). This trial ran from
1960 to 1967 and involved 347
patients. A further 443 patients
treated (nonrandomly) between
1957 and 1959 were included in the
study. Of the total number, 376
patients received radiotherapy fol
lowed by surgery and 414 under
went surgery alone (controls). The
5-year survival was 65% in the
radiation group compared with 67%
in the control group. There was no
difference in the rate of local recur
rence when local lymph nodes were
tumour-free at the time of surgery.
When tumour had spread to region
al lymph nodes, however, there was
266
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a reduced incidence of local recur
rence in the irradiated group. At the
same time the Veterans Administra
tion Surgical Adjuvant Group (VASAG)8 initiated a prospective ran
domized trial in 700 patients with
biopsy-proven rectal carcinoma,
comparing surgery alone to radio
therapy (20 to 25 Gy over 2 weeks)
followed by surgery (Table I); 353
had surgery alone and 347 had
radiotherapy followed by surgery.
The incidence of Dukes’ stage C
disease was lower in the irradiated
group (24%) than in the control
group (38%). Preoperative radio
therapy was found to be beneficial
only in patients who had ab
dominoperineal resection; the
5-year survival in those who had
received preoperative irradiation
was 40.8% compared with 28.4% in
the controls, and the local recur
rence rate was 29% and 40% respec
tively. No difference between the
two groups was found in patients
who underwent other surgical pro
cedures (Hartmann procedure, sub
total colectomy, anterior resection).
In these patients the 5-year survival
was 38.5% in the irradiated group

versus 39.8% in the controls, and
the local recurrence rates were 29%
and 26% respectively. A second pro
spective randomized control trial by
the Veterans group9 compared sur
gery alone to 31.5 Gy of radiothera
py followed by surgery (Table I). A
total of 361 patients were entered
into the study; 180 received surgery
alone and 181 had radiotherapy
followed by surgery. Abdominoperi
neal resection was performed in
94% of cases. The 5-year survival
was 50% in both groups; there was
no comment about the respective
rates of local recurrence.
Kligerman and associates10 de
scribed the Yale University experi
ence. There, 31 patients were ran
domized to receive preoperative ra
diotherapy (45 Gy) followed by sur
gery or to receive surgery alone.
The number of patients in the study
was too small to make statistical
comparisons of 5-year survival. Ra
diotherapy did not increase the
morbidity. Dukes’ stage C disease
was less common in the irradiated
group (23%) than in the control
group (69%).
Between 1960 and 1972 at the

Table 1. Results of Preoperative Radiation for Carcinoma of the Rectum
Patients
Trial
Retrospective
Memorial, 19747
Virginia, 198615
Springfield, 198814
Prospective
VASAG I, 19758
Toronto, 197712
MRC, 198413
E0RTC I, 198416
VASAG II, 1986®
E0RTC II, 1988’8

Local
recurrence

5-year
survival

Dose, Gy

No RT

RT

No RT

RT

No RT

RT

20
40-60
40-50

414
106
109

376
60
40

23
40
51

13*
16
19

65
48
57

671
52
85

20-25

353

347

36
40

13$
29§

5

65

55

5
20
34.5
34.5 + 5-FU
31.5
34.5

275

277
272
121
126
181
166

32
28
35
17
38

40$
41 §
35$
35*
42
40
15
15
50
69

RT = radiotherapy, 5-FU = intravenous 5-fluorouracil.
‘ Patients with Dukes’ stage C disease.
fOverall survival.
$AII patients included.
§Patients having abdominoperineal resection.
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University of Oregon patients with
carcinoma of the rectosigmoid were
treated preoperatively with highdose (50 to 60 Gy) radiotherapy.11
Before initiating the radiotherapy
57 patients were deemed to have
resectable tumours (i.e., the tumour
was mobile). Forty of these patients
underwent potentially curative re
section and 38 (72%) were tumourfree at 5 years. Eight of the 57 died
with a pelvic tumour; of these 1 had
refused surgery, 1 had liver metastases at the time of surgery, 3 had
unresectable tumours and 3 had
tumour in the resection margin at
surgery. Of the 40 patients who
had curative resections, none suf
fered a pelvic recurrence. Most pa
tients suffered from transient diar
rhea; 16 had complications and 1 of
them died. This complication rate
compared favourably with that seen
in a historical control group not
receiving radiotherapy.
Rider and colleagues,12 in Toron
to, described their experience with
preoperative low-dose radiotherapy
(5 Gy in a single dose just before
surgery) (Table I): 125 patients
were randomized to either this
treatment or surgery alone. The
overall 5-year survival was about
40%, with no significant difference
between treatment groups. In pa
tients who had Dukes’ stage C
rectal carcinoma, however, the
5-year survival was over 35% in the
irradiated group but less than 20%
in the group who had surgery
alone. No complications were attri
buted to the radiotherapy; no analy
sis of local recurrence was reported.
A multicentre study in Britain13
compared three groups: one group
(275 patients) had surgery alone, a
second group (277 patients) re
ceived a single dose of 5 Gy fol
lowed by surgery and a third group
(272 patients) received 20 Gy in 10
fractions followed by surgery (Table
I). In all, 824 patients with rectal
carcinoma were randomly assigned

to one of these treatment groups.
There was no difference in 5-year
survival (about 50%) or in the
5-year local disease-free rate (about
55%) among the three groups.
There was no increase in technical
difficulties or postoperative compli
cations associated with either radio
therapy group.
In Springfield, Massachusetts
Reed and collaborators14 reviewed
149 patients with rectal carcinoma
(Table I). Forty patients had re
ceived between 40 and 50 Gy of
radiotherapy preoperatively, fol
lowed by surgery, and 109 patients
underwent surgical resection alone
(controls). The 5-year survival was
better in the irradiated group than
in the controls (85% versus 57%),
as was local recurrence (19% versus
51%). One irradiated patient and
four control patients had an anasto
motic leak. Thirteen irradiated pa
tients had bowel fibrosis attributed
to the treatment; 1 required steroid
enemas to control rectal bleeding
and another required a diverting
colostomy. There was no increased
risk of a second primary tumour
(colonic or extracolonic) postoperatively during the follow-up period
(15% versus 10% in the control
group).
Fortier and associates15 described
the experience at the University of
Virginia between 1972 and 1983
with high-dose preoperative radio
therapy for patients having rectal
carcinoma (Table I). Sixty patients
received between 40 and 60 Gy
before surgery. Fifty-six of these
showed no metastases at the time of
surgery and underwent resection.
They were followed up for a mean
of 43 months. When they were
compared with 106 patients who
had undergone resection alone, no
significant difference in the 5-year
survival was noted (52% versus
48%). Of the group receiving radio
therapy 16% had local recurrence
compared with 40% in the controls.

No difference was observed in the
rates of major complications requir
ing hospitalization (5% in each).
Between 1972 and 1976 the Eu
ropean Organization on Research
and Treatment of Cancer (EORTC)
conducted a prospective random
ized trial of treatment of rectal
carcinoma, comparing 34.5 Gy of
radiotherapy followed by surgery to
34.5 Gy of radiotherapy plus 10
m g/kg of intravenous 5-fluorouracil (5-FU) followed by surgery
(5-FU sensitizes cancer cells to
the lethal effects of radiation)1617
(Table I). There were 247 patients
in the trial, and they were fol
lowed up for a mean of 5.2 years.
Lymph-node involvement was seen
in 29% of patients receiving radio
therapy and surgery compared with
38% in patients receiving radiother
apy, 5-FU and surgery; the differ
ence was of marginal statistical sig
nificance. Local recurrence was
found in 15% of both groups at 5
years, but liver metastases were less
frequent in the group receiving
5-FU.
In 1976 the EORTC initiated a
second prospective randomized tri
al, this time comparing surgery
alone to 34.5 Gy of irradiation
followed by surgery for treatment of
rectal carcinoma18 (Table I). Of the
466 patients entered into the trial,
341 underwent curative resection.
Of these, 175 underwent surgery
alone and 166 received radiotherapy
before surgery. In those who had
curative surgery, the 5-year survival
was 69% in the radiotherapy group
compared with 59% in the control
group (p = 0.08). Local recurrence
at 5 years was 15% in the radiother
apy group compared with 30% in
the control group (p = 0.003).
When all patients (including those
not having curative surgery) were
considered, local recurrence at 5
years was still significantly less fre
quent in the group receiving preop
erative radiotherapy.
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Discussion
There are two distinct uses of
preoperative radiotherapy. One is to
shrink large tumours, making re
section easier or even possible in
tumours previously deemed unresectable. Pilepech and col
leagues19 described 44 patients con
sidered to have unresectable rectal
carcinomas. After irradiation with
40 to 50 Gy, 27 patients underwent
complete resection. Twenty-two of
these patients remained disease-free
for a median of 27 months postoperatively (up to 48 months). Kligerman20 reviewed 15 patients with
unresectable rectal carcinomas.
After receiving between 35 and 58
Gy, nine patients underwent suc
cessful resection, and three re
mained disease-free after 21 to 85
months. Stevens, Allen and Fletch
er11 described 40 patients consid
ered to have unresectable rectal
tumours (i.e., the tumour was fixed)
before receiving radiotherapy. Fol
lowing irradiation 22 tumours were
considered resectable and 20 resec
tions were performed. Three of
these patients were alive and tu
mour-free at 3.5, 7 and 7 years; two
others died without evidence of can
cer. Of patients who did not under
go resection, one was alive and
tumour-free at 7 years and two
others died without evidence of tu
mour. In the whole group of 40
patients, 30 died with tumour; 25
of them had pelvic disease at the
time of death. Complications from
tumour and irradiation were consid
erable in these patients.
The second use of preoperative
irradiation is to facilitate complete
elimination of the tumour at the
primary site. In this regard the
actions of surgery and radiotherapy
are complementary. Although sur
gery effectively removes the bulk of
tumour, microdeposits of cancer are
often left behind; radiation can elim
inate these.21 In this respect preop
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erative radiotherapy offers no ad
vantage over postoperative radio
therapy. However, preoperative ra
diotherapy does possess some in
herent advantages. First, it avoids
the risk of irradiating small bowel,
which may become lodged in the
pelvis after surgery.22 Romsdahl
and Withers23 described 62 patients
who received 50 Gy 3 to 8 weeks
after surgery. Seven patients had
adverse symptoms attributed to the
radiation. One patient died of com
plications, two patients suffered
chronic radiation enteritis and eight
further surgical procedures were
required by these patients because
of adhesions, fistulas, strictures and
intestinal necrosis. However, in the
experience of Hoskins and associ
ates24 from the Massachusetts Gen
eral Hospital where 97 patients re
ceived 50 Gy of radiotherapy after
surgical resection of carcinoma of
the rectum and rectosigmoid, there
was no increase in the complication
rate (4%) when compared to a
group that had surgery only. Sec
ond, preoperative radiotherapy de
creases the number and viability of
cancer cells spilled into the local
tissues or circulation at the time of
surgery.25 Finally, tumour radiosen
sitivity is dependent on tissue oxy
genation, which is likely to be di
minished postoperatively.2126
There are several arguments
against the routine preoperative use
of radiotherapy. Some people have
thought that adenocarcinoma of the
rectum is insensitive to radiation;
however, the studies described
above and the personal experience
of one of the authors (JKM) refute
this notion. Others believe that
postoperative radiotherapy offers
several advantages over preopera
tive radiotherapy. First, it avoids
the delay of 1 month or more before
surgery that preoperative radiother
apy imposes. But although preoper
ative radiotherapy delays surgery it
does not delay the initiation of

treatment. Second, by waiting until
after surgery to decide whether ra
diotherapy should be offered, the
stage and the grade of the tumour
are accurately known (preoperative
staging by computed tomography
and endorectal ultrasonography is
an imperfect process).27 Since sur
gery alone is curative in more than
30% of cases it would be helpful to
be able to select patients with no
risk of local recurrence so that they
could be spared the deleterious ef
fects of radiation.
Unfortunately, this is not possi
ble. In the second EORTC study,18
three of the six patients with
Dukes’ stage A disease treated by
surgery alone suffered local recur
rence. In a series at the Massachu
setts General Hospital 8% of pa
tients with Dukes’ stage A tumours
had local recurrence.28 Several fac
tors are known to correlate with an
increased risk of local recurrence;
these include tumour stage, tumour
grade, the number of involved
lymph nodes and the presence of
blood vessel invasion. In an il
luminating study, Moosa29 at the
University of Chicago gathered data
on 152 patients who had previously
undergone abdominoperineal resec
tion for carcinoma of the rectum
and whose 5-year postoperative
courses were known. All of the
information available about each pa
tient at the end of the postoperative
period (barium enema, operative re
sult and pathology report) was col
lected. This information was pre
sented to a panel of six independent
observers (two surgeons, two pa
thologists, one gastroenterologist
and one radiotherapist) who were
asked to predict which patients
would have local recurrence. In this
series local recurrence was found in
31 patients (20%). The six panelists
predicted local recurrence correctly
in 34% to 68% of cases. Nobody
predicted recurrence correctly at a
rate better than by chance alone.

r

a

‘ 3

-4

*

RADIOTHERAPY FOR RECTAL ADENOCARCINOMA

Hence, even after surgery it is ex
tremely difficult to predict which
patients will or will not suffer local
recurrence.
Third, there is concern about
anastomosing bowel which has
been subjected to radiation, particu
larly in high doses. Schrock, Deveney and Dunphy30 reviewed all
1703 colonic anastomoses per
formed at the University of San
Francisco between 1951 and 1970.
They found anastomotic leakage in
4.5% of cases overall but in 14% of
patients who had previously re
ceived abdominal radiation. Howev
er, it is not clear that the irradiated
patients were comparable to the
group as a whole. Stevens’ group at
the University of Oregon31 com
pared 79 patients who underwent
anterior resection and primary
bowel anastomosis to 13 patients
who had anterior resection and pri
mary anastomosis after receiving 50
Gy of irradiation. Four patients had
protective colostomies; no complica
tions were seen in them. Of the nine
without colostomiy, two had smallbowel obstruction secondary to ad
hesions, two had anastomotic ab
scesses and one had a wound dehis
cence. Stevens, Fletcher and Allen31
concluded that the primary anasto
mosis was safe following irradia
tion, provided that the proximal
bowel was outside the radiation
field; they recommended colostomy
in all cases.
Friedmann and his group32 re
viewed the outcome of 133 patients
who had anterior resections for rec
tal carcinoma. Forty patients had
received 45 Gy preoperatively (65%
had protective colostomy) and the
other 93 patients had no preopera
tive radiotherapy (42% had protec
tive colostomy). The overall compli
cation rate was 25% in those having
radiotherapy and 27% in the control
group. Anastomotic leak rates were
10% in the radiotherapy group and
7% in the controls. The anastomotic

leak rate was much higher in pa
tients with colostomy (14%) than in
those without (1%). This difference
was attributed to an inherent differ
ence in the two groups; a colostomy
was more likely to be used when
the anastomosis was less than ideal.
Finally, in Daytona Beach, Florida,
Robertson and associates33 reviewed
40 patients with rectal carcinoma
who had received 45 Gy over a
5-week period followed by anterior
resection of the rectosigmoid colon
1 to 3 weeks later. One patient had
severe diarrhea pre- and postoperatively, which responded to antidiarrheal medication. There were no se
vere complications or anastomotic
leaks in this group.

Conclusions
There is no ideal systemic adju
vant treatment for rectal carcinoma
currently available to greatly im
prove the prognosis over that pro
vided by surgery alone. The studies
to date of preoperative radiotherapy
have failed to show conclusively an
improvement in survival, let alone
the optimal dose required to achieve
it. Despite the lack of proof that
survival is increased, it is clear that
preoperative radiotherapy may de
crease the rate of local recurrence,
probably in a dose-related fashion.
If this were its only benefit preoper
ative radiotherapy could be consid
ered a success, as local recurrence
is a devastating complication, pro
gressing to a miserable death.
As for the optimal dosage, high,
tumoricidal dose irradiation (50 Gy
or more) seems the most appealing.
Concern about the possible deleteri
ous effects of such treatment have
not been borne out. The greatest
decrease in local recurrence and the
greatest potential for complete cure
reside with this form of therapy.
Chemotherapy and postoperative
radiotherapy will likely play a role

in the treatment of those patients
for whom preoperative radiotherapy
and surgery are less than satisfacto
ry.
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SESAP VI Critique
Item 130

The carcinoid syndrome is seen only in patients with hepatic metastases and is clinically manifested by cutaneous
flushing, hyperperistalsis and diarrhea, asthma, and hemodynamic alterations that may result in vasomotor
collapse. The syndrome was initially believed to be due to excessive amounts of circulating serotonin.
Subsequent observations testify to the inadequacy of this simple hypothesis, and the biochemical aspects of the
malignant syndrome are much more complex.
Etiology of the flushing in these patients remains unknown. Infusion of somatostatin abolished the flushing,
which suggests that is humorally mediated.
The tumor originates from the embryologic midgut in patients with the classic carcinoid syndrome. Patients
with metastatic disease generally have elevated levels of serotonin and substance P in the peripheral blood.
Several agents have been used to provoke the carcinoid symptoms, including alcohol and catecholamines,
calcium, and most recently pentagastrin. In a recent series of 17 patients with known midgut carcinoids, 16 of
whom had hepatic metastases, pentagastrin caused flushing in all. It induced gastrointestinal symptoms in all
but one and universally elevated circulating serotonin levels. The pentagastrin test with measurements of
setononin levels in the peripheral blood seems to be superior to infusion of calcium as a provocative test to
document the diagnosis of carcinoid syndrome. Partial resection of hepatic metastases may ameliorate some of
the symptoms of carcinoid syndrome.
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Preoperative Chest X-ray Films in
Elective Surgery: a Valid Screening Tool
M. Gagner, MD, CSPQ;* A. Chiasson, MD, CSPQ
The authors reviewed retrospectively 1000 patients who had a preoperative chest
x-ray film made and who underwent elective surgery. Results showed that 5.8% of
women and 10.5% of men (7.4% of all patients) had an abnormal preoperative chest
x-ray film. These abnormalities were much more frequent (30%) in patients over 50
years of age than in younger patients (3%). Of the 74 patients whose films revealed
abnormalities, 68 (92%) had a history or symptoms of cardiorespiratory disease. Of
the six patients with x-ray film abnormalities but without symptoms or a pertinent
history, none had a change in clinical outcome because of radiography. Guidelines
are recommended for selectively ordering preoperative chest x-rays in surgical
patients.

Les auteurs ont etudie retrospectivement 1000 patients avec radiographie pulmonaire preoperatoire ayant eu une chirurgie elective. Les resultats demontrent que 5.8%
des femmes et 10.5% des hommes (7.4% du total) ont une radiographie pulmonaire
preoperatoire anormale. Ces anormalitees sont plus frequentes (30%) chez les
patients ages de plus de 50 ans, compare a les patients moins de 50 ans (3%). Sur
les 74 cas d’anormalitees, 68 (92%) ont une histoire positive ou ont des symptomes
ou histoire cardiorespiratoires. Les six cas d’anormalitees sans symptomes ou
histoire pertinente, n’ont influence le resultat clinique. Des recommendations sont
proposees pour l’ordonnance de radiographie pulmonaire preoperatoire chez les
patients ayant a subir une chirurgie elective.

history, physical examination
and work-up form the basis for
excellent preoperative care. Chest
radiography is often ordered rou
tinely and accounts for more than
50% of all diagnostic radiologic
procedures. That surely represents
a major health care expenditure,
and for the patients significant ex

A

posure to ionizing radiation.1 There
is controversy over the use of this
investigative procedure, and wheth
er it should be considered a valid
screening tool or should be reserved
for selected patients who stand to
benefit most from it.2 This retro
spective study was undertaken to
evaluate the role and the impor
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tance of preoperative chest x-ray
films in elective surgery, in the
setting of a small community hospi
tal.

Patients and Methods
We retrospectively studied pa
tients who had been admitted to our
hospital for elective surgery, minor
and major, during a 45-month peri
od (Sept. 1, 1981 to May 31, 1985).
Patients were included when a pre
operative chest x-ray film had been
made within the 3 months preced
ing the operation. The charts of
1000 such patients were reviewed,
and the sex, age, pertinent history,
physical findings and radiologists’
reports were recorded.

Findings
There were 657 females and 343
males. The proportion of chest
x-ray films showing an abnormality
is presented by age group in Fig. 1.
Overall, 7.4% of the patients —
5.8% of females and 10.5% of males
— had an abnormal chest x-ray
film. There was a progressive in
crease in the rate of abnormalities
above the age of 29 years. The
lowest was 1%, in the 20 to 29-year
age group, and the highest was
56%, in patients more than 70 years
old. Children had a slightly higher
proportion of abnormalities (3% for
CJS, VOL. S3, NO. 4, A U G U S T 1990
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those 0 to 9 years old and 2% for
those 10 to 19 years old) than
young adults (1%).
A marked elevation in the fre
quency of abnormalities was noted
in patients over 50 years of age
(Table I); 30% had a abnormal chest
x-ray film, compared with 3% in
patients under this age. In women,
23% over the age of 50 years had
abnormalities compared with 2.7%
for those younger than 50 years.
The difference was even more pro
nounced among men above and
below the age of 50 years, 41%
versus 3.6% (Table I).
The clinical records of the 74
patients who had an abnormal chest
x-ray film revealed that 68 (92%) of
them had had an associated illness,
pertinent medical history or symp
toms that explained the radiologic
findings (Table II). The majority of

patients with an associated illness
had had either pulmonary or pleural
fibrosis, or chronic obstructive pul
monary disease. Others had had a
cardiovascular disease, a recent or
prior respiratory infection, asthma,
sarcoidosis, recent chest trauma or
previous cardiothoracic surgery.
Cough, hemoptysis and dyspnea
were the relevant symptoms.
Of the six patients with an abnor
mal chest x-ray film, but no perti
nent clinical history or signs, two
had apical pulmonary calcifications,
one had early lobar pneumonia as
sociated with early peritonitis, one
had granulomatous lesions of the
left hilum, one had a small focus of
atelectasis and one had cardiomegaly associated with signs of chronic
obstructive pulmonary disease.
None of these radiologic findings
had clinical implications, except in

the patient with an early lobar
pneumonia, who also needed an
appendectomy, and who was treated
with antibiotics for both conditions
concomitantly.

Comments
For decades a basic preoperative
work-up has been routine because
surgeons heed that most important
surgical aphorism: “avoid sur
prises”. Consequently unnecessary
examinations have been performed
on a large number of patients. In
recognition of this, guidelines have
been issued for the selection of
patients. Theoretically, preoperative
chest x-ray films can serve as a
screening tool or as a baseline for
comparison if a postoperative x-ray
film becomes necessary.
Ten years ago, one multicentre
study (10 619 patients) in the Unit
ed Kingdom showed that no ratio
nal guidelines were in use for pre
operative chest radiography.3 It also
showed that preoperative x-ray
films did not influence the decision
to operate or the management of
anesthesia, and that they did not
provide baseline values. Following
that study, norms were established
for ordering preoperative x-ray
Table II. Associated Illnesses or Symptoms
in 74 Patients With an Abnormality on the
Preoperative Chest X-ray Film

F IG . 1. F req u en cy o f ab n o rm al c h e s t x-ray film s by age g ro u p .

Table 1. Incidence of Abnormalities on Chest X-ray Films in Patients Younger or Older than 50
Years
No. abnormal/total (%)
Female

Male

< 50
> 50

15/557 (2.7)
23/100 (23.0)

10/280 (3.6)
26/63 (41.2)

25/837
49/163

Totals

38/657 (5.8)

36/343 (10.5)

74/1000 (7.4)

Age, yr
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All
(3.0)
(30.1)

Associated Illness/Symptoms

No.

Pulmonary or pleural fibrosis
Chronic obstructive pulmonary
disease
Cardiovascular disease
Recent respiratory infection (or
prior pneumonia)
Asthma
Sarcoidosis
Recent chest trauma
Previous cardiothoracic surgery
Other (hereditary metabolic disease)
Cough
Hemoptysis
Dyspnea
No important associated illness or
symptoms

25
22
5
3
3
2
2
1
1
2
1
1
6

PREOPERATIVE X-RAYS IN ELECTIVE SURGERY

films. Radiologists subsequently
noted a decline in the number of
such films requested.4 The use of
the Royal College of Radiologists’
(England) guidelines (Table III) has
since been studied in four English
hospitals.4 Seventy-five percent of
the patients so examined had indi
cations for chest radiography, and
it was concluded that these guide
lines were suitable for wider imple
mentation in the National Health
Service. These recommendations
are similar to those of the World
Health Organization scientific
group on the indications and limita
tions of major x-ray diagnostic in
vestigations.1
According to Mendelson and col
leagues,5 the properative chest ra
diograph could still be valuable as a
baseline examination. Their data
showed that in 65 of 369 consecu
tive general surgical patients, sur
geons had postoperative chest x-ray
films made. They stated that a
preoperative baseline radiograph
was essential in making an accurate
interpretation in 33 (51%). But if
one reviews the data carefully, it
can be seen that 27 of these 33
patients had radiographic changes
compatible with postoperative ate
lectasis, and in most cases this
followed cholecystectomy or bowel
surgery. The presence of abnormali
ties on chest x-ray films after ab
dominal surgery is well known, and
these changes are often minor and
Table III. Guidelines for Preoperative Chest
Radiography Among Patients Admitted for
Elective Noncardiopulmonary Surgery,
Recommended by the Royal College of
Radiologists (England)
1. Those with acute respiratory symptoms
2. Those with possible metastases
3. Those with suspected or established
cardiorespiratory disease who have not
undergone chest radiography in the
previous 12 mo
4. Recent immigrants from countries
where tuberculosis is still endemic, who
have not had chest radiography within
the previous 12 mo

without signs or symptoms.6 Still,
some technical aspects of preopera
tive baseline chest x-ray films may
be important. Harris7 suggested
that if these films are indicated,
they should be made with the pa
tient supine or sitting in bed, to
make comparison with a postopera
tive chest x-ray more accurate.
In another study,8 the records of
318 eligible patients out of 341
admitted to a vascular service ward
were studied to examine the value
of preoperative chest x-ray films
with regard to postoperative chest
complications. Of those whose
chest films had shown a major
abnormality, 40% had a postopera
tive complication compared with 9%
in those whose preoperative film
had been normal. In only 3% of all
the patients did the findings lead to
changes in management, and no
operation was cancelled for that
reason. The authors concluded that
the making of routine preoperative
chest x-ray films did not improve
the outcome and that they should
be ordered only in selected cases.
Similarly, if a routine chest x-ray
film was made during an emergency
admission, no improvement of care
resulted.9
A protocol for selectively order
ing preoperative chest x-ray films
was assessed by Charpak and col
leagues.10 The indications for pre
operative chest x-ray films after full
clinical history and physical exami
nation were: any lung disease,
major surgical emergencies (e.g.,
peritonitis, multiple trauma), a cur
rent history of smoking in patients
older than 50 years, immunosup
pression (including that caused by
malnutrition, steroid therapy or
chemotherapy) and lack of a prior
health examination in immigrants.
Preoperative chest x-ray examina
tions were done in 1101 of 3866
available patients (28%). In 52% of
these, chest x-ray films were abnor
mal. In only 5% of the 1101 pa

tients did chest x-ray lead to modifi
cation of management or treatment.
No deaths or pulmonary complica
tions could be linked to the lack of
preoperative chest x-ray films.
In a prospective study on the
value of preoperative investigations,
McKee and Scott11 showed that
16% of 400 preoperative radiographic investigations revealed an
abnormality, but only 0.013%
changed the management of the
patient. They recommended that
chest x-ray films be made in pa
tients over the age of 60 years.
There is certainly a rational basis
for ordering chest x-ray films after
a certain age, because abnormalities
are more frequent. However, this is
mainly because the frequency of
cardiopulmonary disease is higher
and because the effect of tobacco
use becomes tangible. In our study,
men over the age of 70 years had
two-and-a-half times as many abnor
malities as women in the same age
group, presumably because the pro
longed use of tobacco is much more
common in men.
With regard to chest x-ray exami
nations in children, Sane and asso
ciates12 reported that in 3.8% the
results changed the management of
the anesthesia or the operative
treatment. But Wood and Hoekelman,13 in a more recent study also
done in children, found clinically
significant changes in only 1.2%;
0.4% of operations were cancelled.
This last study is more in accor
dance with our findings, where 2%
to 3% of children’s chest x-ray films
had an abnormality and no opera
tions were cancelled.
In an effort to resolve the issue
of whether strict guidelines should
be implemented, or, instead, a wide
screening be practised, some au
thors have proposed a controlled
prospective and randomized trial
with clinical outcome as the end
point.1415 One could question the
feasibility of such a study on the
CJS, VOL. 33. NO. 4. AUG V S T 1990
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grounds that it would require a
large group of patients if death was
the end point, and that it could be
unethical.
Our study, in a small community
hospital, demonstrated that abnor
malities are present on preoperative
chest x-ray films in only 7.4% of
patients and that such abnormali
ties are 10 times more frequent in
patients over the age of 50 years
than under. If preoperative chest
x-ray films had been made only in
cases in which there were clinical
symptoms or a pertinent cardiore
spiratory history, 92% of these ab
normalities would have been no
ticed. Of the 8% that would have
been missed (0.6% of all patients),
none of these patients would have
suffered from a clinical prejudice or
would have had their operation can
celled.
We believe it is reasonable to
order a preoperative chest x-ray
film when there is a cardiorespirato
ry disease or when the surgeon
suspects such a disease after a
thorough clinical history and physi
cal examination. Preoperative chest
x-ray films should not be routine in
all patients in any age group. We
highly recommend application of
the guidelines of Charpak and asso
ciates,10 the Royal College of Radi
ologists of England3 or the World
Health Organization.1
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Treatment with broad-spectrum antibiotics may alter normal flora of the colon
and may permit overgrowth of Clostridia. Studies indicate a toxin produced
by Clostridium difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone.

A highly effective cost efficient
choice for parenteral
cephalosporin therapy
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
Cefotetan Disodium is a semisynthetic, beta-lactamase resistant (refer to
STABILITY TO BETA-LACTAMASES), cephalosporin (cephamycin) antibiotic.
In vitro studies indicate that the bactericidal action of cefotetan results from
an interference of bacterial cell wall synthesis by inhibiting the cross-linking
of peptidoglycan. Studies with 14C-labelled cefotetan have shown that on
reaching the target penicillin-binding proteins (PBPs) in the inner membrane,
the radiolabelled antibiotic binds principally to PBP 3 followed by PBP 1A
and 1B. Cefotetan, like other cephamycins, does not bind to PBP 2.
The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either
intravenous or intramuscular administration. In normal patients, from 51 % to
81 % of the administered dose is excreted unchanged by the kidney in 24
hours. The biliary tract is the other major route of elimination.
INDICATIONS AND CLINICAL USE
CEFOTAN (Cefotetan Disodium) is indicated for the treatment of the following
infections when caused by susceptible strains of the designated organisms:
Urinary tract infections caused by E. coli and Klebsiella species (including
K. pneumoniae), Proteus mirabilis and indole-positive Proteus.
Lower respiratory tract infections caused by Streptococcus pneumoniae
(formerly D. pneumoniae), Staphylococcus aureus (penicillinase and non
penicillinase-producing), Haemophilus influenzae (including ampicillinresistant strains), Klebsiella species (including K. pneumoniae) and E. coli.
Skin and skin structure infections caused by Staphylococcus aureus (penicil
linase and non-penicillinase-producing), Staphylococcus epidermidis, Strep
tococcus pyogenes, Streptococcus species (excluding Enterococci) and
E. coli.
Gynecologic infections caused by Staphylococcus aureus (penicillinase and
non-penicillinase-producing), Staphylococcus epidermidis, Streptococcus
species (excluding Enterococci), E. coli, Proteus mirabilis, Neisseria gonorrhoeae, anaerobic gram-positive cocci and gram-negative bacilli, Bacteroides
species (excluding B. distasonis, B. ovatus and B. thetaiotaomicron).
Intra-abdominal infections caused byE. coli, anaerobic gram-negative bacilli,
Bacteroides species (excluding B. distasonis, B. ovatus and B. thetaiotao
micron).
Bone and joint infections caused by Staphylococcus aureus.
Specimens for bacteriological examination should be obtained prior to therapy
in order to isolate and identify causative organisms and to determine their
susceptibilities to CEFOTAN. Therapy may be instituted before results of
susceptibility studies are known. However, once these results become avail
able, the antibiotic treatment should be adjusted accordingly.
CONTRAINDICATION
CEFOTAN (Cefotetan Disodium) is contraindicated in patients with Type 1
hypersensitivity reactions (ie, hives, angioedema, bronchospasm or ana
phylactic shock) to the cephalosporin group of antibiotics.
WARNINGS
BEFORE THERAPY WITH CEFOTAN (Cefotetan Disodium) IS INSTITUTED,
CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE
PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO
CEFOTETAN DISODIUM, CEPHALOSPORINS, PENICILLINS OR OTHER
DRUGS. CEFOTAN SHOULD BE GIVEN CAUTIOUSLY TO PENICILLINSENSITIVE PATIENTS. ANTIBIOTICS, INCLUDING CEFOTAN, SHOULD BE
ADMINISTERED WITH CAUTION TO ANY PATIENT W HO HAS DEMON
STRATED SOME FORM OF ALLERGY, PARTICULARLYTO DRUGS. IF AN
ALLERGIC REACTION TO CEFOTAN OCCURS, ADMINISTRATION OF
CEFOTAN SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSEN
SITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER
EMERGENCY MEASURES.
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE
OF CEPHALOSPORINS, INCLUDING CEFOTAN, (AND OTHER BROADSPECTRUM ANTIBIOTICS); THEREFORE, IT IS IMPORTANTTO CONSIDER
THIS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION
WITH ANTIBIOTIC USE.

Moderate to severe cases should be managed with fluid, electrolyte and
protein supplementation as indicated. When the colitis is not relieved by drug
discontinuance or when it is severe, consideration should be given to the
administration of oral vancomycin for antibiotic-associated pseudomembranous
colitis produced by C. difficile. Other causes should also be considered.
PRECAUTIONS
General: Prolonged use of CEFOTAN (Cefotetan Disodium) may result in
overgrowth of non-susceptible organisms and organisms initially sensitive to
the drug. Careful observation of the patients is essential. If superinfection
does occur during therapy, appropriate measures should be taken.
CEFOTAN may be associated with a fall in prothrombin activity. Those at risk
include patients with renal or hepatic impairment, poor nutritional state, the
elderly, and patients with cancer. Prothrombin times should be monitored in
patients at risk and exogenous Vitamin K administered as indicated.
CEFOTAN should be used with caution in individuals with a history of gastro
intestinal disease, particularly colitis.
A disulfiram-like reaction characterized by flushing, sweating, headache and
tachycardia may occur when alcohol (beer, wine, etc.) is ingested within 72
hours after CEFOTAN administration. Patients should be cautioned about the
ingestion of alcoholic beverages following the administration of CEFOTAN.
Patients with impaired renal function; ie, creatinine clearance of 30 ml/min or
less, should be placed on a special dosage schedule for CEFOTAN recom
mended under DOSAGE AND ADMINISTRATION.
Drug Interactions
Renal function should be carefully monitored, especially if high dosages of
the aminoglycosides are to be administered or if therapy is prolonged, because
of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
Although, to date, this has not been noted when CEFOTAN was given alone,
increased nephrotoxicity has been reported following concomitant adminis
tration of cephalosporins and aminoglycoside antibiotics. However, at the
recommended doses, enhancement of nephrotoxicity is unlikely to be a
problem with CEFOTAN.
Drug/Laboratory Test Interactions
A false positive reaction for glucose in urine may occur with Benedict’s or
Fehling’s solution.
High concentrations of cefotetan may interfere with measurement of serum
and urine creatinine levels by Jaffe reaction and produce false increases in
the levels of creatinine reported.
Use in Pregnancy
The safety of CEFOTAN in the treatment of infection during pregnancy has
not been established. The use of CEFOTAN in pregnant women requires that
the likely benefit from the drug be weighed against the possible risks to the
mother and fetus. Reproduction studies have been performed in rats and
monkeys at doses up to 20 times the human dose and have revealed no
evidence of impaired fertility or harm to the fetus due to cefotetan. There are,
however, no adequate and well-controlled studies in pregnant women. Because
animal reproductive studies are not always predictive of human response,
CEFOTAN should be used during pregnancy only if clearly needed.
Use in Nursing Mothers
Cefotetan is excreted in human milk in very low concentrations. Caution
should be exercised when CEFOTAN is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in children have not been established.
ADVERSE REACTIONS
In clinical studies, the following adverse effects were considered related to
CEFOTAN (Cefotetan Disodium) therapy.
Gastrointestinal: Gastrointestinal symptoms occurred in 1.5% of patients,
the most frequent were diarrhea (1 in 80) and nausea (1 in 700).
Hematologic: Hematologic laboratory abnormalities occurred in 1.4% of
patients and included eosinophilia (1 in 200), positive direct Coombs' test
(1 in 250) and thrombocytosis (1 in 300). Transient thrombocytopenia and
leucopenia have been reported.
Hepatic: Hepatic enzyme elevations occurred in 1.2% of patients and in
cluded a rise in SGPT (1 in 150), SGOT (1 in 300), alkaline phosphatase
(1 in 700) and LDH (1 in 700).
Hypersensitivity: Hypersensitivity reactions were reported in 1.2% of
patients and included rash (1 in 150) and itching (1 in 700). During post
marketing experience with CEFOTAN, anaphylactic reactions have been
reported.

Local Effects: Local effects were reported in less than 1% of patients
and included phlebitis at the site of injection (1 in 300) and discomfort
(1 in 500).
SYMPTOMS AND TREATMENT OF OVERDOSAGE
To date, there have been no documented cases of overdosage with
CEFOTAN (Cefotetan Disodium). If overdosage should occur, it should be
treated symptomatically. CEFOTAN may be removed by dialysis.
DOSAGE AND ADMINISTRATION
DOSAGE: Adults: The usual adult dosage is 1 or 2 g of CEFOTAN (Cefotetan
Disodium) administered intravenously or intramuscularly every 12 hours for
5 to 10days. Proper dosage and route of administration should be determined
by the condition of the patient, severity of the infection and susceptibility of the
causative organism. Therapy may be started while awaiting the results of
susceptibility testing.
The intravenous route is preferable for patients with bacteremia, bacterial
septicemia, or other severe or life-threatening infections, or for patients who
may be at risk particularly if shock is present or impending.
GENERAL GUIDELINES FOR CEFOTAN DOSAGE
Type of Infection
Daily Dose
Frequency and Route
Urinary T ract

1-4 g

Other Sites

2-4 g

Severe
Life Threatening

4g
6 g tt

500 mg every 12 hours IV or IM
1 or 2 g every 24 hours IV or IM
1 or 2 g every 12 hours IV or IM
1 or 2 g every 12 hours IV or IM
2 g every 12 hours IV

PHARMACEUTICAL INFORMATION
Chemistry
Trade Name:
CEFOTAN +
Proper Name:
Sterile Cefotetan Disodium U.S.P.
Chemical Name:
CEFOTAN is the disodium salt of [6R-(6(*, 7«)]-7-[[[4(2-amino-1 -carboxy-2-oxoethylidene)-1,3-dithietan-2yljcarbonyl] am ino]-7-methoxy-3-[[(1 -methyl-1 Htetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo
[4.2.0]oct-2-ene-2-carboxylic acid.

Molecular Formula:
Molecular Weight:

Description
A white to pale yellow powder which is very soluble in water. The solution
varies from colorless to yellow depending on the concentration and contains
approximately 80 mg (3.5 mEq) of sodium per gram of cefotetan activity. The
pH of freshly reconstituted solutions is usually between 4.5 to 6.5.
RECONSTITUTION
For Intramuscular Use
Reconstitute with Sterile Water for Injection; Normal Saline, USP; 0.5%
Lidocaine HCL; or 1.0% Lidocaine HCL. Shake to dissolve and let stand until
clear.

3 g every 12 hours IV

t t Maximum daily dosage should not exceed 6 g.
IMPAIRED RENAL FUNCTION
When renal function is impaired, a reduced dosage schedule must be employed.
The following dosage guidelines may be used.
DOSAGE GUIDELINES FOR PATIENTS WITH IMPAIRED RENAL
FUNCTION
Creatinine Clearance
ml/min
Dose
Frequency
> 30
10-30
<10

Usual Recommended Dose**
Usual Recommended Dose**
Usual Recommended Dose**

Vial Size

Alternatively, the dosing interval may remain constant at 12-hour intervals,
but the dose reduced to one-half the usual recommended dose for patients
with a creatinine clearance of 10 - 30 ml/min and one-quarter the usual recom
mended dose for patients with a creatinine clearance of less than 10 ml/min.
When only serum creatinine levels are available, creatinine clearance (ml/min)
may be calculated from the following formulae. The serum creatinine level
should represent a steady state of renal function.
Creatinine Clearance (ml/min):

Males:

Traditional Units
Weight (kg) x (140 - age)

S.l. Units
Weight (kg) x (140 - age)
0.8 x serum creatinine
(A mol/L)

Females:

72 x serum creatinine
(mg/100 ml)
0.9 x male value

Cefotetan is dialyzable and it is recommended that for patients undergoing
intermittant hemodialysis, one-quarter of the usual recommended dose be
given every 24 hours on days between dialysis and one-half the usual recom
mended dosage on the day of dialysis.
Children
The safety and effectiveness in children has not been established.
ADMINISTRATION
Intravenous
For intermittent intravenous administration, a solution containing 1 g or 2 g of
CEFOTAN in Sterile Water for Injection can be injected over a period of three
to five minutes. Using an infusion system, it may also be given over a longer
period of time through the tubing system by which the patient may be
receiving other IV solutions.
Butterfly or scalp vein-type needles are preferred for this type of infusion.
However, during infusion of the solution containing CEFOTAN, it is advisable to
discontinue temporarily the administration of other solutions at the same site.
NOTE: Solutions of CEFOTAN must not be admixed with solutions containing
aminoglycosides. If CEFOTAN and aminoglycosides are to be administered
to the same patient, they must be administered separately and not as a mixed
injection.
Intramuscular
CEFOTAN should be injected well within the body of a relatively large muscle
such as the upper outer quadrant of the buttock (ie, gluteus maximus); aspiration
is necessary to avoid inadvertent injection into a blood vessel.

Amount of
Diluent To
Be Added
(ml)

Approximate
Withdrawable
Vol (ml)

Approximate
Average
Concentration
(mg/ml)

1 g

2

2.5

400

2 g

3

4 .0

500

For Intravenous Use
Reconstitute with Sterile Water for Injection, 0.9% Sodium Chloride Injection
or 5% Dextrose Injection. Shake to dissolve and let stand until clear.

Every 12 hours
Every 24 hours
Every 48 hours

** Dose determined by the type and severity of infection, and susceptibility of
the causative organism.

C17Hi5N7Na208S4
619.56

Vial Size

Amount of
Diluent To
Be Added
(ml)

Approximate
Withdrawable
Vol (ml)

Approximate
Average
Concentration
(mg/ml)

1 g

10

10.5

95

2 g

10 - 20

11 - 21

182 - 95

A solution prepared with Sterile Water for Injection may be further diluted to
the desired volume with any of the “ Solutions for I.V. Infusion” listed below.
Solutions for I.V. Infusion
0.9% Sodium Chloride for Injection
5% Dextrose Injection
10% Dextrose Injection
Ringers Injection
Lactated Ringers Injection
5% Dextrose and 0.9% Sodium Chloride Injection
5% Dextrose and 0.225% Sodium Chloride Injection
5% Dextrose and Ringers Injection
5% Dextrose and Lactated Ringers Injection
10% Invert Sugar Injection
5% Sodium Bicarbonate Injection
Sodium Lactate Injection, 1/6 Molar
Isolyte-S Injection
Compatibility and Stability
CEFOTAN reconstituted as described above (Reconstitution) maintains
satisfactory potency for 24 hours at room temperature (25°C), or 72 hours
under refrigeration (5°C).
Any unused portions of the reconstituted solutions should be discarded.
CEFOTAN should not be physically mixed with other antimicrobial agents.
NOTE: Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration, whenever solution and
container permit.
DOSAGE FORM
Availability
CEFOTAN (Cefotetan Disodium) is a dry, white to pale yellow powder supplied
in vials containing cefotetan disodium equivalent to 1 g and 2 g cefotetan
activity for intravenous and intramuscular administration. The 1 g dose
(No. 961) is available in 10 ml vials, and the 2 g dose (No. 962) is available in
20 ml vials. The vials should not be stored in excess of 25°C and should be
protected from light.
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Simultaneous Liver and Whole Pancreas
Harvesting in the Multiorgan Cadaveric
Donor
Jacques Corman, MD, FRCSC; Pierre Daloze, MD, FRCSC; Christian Smeesters, MD, FRCSC;
Maroun Aboujaoude, MD; Stephan Busque, MD; Gilles St-Louis, MD, FRCPC;
Hugues Beauregard, MD, FRCPC

Simultaneous harvesting of the liver and whole pancreas is usually not performed
because it is believed that the shared vascular supply of both organs is incompatible
with safe grafting. A careful review of the vascular anatomy, however, shows that
simultaneous removal of the two organs is feasible, and a technique is described by
which the liver is revascularized in the recipient through the celiac axis or the
common hepatic artery and the pancreas is revascularized through the superior
mesenteric and splenic arteries. When the vascular supply is abnormal,
reconstruction of the vascular tree of one or both organs may be needed. The results
of this technique used on 10 recipients are analysed.
Le prelevement simultane, pour fin de greffe, du foie et du pancreas entier n’est
habituellement pas pratique parce qu’on croit que le partage du lit vasculaire des
deux organes est incompatible avec la securite de la greffe. Une etude approfondie
de l’anatomie vasculaire montre toutefois que le prelevement des deux organes est
possible et on decrit une technique permettant la revascularisation du foie chez le
receveur a partir du tronc coeliaque ou de l’artere hepatique commune, et la
revascularisation du pancreas, a partir des arteres mesenterique superieure et
splenique. Quand l’apport vasculaire est anormal, il peut etre necessaire de
reconstruire l’arbre vasculaire d’un, ou meme des deux organes. On analyse les
resultats obtenus a l’aide de cette technique chez 10 receveurs.

he need for organ transplanta
tion far exceeds the availability
of cadaveric donor organs. There
fore, optimal use of a donor’s or
gans is mandatory, and multiorgan
harvesting has become common in
most transplant centres.
Simultaneous removal of the liver
and the whole pancreas is seldom
performed because the partially

T

shared vascular supply of the two
organs is considered incompatible
with safe grafting in the recipi
ents.1'2 Thus, in those conditions
one of the organs is wasted for
transplantation.
Careful review of the vascular
anatomy of the liver and pancreas
suggested to us that, in most in
stances, both organs can be simul
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taneously harvested and successful
ly transplanted.3

Vascular Anatomy
The most common (approximate
ly 60% of cases4'6) disposition of the
liver and the duodenopancreatic ar
teries is described in Fig. 1. The
three main arterial supplies of the
pancreas (gastroduodenal, superior
mesenteric and splenic arteries)
communicate with one another by
anastomosis within the gland, ei
ther by pancreaticoduodenal ar
cades or by branches of the splenic
or the inferior pancreatic arteries.7'8
Thus, a whole duodenopancreas
can be safely revascularized
through the superior mesenteric
and the splenic arteries in the recip
ient.
However, considerable anatomic
variation may be encountered, espe
cially at the level of the liver where
the main hepatic artery may arise
directly from the aorta instead of
the celiac axis or the left and right
hepatic arteries may originate from
a variety of sites (Fig. 2).
The vascular anatomy of the pan
creas is more constant, and most of
the variations are found within the
gland, downstream of the three
main vessels, except for the posteri
or branch of the superior pan
creaticoduodenal artery, which origCJS, VOL. 33, NO. 4, AUGUST 1990
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inates from the hepatic artery in
2.7% of the cases, the anterior and
posterior branches of the inferior
pancreaticoduodenal artery, which
arises from the first jejunal artery
in 7.4%, and the dorsal pancreatic
artery, which finds its origin on the
celiac axis or the common hepatic
artery in 33% of cases.7'8 Whatever
the origin of these vessels, they
usually communicate within the
pancreas. With respect to the ve
nous circulation, the portal vein
usually supplies the liver through a
common trunk, and its pancreatic
branches are located in the gland
(Fig. 3).
Thus, harvesting of the whole
pancreas and the first, second and
third parts of the duodenum with
intrapancreatic segments of the su

perior mesenteric, inferior mesen
teric, splenic and portal veins
should not jeopardize venous re
turn.

Harvesting Technique
Of the different approaches used
for multiorgan harvesting, the most
common technique, described by
Starzl and colleagues1 consists of a
step-by-step dissection and skele
tonization of the organs to be re
moved in the heart-beating donor
with in situ flush cooling at or near
the end of the dissection. A recent
variation is that of rapid cooling in
situ and en bloc removal of all the
splanchnic organs followed by fur
ther bloodless ex vivo dissection.9

We use Starzl’s method for the
hemodynamically stable donor. In
the unstable donor we use an inter
mediate method: rapid, flush cool
ing in situ removal of the heart or
lungs, or both, and progressive in
vivo dissection of the abdominal
organs in a bloodless field under
cold perfusion.

FIG. 2. Variation of hepatic arterial
supply. Common hepatic (CHA) or
right hepatic artery (RHA) arises from
superior mesenteric artery (SMA), and
left hepatic artery (LHA) originates
from left gastric artery (LGA). PV =
portal vein, GDA = gastroduodenal
artery, SA = splenic artery, DPA =
dorsal pancreatic artery.

FIG. 1. Normal arterial supply of liver and pancreas. RHA = right hepatic artery,
LHA = left hepatic artery, CA = cystic artery, PHA = proper hepatic artery, PV =
portal vein, RGA = right gastric artery, CBD = common bile duct, CHA = common
hepatic artery, LGA = left gastric artery, DPA = dorsal pancreatic artery, SA =
splenic artery, GDA = gastroduodenal artery, PSPDA = posterior superior
pancreaticoduodenal artery, ASPDA = anterior superior pancreatiocoduodenal
artery, PDA = pancreaticoduodenal arcades, PIPDA = posterior inferior pan
creaticoduodenal artery, AIPDA = anterior inferior pancreaticoduodenal artery,
GPA = great pancreatic artery, IPA = inferior pancreatic artery, FJA = first jejunal
artery, SMA = superior mesenteric artery, SMV = superior mesenteric vein, IMV =
inferior mesenteric vein.
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FIG. 3. Venous anatomy of pancreas.
PV = portal vein, LG = left gastric
vein, SPD = superior pancreaticoduo
denal vein, SV = splenic vein, IPD =
inferior pancreaticoduodenal vein, SM
= superior mesenteric vein, IM =
inferior mesenteric vein, LGE = left
gastroepiploic vein.

LIVER AND PANCREAS HARVESTING

A generous midline incision is
made from the suprasternal notch
to the pubis, with sternotomy and
transverse extensions laterally to
both sides of the abdomen. The
pericardium is opened, and heart
function is assessed. The Toldt fas
cia is opened, and the left colon is
retracted medially. The aortoiliac
carrefour is dissected free, and the
inferior abdominal aorta is cannulated with a no. 16 French cathe
ter through the left common iliac
artery. A no. 24 French cannula is
inserted into the inferior vena cava
to permit venous decompression
and drainage when hypothermic
flush perfusion has started. The
infradiaphragmatic aorta is ap
proached through the diaphragmat
ic crura and encircled with an um
bilical tape. The superior mesenteric
vein is isolated and prepared for
further precooling of the liver.
Those first maneuvers take only a
few minutes and allow rapid cold
perfusion of the abdominal organs
and quick harvesting of the heart
when the donor is unstable.
In normal situations or after
rapid cooling the aorta is progres
sively skeletonized from the aor
toiliac carrefour up to the celiac
axis with section-ligatures of the
inferior mesenteric and lumber ar
teries. The left renal and adrenal
veins are isolated, as are the renal
and superior mesenteric arteries and
the celiac axis. The left adrenal vein
is transected between ligatures, and
the renal arteries are located in
order to protect them from the
clamp that will be placed later on
the aorta, just below the superior
mesenteric artery.
After a Kocher maneuver has
been performed the hepatic pedicle
is carefully examined for anomalous
arterial vascularization. The various
elements are dissected as far as
possible from the hilum. The com
mon duct is ligated at the level of
its entrance in the head of the

pancreas and transected. The gall
bladder is opened and washed free
of bile. The common hepatic artery
is dissected toward the celiac axis,
with isolation of the gastroduode
nal, splenic and left gastric arteries.
A search is made for a left hepatic
artery originating from the left
gastric artery; if not present, the
left gastric artery is ligated and
transected at the level of the celiac
axis.
The portal vein is then isolated
down to the confluence of its two
tributaries, the superior mesenteric
and splenic veins. Small accessory
pancreatic and left gastric veins are
transected between ligatures. The
gastrocolic ligament is divided, and
the first portion of the duodenum
isolated. The right gastric artery
and the short gastric vessels are
ligated and divided, and the spleen
is mobilized upward and medially
together with the tail and body of
the pancreas. Superior and inferior
edges of the gland are progressively
freed of areolar tissues. The inferior
mesenteric vein is severed between
ligatures. The dissection is extend
ed to include the aortic origin of the
celiac axis and superior mesenteric
artery.
The uncinate process is then
freed from the retroperitoneal struc
tures. The first portion of the duo
denum is divided as close as possi
ble from the pylorus. The fourth
portion of the duodenum is mobi
lized and staple closed. The superi
or mesenteric artery is transected
distal to the first jejunal branch,
and the superior mesenteric vein is
cannulated. Liver pediculization is
completed later, after the organs
have been satisfactorily cooled, by
dividing the ligaments and isolating
the supra- and infrahepatic vena
cavae.
When the abdominal dissection
has been completed, 70 U /kg of
heparin is given intravenously and
dissection of the heart is begun.

During this time precooling of the
liver is performed through the supe
rior mesenteric vein with cold (4°C)
Ringer’s lactate solution. As soon
as the cardioplegia solution is start
ed and effective circulation has
ceased, the infradiaphragmatic
aorta is cross-clamped, and the a
cold intracellular preservation flush
is started through the cannulated
left iliac artery. Ringer’s lactate
portal perfusion is replaced by the
preservation fluid.
The venous effluent is drained
initially through the cannulated in
ferior vena cava; when the heart has
been removed, the effluent is aspi
rated from the transected inferior
vena cava in the pericardial cavity.
When the abdominal organs are
uniformly perfused and satisfactori
ly cooled, they are detached one by
one from their aortic and venous
connections. Both kidneys are har
vested with a patch of aorta and
vena cava. The gastroduodenal ar
tery is transected between ligatures,
as close as possible to its origin.
The arterial supply of the liver
along with a patch of aorta is
detached from the aorta at the level
of the celiac axis. The splenic artery
is also divided close to its origin,
and the distal stump is left open
(Fig. 4). The portal vein is transect
ed at the level of the superior edge
of the pancreas (Fig. 4), and the
suprahepatic and infrahepatic vena
cavae are transected. The retrohepatic vena cava is freed, the
right adrenal vein is ligated and
divided, and the liver is removed.
The duodenopancreas is har
vested with an aortic patch at the
level of the superior mesenteric ar
tery, and the spleen is detached
from the gland after the splenic
vessels are ligated. Figure 5 shows
both organs detached from their
normal vascular supply. Harvesting
is terminated with removal of lymph
nodes, for immunologic studies, and
both common iliac arteries and their
CJS, VOL. 33, NO. 4, AUGUST 1990
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external and internal branches, for
further arterial reconstruction if
needed.
If a right or common hepatic
artery arises from the superior mes
enteric artery, the surgeon must
determine whether the liver and the
whole pancreas can be harvested
simultaneously. This decision de
pends on the calibre of the aberrant
vessel. When its diameter is 4 mm
or more, both organs can be har
vested and the liver will be revas
cularized in the recipient through
an arterial reconstruction performed
later. If the diameter is satisfactory,
the aberrant artery is cut at the
level of the superior edge of the
head of the pancreas, and the distal
part is ligated while the left arterial
supply is provided by the celiac
axis. If the arterial diameter is too
small for safe reconstruction, the
liver is removed with an aortic
patch, including both the celiac and
superior mesenteric arteries. The
head of the pancreas and the duode
num are sacrificed, and a segmental
pancreas is harvested on the splenic
arterial and venous vessels.

graft instead of the more fragile
segmental graft. Careful review of
the vascular anatomy of the liver
and pancreas suggested to us that
in most instances both organs can
be simultaneously harvested and
successfully transplanted.3
During harvesting it is important
to be familiar with the vascular
anatomy in order to trace aberrant
or accessory vascular supplies
which, if not respected, preclude
successful grafting. This vascular
anatomical “map” can be well dem
onstrated on arteriograms, but arte
riography complicates donor sur-

veillance and may jeopardize the
delicate hemodynamic equilibrium
of the brain-dead donor. Thus, we
prefer to rely on a careful and
precise dissection of the vascular
tree. This important step-by-step
dissection is best done by an experi
enced surgical team that harvests
all abdominal and, if possible, tho
racic organs, thus avoiding the un
coordinated and troublesome efforts
of several teams.
Because the three main arterial
supplies of the pancreas (gas
troduodenal, superior mesenteric
and splenic arteries) communicate
one way or another, the whole
duodenopancreatic graft can be
safely revascularized by anastomos
ing the superior mesenteric and
splenic arteries in the recipient, pre
serving the normal arterial supply
for the hepatic homograft. The only
4-

Discussion
Current techniques of multiorgan
harvesting stem from Starzl’s pio
neer work in transplantation.910
However, most transplantation
teams avoid simultaneous harvest
ing of the liver and the whole
pancreas, because the technique is
considered incompatible with safe
grafting in the recipient1'2 unless a
segmental graft is chosen for pan
creatic replacement. In this situa
tion, one of the organs is wasted for
transplantation; however, the pauci
ty of the donor pool commands
optimal use of all donated organs.
The experience of our unit with
pancreas transplantation has been
described previously.1112 We prefer
to use whole duodenopancreatic
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FIG. 4. Level of section of vascular
supply for simultaneous harvesting of
liver and pancreas. (Top) Arterial lev
els: CHA = common hepatic artery,
GDA = gastroduodenal artery, SA =
splenic artery, DPA = dorsal pancreat
ic artery, SMA = superior mesenteric
artery. (Bottom) Venous levels: PV =
portal vein, SV = splenic vein, SMV =
superior mesenteric vein, IMV = in
ferior mesenteric vein.

FIG. 5. Separation of vascular supply
of both liver and duodenopancreas.
Gastroduodenal and splenic arteries
have been transected as close as possi
ble to vessel of origin to preserve
pancreatic vascularization through su
perior pancreaticoduodenal and dorsal
pancreatic arteries. Both grafts are
harvested on Carrel patch of aorta at
level of celiac trunk and superior mes
enteric artery. GDA = gastroduodenal
artery, RGA = right gastric artery,
LGA = left gastric artery, SA = sple
nic artery, CHA = common hepatic
artery, PV = portal vein, DPA =
dorsal pancreatic artery, SMV = supe
rior mesenteric vein, SMA = superior
mesenteric artery, FJA = first jejunal
artery, IMV = inferior mesenteric vein.

LIVER AND PANCREAS HARVESTING

exception would be a dorsal pancre
atic artery arising directly from the
donor celiac axis or aorta. In such
cases, the duodenopancreatic homo
graft can be revascularized on a
double patch of celiac and mesen
teric vessels, providing there is one
common hepatic artery and its ca
libre is sufficient to permit an endto-end anastomosis with the recipi
ent’s common hepatic artery.
Abnormal origin of the right or
the common hepatic artery from the
donor superior mesenteric artery
does not contraindicate simulta
neous removal of both hepatic and
whole-pancreatic grafts, if the ca
libre of this aberrant vessel permits
a safe arterial reconstruction. If
necessary, an interposed Y-shaped
arterial iliac carrefour from the
donor can provide easier revascular
ization of the liver through a large
single vessel.13-17
We have performed five simulta
neous liver and whole-duodenopancreas harvestings. Subsequent
transplantation of the liver and the
whole pancreas have been realized
in 10 different recipients. Four
duodenopancreatic homografts have
been revascularized by anastomos
ing the superior mesenteric Carrel
patch onto the recipient common
iliac artery, and the splenic artery
onto the recipient internal iliac ves
sel, without an interposed arterial
graft. The corresponding livers
have been revascularized either
through the recipient common he
patic artery or directly through the
recipient aorta, using the donor
celiac Carrel patch. None of those
grafts suffered vascular stenosis or
thrombosis and all of them achieved
good function in the postoperative
period.
One duodenopancreas has been
anastomosed to the recipient com
mon iliac artery through the donor
aortic patch comprising the celiac

trunk and the superior mesenteric
artery. The patient’s recovery was
uncomplicated and long-term func
tion of the graft adequate. However,
the corresponding liver, which had
been revascularized by anastomos
ing the donor proper hepatic artery
to the recipient common hepatic
artery, sustained an arterial throm
bosis 5 days postoperatively. The
problem has been related to a
marked discrepancy between the
donor and the recipient hepatic ar
teries. Retrospectively, it would
have been advantageous to inter
pose an arterial segment of the
donor iliac carrefour between both
vessels. The recipient has since un
dergone a successful retransplanta
tion.
Other transplant teams have also
performed simultaneous liver and
whole pancreas harvesting and have
recently reported success.16'18

Conclusions
Contrary to general belief we
think that the rich and intricate
vascular supply of the pancreas,
once it is carefully outlined, allows
simultaneous harvesting of both
liver and whole pancreas in most
instances. This permits optimal use
of all donated organs, at a time
when recipients desperately await
life-saving transplants.
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Volvulus of the Gallbladder: a Case
Report
P.H. Macdonald, BSc, MD, FRCSC; R.F. Pace, MD, FRCSC
Torsion of the gallbladder is a surgical emergency that occurs predominantly in the
elderly and whose presentation is indistinguishable from acute cholecystitis. If
patients being treated conservatively for acute cholecystitis fail to improve promptly,
laparotomy is indicated, because the diagnosis of gallbladder torsion cannot be
excluded. Cholecystectomy before the onset of gangrene and rupture of the
gallbladder is curative.

La torsion de la vesicule biliaire constitue une urgence chirurgicale. Elle survient
surtout chez des personnes agees et son tableau clinique est indifferenciable de celui
d’une cholecystite aigue. Quand un patient traite de fa?on conservatrice pour
cholecystite aigue n’arrive pas a s’ameliorer promptement, il y a lieu de proceder a
une laparotomie car le diagnostic de torsion de la vesicule biliaire ne peut etre exclu.
La cholecystectomie est curative lorsqu’elle est pratiquee avant qu’il n’y ait
gangrene et rupture de la vesicule biliaire.

of the gallbladder is a
V olvulus
rare condition, indistinguish
able from acute cholecystitis at the
time of presentation. Clinical and
radiologic findings are not defini
tive. Although the diagnosis can
only be made by laparotomy, chole
cystectomy is curative, and surgery
is facilitated by the lax peritoneal
attachments that predispose to the
condition. A recent case highlights
the clinical features.

Case Report
A 74-year-old man presented with
a 3-day history of cramping mid
abdominal pain, with increasing dis
comfort localized to the right upper
quadrant. He was anorexic and nau

seated, but had not vomited. He had
a known aortic aneurysm, chronic
obstructive pulmonary disease and
early senile dementia.
He appeared extremely frail and
in moderate distress. His vital signs
were within normal limits, and ex
amination of the abdomen disclosed
the presence of moderate abdominal
distension, with tenderness and full
ness in the right upper quadrant. A
nontender abdominal aortic aneu
rysm was easily palpated to the left
of the midline.
The leukocyte count was 12.8 X
109/L , and computed tomography
showed the presence of the abdomi
nal aortic aneurysm (6.3 cm in
diameter) but no evidence of a leak.
The gallbladder was distended, with
a thickened wall, suggestive of
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acute cholecystitis. Abdominal ul
trasonography showed the addition
al presence of gallstones within the
gallbladder.
Initial management consisted of
intravenous administration of fluids
and broad-spectrum antibiotics, but
over the next 3 days the patient
experienced increasing tenderness
with a palpable mass in the right
upper quadrant. At surgery, the
gallbladder was found to be grossly
distended with extensive gangrene
of the gallbladder wall. Further, the
gallbladder was suspended from the
liver by a long mesentery and had
undergone torsion about the level
of the cystic duct (Fig. 1). Detor
sion was easily performed. A chole
cystectomy was then carried out.
The patient’s recovery was uncom
plicated and he was discharged
home 7 days after the operation.
Pathological examination confirmed
the presence of gallstones and gan
grene of the gallbladder wall.

Discussion
Sporadic reports of gallbladder
torsion have followed the initial
case reported by Wendel in 18981
of a floating gallbladder. Although
the entity has been described in
young patients, the majority of
cases involve the elderly.
In order for the gallbladder to
undergo torsion it must be suspend
ed by a long mesentery. True con
genital mesenteries of the gallblad
der occur in less than 5% of the

VOLVULUS OF GALLBLADDER

population,2 but since this is pre
dominantly a disease of the aged, it
is likely that some additional ac
quired features are necessary.34 The
loss of visceral fat and elasticity
with aging may serve to elongate
the mesentery, and spinal deformi
ty, such as kyphosis, may place the
gallbladder in a more dependent
position and increase its susceptibil
ity to torsion.
In predisposed persons, torsion
may be initiated by any of three
factors: vigorous peristalsis of adja
cent viscera, cholelithiasis with
acute dilatation of the gallbladder,
and atherosclerosis of the cystic
artery, which then acts as a rigid
fulcrum for torsion.4-6 In our pa
tient, gallstones may have increased
the predisposition to volvulus and
precipitated the acute event. An
analogous situation occurs in the
colon where chronic constipation
leads to lengthening of the sigmoid
and its mesentery; acute torsion
may follow a sudden rise in intrasigmoid pressure because of retained
stool.3

The clinical presentation of acute
gallbladder torsion (right upper
quadrant abdominal pain and a ten
der mass) is indistinguishable from
acute cholecystitis. If left untreated,
it will lead to rupture of the gall
bladder, peritonitis and sepsis. Un
fortunately, there are no diagnostic
tests or features which can distin
guish the condition with certainty.
Ultrasonography or computed to
mography may disclose gallstones
or show evidence of gallbladder
inflammation by virtue of thicken
ing of the gallbladder wall or by the
presence of pericholecystic fluid.
Hydroxyiminodiacetic acid (HIDA)
scanning will only demonstrate oc
clusion of the cystic duct, although
a “bull’s-eye” image that may be
characteristic of this condition has
been described.7
Although torsion of the gallblad
der is a rare condition, the diagno
sis should be considered in elderly
patients who present with signs and
symptoms of acute cholecystitis. In
patients without gallstones, scan
ning evidence of gallbladder inflam

mation or cystic duct obstruction
should suggest the possibility of
either acalculous cholecystitis or
gallbladder torsion, both of which
are best managed by cholecystecto
my. In patients who are operated on
early for acute gallstone cholecysti
tis, the diagnosis of torsion will be
made at the time of laparotomy, and
cholecystectomy will be facilitated
by the lax peritoneal attachments
and will be curative.3 If patients
being treated conservatively for
acute gallstone cholecystitis fail to
improve promptly, then laparotomy
is indicated, as the diagnosis of
torsion cannot be excluded and
delay in treatment may lead to
gallbladder rupture.
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Cefizox"
sterile ceftizoxime sodium

THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from inhibition of
cell-wall synthesis in aerobic and anaerobic gram-positive and gram-negative organisms. In
vitro, ceftizoxime shows a strong affinity for penicillin-binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the infections
listed below when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (including S.
pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; Escherichia coli;
Haemophilus influenzae (including ampicillin-resistant strains); Staphylococcus aureus
(including penicillinase-producing but excluding methicillin-resistant strains); Serratia sp.;
and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis;
Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia marcescens; and
Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to Pseudo
monas infections of the urinary tract, a good clinical response accompanied by bacterial
eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis;
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including 8.
fragilis)', Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. pneumoniaeY, Staphylococcus aureus (excluding methicillin-resistant strains); Escherichia coli;
Bacteroides sp. (including 8. fragilis); Klebsiella sp.; and Serratia marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillinresistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K.
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic
Streptococcus pyogenes); Proteus mirabilis; Serratia sp.; Enterobacter sp.; Bacteroides sp.
(including 8. fragilis); Peptococcus sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding methicillinresistant strains); Proteus mirabilis; Peptococcus sp.; and Peptostreptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify
the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with
CefizoxTM may be initiated before results of the susceptibility studies are known. However,
modification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry
should be made to determine whether the patient has had previous hypersensitivity
reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given
cautiously to penicillin-sensitive patients. Antibiotics, including CefizoxTM, should be
administered with caution to any patient who has demonstrated some form of allergy,
particularly to drugs. If an allergic reaction to CefizoxTM occurs, its administration should
be discontinued. Serious acute hypersensitivity reactions may require epinephrine and other
emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other anti
biotics). Therefore, it is important to consider this diagnosis in patients administered
CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit
overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases
should be managed with fluid, electrolyte and protein supplementation as indicated. When
the colitis is not relieved by drug discontinuance or when it is severe, consideration may be
given to the administration of oral vancomycin or other suitable therapy. Other possible
causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in clinical
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has
produced alterations in renal function. Renal status should be periodically evaluated,
especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible organisms
including species originally sensitive to the drug. Careful observation of the patient is
essential. If superinfection occurs during therapy, appropriate measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of gastro
intestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, patients with
impaired renal function (i.e., creatinine clearance 5il.32 mL/s or £ 79 mL/min) should be
placed on a special dosage schedule recommended under DOSAGE AND ADMINISTRATION.
Normal dosages in these individuals are likely to produce excessive serum concentrations
of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM jn pregnancy has not been established. The use of
CefizoxTM jn pregnant women requires that the likely benefit from the drug be weighed
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM jn
pregnant patients has not been investigated. Reproduction studies performed in rats and
rabbits have revealed no evidence of imoaired fertility or harm to the fetus caused by cefti
zoxime. Animal reproduction studies, however, are not always predictive of human
response.

Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and delivery
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is
unknown; therefore caution should be exercised if CefizoxTM is to be administered to a
nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age has not
been established. In children six months of age and older, treatment with CefizoxTM has
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK
(creatine phosphokinase). The CPK elevation may be related to intramuscular
administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-dependent
reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.

Adverse
Reaction

Incidence
< 1%

Incidence
>1 % but <5%

Hypersensitivity:

Rash
Pruritus
Fever

Liver:

Transient elevation of SGOT,
SGPT and alkaline phosphatase

Blood:

Neutropenia
Leukopenia
Thrombocytopenia

Renal:

Transient elevation
of BUN and creatinine

Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Local:

A

jl
1

Injection site: burning, cellulitis,
phlebitis (with IV administration),
pain, induration, tenderness,
parasthesia

Genitourinary:

Vaginitis

Gastro
intestinal:

Diarrhea, Nausea, Vomiting, Pseudomembranous colitis

No disulfiram-like reactions have been reported with CefizoxTM

TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no specific
information available on symptoms or treatment. In cases of suspected overdosage,
supportive therapy should be instituted according to symptoms. Serum ceftizoxime levels
can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intra

venously after reconstitution.
Dosage and route of administration should be determined by the condition of the patient,
severity of the infection and susceptibility of the causative organism(s). The intravenous
route may be preferable for patients with bacterial septicemia, or other severe or life
threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at least 48
hours after evidence of bacterial eradication has been obtained. For B-hemolytic strepto
coccal infections, a minimum of 10 days of treatment is recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams administered in
equally divided doses every 8 or 12 hours (see Table 1 below).

Type of Infection

Daily Dose
(Grams)

Frequency and Route

Uncomplicated
Urinary Tract

1

500 mg q12h, IV or IM

Other Sites

2-3

1 g q8h or q12h, IV or IM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2g q8h orq12h, IVor IM*

Life-Threatening

9-12

3or4 g q8h IV

^

‘ When administering 2 g intramuscularly, the dose should be divided and injected into
different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas aeruginosa
and because many strains are only moderately susceptible to CefizoxTM, higher dosage
may be appropriate when urinary tract infections are caused by these organisms. Other .
therapy should be instituted if the response is not prompt.
Adults with Impaired Renal Function: In patients in whom the creatinine clearance is
1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Following an initial
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in
Table 2 should be followed in patients with reduced renal function.
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TABLE 2
Renal
Function

Reconstitution Table for Standard Vials - I.M. Injection

Creatinine
Clearance
mUs
mUmin

Less Severe
Infections

Life-Threatening
Infections

Mild
Impairment

0.83-1.32

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

Moderate to severe
impairment

0.08-0.82

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

500 mg q48h or
250 mg q24h

500 mg to 1.0g
q48h or 500 mg
q24h

Hemodialysis
patients*

0-0.07

0-4

*ln patients undergoing hemodialysis no additional supplemental dosing is required.
DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT RECEIVES THE
DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.

hen only the serum creatinine level is available, creatinine clearance may be calculated
om the following formulae (for patients 18 years and over only). The serum creatinine level
ould represent renal function at the steady state.
ies:
atinine Clearance

72 x serum creatinine (mg/100 mL)
Weight (kg) x (140 • age)

eatinine Clearance

49 x serum creatinine ( /imol/L)

(mL/s)

Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group
Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

Diluent to be
Added to Vial

Approximate
Available
Volume

Approximate
Average
Concentration

19
2g

3.0 mL
6.0 mL

3.7 mL
7.4 mL

270 mg/mL
270 mg/mL

Shake well until dissolved.
For Intravenous Injection: Reconstitute only with Sterile Water for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Vial
Size

Diluent to be
Added to Vial

Approximate
Available
Volume

Approximate
Average
Concentration

1g
g

10 mL
20 mL

10.7 mL
21.4 mL

95 mg/mL
95 mg/mL

2

Shake well until dissolved.
For Intravenous Infusion: Reconstitute as for intravenous injection. Further dilute the
reconstituted solution to 50 to 100 mL with one of the “ Solutions for Intravenous
Infusion" (see below).

Weight (kg) x (140 • age)

(mUmin)

Vial
Size

Unit Dosage

Frequency and Route

50 mg/kg IV or IM

q6h or q8h, IV or IM

The pediatric dosage should not exceed the maximum adult dosage for serious infections.
ADMINISTRATION
Intramuscular The reconstituted solution of CefizoxTM should be injected well within the
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the
dose should be divided equally and then injected into different large muscle masses.
Intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be injected
slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is
receiving another compatible intravenous solution. During administration of the solution
containing CefizoxTM, jt js desirable to temporarily discontinue administration of the other
solution.

TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated Ringer's Injection
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile Water for Injection
5% Dextrose in Lactated Ringer’s Injection ONLY when reconstituted with 4% Sodium
Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: All reconstituted solutions and those further diluted should be used within 24
hours if stored at room temperature or within 48 hours if refrigerated. These storage lim its
are from the time of the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein hydrolysates
or amino acids. CefizoxTM should not be mixed together with an aminoglycoside.
DOSAGE FORMS
Availability: CefizoxTM jS available as a sterile powder in Standard Vials of 1 gram or
2 grams, containing ceftizoxime as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature (15°-30°C).
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Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM
should be administered over a 20 to 30 minute period.
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Structural Formula:

JXJ

-C-CONH— J------ ^

J

Molecular Formula: C i 3 H i 2 N50 sS2 Na
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow crystalline powder.
Composition: CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free
acid). The sodium content of each gram of CefizoxTM jS approximately 60 mg (2.6 mEq
sodium ion).

PAAB
CCPP

Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent
and volume used. The solution should be discarded if it becomes cloudy. The pH of
freshly reconstituted solutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile Water for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 GRAM and 2 GRAMS)
For Intramuscular Injection: Reconstitute with Sterile Water for Injection or Bacteriosta
tic Water for Injection.
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ORIGINAL ARTICLES

Intramedullary Rod Fixation of Femoral
Shaft Fractures: Comparison of Open and
Closed Insertion Techniques
A.C. McLaren, MD, FRCSC; J.H. Roth, MD, FRCSC; C. Wright, MD

Meta-analysis of published series of intramedullary rod fixation in fractured femurs
revealed significantly higher union rates, lower deep infection rates and a better
range of knee motion when closed rather than open techniques of insertion were
used. A separate retrospective review of 58 femoral fractures at one hospital showed
outcomes consistent with those reported in the literature; these results were
obtained during a 6-year period when staff were learning closed techniques.
Technical failures of the closed technique can be avoided by paying attention to
well-established operative details. A system for grading outcomes was developed to
compare objectively the results of treatment of fracture patients. The literature and
the authors’ experience support the adoption of closed techniques for intramedullary
rod insertion in femoral shaft fractures.

Une meta-analyse des series publiees sur l’osteosynthese des fractures femorales par
tige intramedullaire, revele un taux significativement plus eleve de fusion, un taux
moins eleve d’infection profonde et une meilleure amplitude des mouvements
lorsque des techniques d’insertion fermee sont utilisees plutot que des techniques
ouvertes. Une etude retrospective independante de 58 fractures femorales reduites
dans un hopital montre des resultats compatibles avec ceux de la litterature; ces
resultats ont ete obtenus sur une periode 6 ans, alors que le personnel se
familiarisait avec les techniques d’osteosynthese fermees. Les echecs techniques de
la methode fermee peuvent etre evitees en portant une attention particuliere a des
details operatoires bien etablis. Une echelle devaluation des resultats a ete mise au
point afin d’objectiver la comparaison des resultats therapeutiques chez les patients
victimes de fractures. La litterature, de meme que l’experience des auteurs,
favorisent l’adoption des techniques fermees pour l’insertion de tiges intramedullaires lors des fractures du corps du femur.

union rates and a lower frequency
of infection.3-6-8- 10-12-15-18-20-39
In spite of a consensus in favour
of the closed technique, the techni
cal demands and specialized equip
ment required are a continuing con
cern.'-5-7-40
Our purposes in this investiga
tion were to analyse the pooled
results from the literature (meta
analysis) and to review our institu
tion’s experience with respect to
open and closed intramedullary rod
fixation of femoral shaft fractures
during the period when our hospi
tal’s staff was learning the closed
technique. Two questions were ad
dressed. First, can the results re
ported in the literature be achieved
during the learning period, and sec
ond, is the effort o f learning the
closed technique justified by im
proved outcome?

Methods
ntramedullary fixation o f frac
tures o f the femoral shaft has
becom e established as the optimal
m eans o f fixation for diaphyseal
fractures o f the femur. 1-11 Recently,
this w as extended to many m eta
physeal fractures, using locked in
tramedullary rods.2-5-6'12-13 However,
the closed insertion technique advo

I

cated by Kuntscher14 was initially
replaced by open techniques to en
sure anatomical reduction and add
supplemental fixation.415- 19 There
have been many reports, generally
retrospective,8-9-15-17-20-21 on both ap
proaches. Modern closed techniques
and implants achieve stable fixation
in good position and have higher
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To obtain an overview o f out
com es,41 data published up to 1987
were subjected to nonparametric
analysis using the x 2 test. The
comparable outcom e criteria were
delayed union, nonunion and malunion, infection and range o f knee
motion. The raw data for series
with consistent definitions of each
criterion were pooled and analysed.3"6-8-10-12- 15- 18.20-39
The clinical charts and x-ray
films of all patients aged 16 years

INTRAMEDULLARY ROD FIXATION

or older who had been treated at
our hospital between January 1981
and December 1986 with in
tramedullary rod fixation of a femo
ral shaft were reviewed. This was
the period when closed intramedul
lary fixation techniques were being
learned by our consulting staff.
Pathologic fractures were excluded.
Fractures were classified as prox
imal, mid-shaft or distal shaft. Com
minution was graded from 1 to 4,
according to the method of Winquist and Hansen.42 Open fractures
were graded as I, II or Ilia, Illb,
IIIc, after Gustilo and Anderson.43
Bridging callus was defined radiologically as continuous mineralized
callus between the most distal and
the most proximal fragments across
the fracture site. Union was defined
as the ability of the patients to bear
their weight without pain, with cal
lus bridging the fracture (the frac
ture line was generally obscured but
still visible). Removal of the in
tramedullary rod was usually car
ried out when sufficient remodelling
had taken place to obliterate the
fracture line. Delayed union was
defined as progressive but incom
plete healing at 6 months. Nonun
ion was defined as failed union after
more than 6 months, with no pro
gression of fracture healing for
more than 3 months; bridging cal
lus would be lacking, and additional
treatment would be required to
stimulate healing of the fracture.
We developed a scoring system to
quantify the end result, with points

being assigned to complications.
These included one point for prob
lems without functional implica
tions, two points were assigned for
problems with short-term functional
implications, three points for prob
lems with long-term functional im
plications, five points for failure of
operative treatment. A cumulative
score of 0 was an excellent result, 1
to 2 was considered a good result, 3
to 4 fair and 5 or more poor.

Results
Meta-analysis of published series
was used to compare outcomes in
2529 fractures treated by the closed
technique with outcomes in 714
fractures treated using the open
technique. Not all criteria could be
consistently applied to every case,
so the denominators varied (Table
I). The pooled results showed that
the closed technique had signifi
cantly (p < 0.001) better results
with respect to nonunion, delayed
union and knee range of motion.
There were fewer deep wound infec
tions with the closed technique (p <
0.01). Rotation and shortening,
however, were better when the open
technique had been used (shorten
ing p < 0.001, rotation p < 0.01).
There was no difference between
open and closed techniques with
respect to superficial wound infec
tion and angulatory deformity.
In the series from our hospital
there were 61 patients. Six were

Table I. Pooled Data From 31 Published Series 3_6‘ 8'10-12' 15_18-20-39 of Femoral Fractures Treated
With Intramedullary Rod Fixation
No./no. fractures (°/o)
Outcome criteria
Nonunion
Delayed union
Deep infection
Superficial infection
Malunion - angulation
- rotation
- shortening
Range of knee motion < 90°

Open
21/714(2.9)
12/714(1.7)
18/714(2.5)
18/714(2.5)
7/422(1.7)
11/422 (2.6)
24/603 (4.0)
46/417(11.0)

Closed
10/2503
14/2503
30/2503
21/2529
13/1782
164/2144
194/2185
94/1801

(0.4)
(0.6)
(1.2)
(0.8)
(0.7)
(7.7)
(8.9)
(5.2)

lost to follow-up, leaving 55 pa
tients with 58 fractures available for
analysis. Thirty-eight fractures had
been treated with open techniques
and 20 with closed techniques. The
characteristics of the patient groups
are outlined in Table II. A majority
in both groups were young men. All
injuries resulted from high energy
impacts, motor vehicle accidents
being most common. A high pro
portion of patients had multiple
injuries; three had bilateral femoral
fractures. The details of the injuries
are presented in Table III. Open
fractures in the closed treatment
group were generally debrided on
the first day and the patient was
returned for closed rod insertion,
concurrent with wound closure,
after 4 days of traction. Open frac
tures in the open treatment group
were treated by immediate fixation
in multiply injured patients, includ
ing grades I, II and Ilia fractures,
or by delayed open rod insertion for
isolated injuries.
Table II. Characteristics of Patients and
Their Injuries
Features

Open
(n = 35)*

Closed
(n = 2 0 )t

Mean age, yr
(range)
24 ( 1 7 - 59) 27.6 (15 - 72)
Sex, M/F
Cause
Motor
vehicle
accident
Fall
Industrial
No. with
multiple
injuries
Other injuries
Lower
limbs
Upper
limbs
Head
Face
Spine
Chest
Abdomen
Pelvis

26/11

19/5

34
2
1

21
1
2

30

21

18

11

11
16
11
2
7
1
0

7
6
5
0
5
1
2

*Two patients were lost to follow-up.
tF our patients were lost to follow-up.
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The clinical results from the time
of the operation to final outcome
are presented in Table IV. Operative
details were appropriate only in
cases in which fixation of the femo
ral shaft fracture was the sole pro
cedure. As with blood loss during
surgery, the operative time (109
versus 140 minutes) was less for
the closed than the open technique.
There were seven cases of iatro
genic comminution, four in the
closed and three in the open treat
ment group (Table IV). These were
usually small, medial, butterfly frag
ments related to the lateral entry
point of the intramedullary rod
proximally. This complication rep
resents technical misadventure in
either technique.
In three cases, closed rod inser
tion was attempted, but when re
duction could not be obtained the
fracture site was opened. This hap
pened early in the course of learn
ing the closed technique. In one of
these cases, a minimal amount of
opening was required in order to
T a b le III. C h a ra c te ris tic s o f F e m o ra l
F ra c tu re s T re a te d W ith In tra m e d u lla ry R od
F ixa tio n

pass a guide wire through the sec
ond level of a grossly unstable
segmental fracture. This opening
was considered to be biologically
consistent with closed techniques.
In the other two cases, technical
failure of the closed technique on
the part of the surgeon was handled
by formal open rod insertion, and
these two were considered as part
of the open treatment group.
Union was delayed in 14 of 38
cases in the open treatment group
but not in any of the closed treat
ment group. There were four non
unions in the open treatment group
and none in the closed group. All
fractures had healed within 23
months of injury, nonunions being
treated by revision of fixation, with
or without bone grafting.
The closed group had a shorter
average time to the formation of a
bridging callus (6.5 versus 8 weeks)
and to full weight-bearing without
aids (8 versus 12 weeks). Cases of
delayed union and nonunion were
not included in calculating the heal
ing times.
Malunion (angulation, rotation,

shortening) occurred in both
groups (Table IV). In general, malunions in the open treatment
group were the result of loss of
reduction. In the closed treatment
group, unstable fractures were gen
erally treated with locked in
tramedullary rods and so loss of
reduction was not encountered. Malunions were generally the result of
fixation in a malreduced position.
The outcome score (Tables V and
VI) was excellent in almost threequarters of the patients in the
closed treatment group but in less
than one-third of the patients in the
open group (p < 0.001). The aver
age score was 2.7 in the open
group and 0.85 in the closed group.

Discussion
Analysis of the literature showed
superior results using the closed
treatment technique, with higher
rates of union and lower infection
T a b le V . O u tc o m e S c o rin g S y s te m Based
on F u n c tio n a l Im p a irm e n t and Failure o f
T re a tm e n t
Points

N o. of fra c tu re s *

F e a tu re
C lo s e d fra c tu re s
O p e n fra c tu re s
G rad e 1
G rad e II
G rad e III
S ite
P ro x im a l
M id -s h a ft
D is ta l
C o m m in u tio n
G rad e 1
G rad e 2
G rad e 3
G ra d e 4
F ra c tu re ty p e
T ra n s v e rs e /s h o rt
o b liq u e
L o n g o b liq u e
S p ira l
S e g m e n ta l
C o m m in u te d
'T h r e e o f th e
fra c tu re s .

288

Open
(n = 3 8 )

C losed
(n = 2 0 )

30

17

4
4
0

0
1
2

10
19
9

2
12
8

7
10
4
2

3
4
4
2

15
2
4
3
23

55 p a tie n ts

8
2
0
1
13
had

b ila te ra l
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T a b le IV . C lin ic a l R e s u lts W ith
In tra m e d u lla ry Rod In s e rtio n fo r F em oral
F ra c tu re s

1

N o. of fra c tu res (% )

2

Open
(n = 3 8 )

Closed
(n = 20)

3

13 (7 2 )

1 (9)

5

R e su lts
B lo o d lo s s d u rin g
s u rg e ry , < 1 u n it
Ia tro g e n ic
c o m m in u tio n
W o u n d in fe c tio n
D eep in fe c tio n
A n g u la tio n < 1 0 °
A n g u la tio n > 1 0 °
R o ta tio n > 1 0 °
S h o rte n in g > 1 cm
F a ile d fix a tio n
D e la ye d u nion
N o n u n io n
R ange o f h ip m o tio n
> 90°
R ange o f knee
m o tio n
90° -1 2 0 °
< 90°

3 (7 .9 )
1 (2 .6 )

4 (2 0 )

1 (2 .6 )
5 (1 3 )
3 (7 .9 )
1 (2 .6 )
4 (1 0 .5 )
2 (5 .3 )
14 (3 7 )
4 (1 0 .5 )

1 (5)
2 (1 0 )
0

4 (1 0 .5 )

1 (9)

4 (1 0 .5 )
1 (2 .6 )

2 (1 0 )
0

F eatures
A n g u la tio n < 1 0 °, ro ta tio n <
1 0 ° , s h o rte n in g < 1 c m ,
range o f knee m o tio n < fu ll
but > 90°
D e la ye d u n io n , su p e rfic ia l
in fe c tio n
A n g u la tio n > 1 0 °, ro ta tio n >
1 0 ° , s h o rte n in g > 1 cm ,
ra n g e o f knee m o tio n < 9 0 °
N o n u n io n , fa ile d fix a tio n , deep
in fe c tio n

1 (5)

1 (5)
1 (5)
0
0
0

T a b le V I. P a tie n t O u tc o m e fo r Each
F ra c tu re (S c o re d A c c o rd in g to S y s te m in
T a b le V)
No. of fra c tu res (% )

O utcom e

Open
(m = 3 8 )

Closed
(n = 2 0 )

E x c e lle n t (0 )
G ood ( 1 - 2 )
F a ir (3 - 4)
P o o r (5 )

11 (2 9 )
15 (3 9 )
4 (1 1 )
8 (2 1 )

14 (70)
2 (1 0 )
3 (1 5 )
1 (5)

M ea n sc o re

2 .7

0 .8 5

INTRAMEDULLARY ROD FIXATION

rates. Meta-analysis is an attempt to
pool multiple series, thereby de
creasing random sampling error and
local bias. A diligent effort was
made to include data from series in
which similar analysis criteria and
assessment would allow pooling. In
no report was the unacceptable data
contrary to the final result of the
analysis. The pooled series were
generally retrospective in nature
and the overview results must be
considered consistent with the limi
tations of retrospective reviews.
Even so, the results of the meta
analysis are so strongly in favour of
the closed treatment technique that
a prospective controlled trial would
be unwarranted.
The results of our hospital series
are consistent with the published
data. One of the difficulties in com
paring results from one series to
another is the lack of a quantitative
assessment for fracture patients.
We therefore developed a scoring
system based on objective data re
lated to outcome; union, alignment,
joint motion and complications.
When applied to this series, the
average score was significantly bet
ter in the closed treatment group.
The area of greatest difference was
in the frequency of delayed union
and nonunion, which was markedly
lower in the closed treatment
groups (p < 0.005).
As recently trained surgeons
enter practice, the standard of treat
ment for femoral shaft fractures is
increasingly the closed insertion
technique. The established surgeon
faces learning new techniques, as
justified by improved outcome.
Several technical points will mini
mize the difficulties of learning this
procedure. They have been well
documented and include the equip
ment, patient position, placement of
a distal femoral traction pin, entry
site for the rod and locking of
unstable fracture patterns.13 5'7'40 A
fracture table and C-arm fluorosco

py unit that are compatible with
each other are required. These are
generally available in institutions
treating hip fractures.
There are several contraindica
tions to placing the multiply injured
patient in the lateral position. The
supine position is used for all pa
tients at our institution; technical
problems that would prohibit femo
ral rod fixation using this position
have not been encountered. The
patient should be placed with the
trunk and pelvis in neutral axial
alignment and the fractured lower
extremity in neutral abductionadduction. Adduction of the lower
extremity tends to create tension in
the iliotibial band, making reduc
tion more difficult; it should be
avoided. Sufficient traction should
be maintained on the opposite leg
to prevent tilting of the pelvis dur
ing traction on the injured leg.
Pelvic tilting limits access to the
trochanteric area. The injured ex
tremity is placed in 10° to 20° of
flexion at the hip by elevating the
traction through a distal femoral
pin. This allows access posterior to
the most lateral portion of the iliac
crest.
Traction generally is best applied
through a distal femoral pin placed
at the physeal scar. Fluoroscopy is
used to make certain that the Den
ham pin is placed neutrally (with
respect to varus and valgus) in
relation to the joint line, and in line
with the central axis of the canal in
the anterior-posterior dimension.
Accurate placement of the traction
pin prevents the traction from be
coming a deforming force during
reduction. With the pin at the level
of the physeal scar, the tip of the
intramedullary rod is not obstructed
by the traction pin, as it would be if
the pin were placed more proximally-

The uninjured leg can be abduct
ed sufficiently to allow anteropost
erior and lateral fluoroscopy of the

trochanteric region, as in hip pin
ning. This allows the surgeon to
ensure that the entry point is in line
with the centre of the medullary
canal in both the anteroposterior
and mediolateral planes. The iatro
genic fractures in our series were
related to unacceptable entry
points. The entry point can be opti
mized in the open treatment group
by a complete exposure of the tro
chanter and the piriformis fossa or
by retrograde penetration with a
large T-Bar reamer. In the closed
treatment group, the entry point is
confirmed accurately by fluorosco
py. This eliminates iatrogenic frac
ture due to eccentric entry points.
With accurate positioning of the
distal femoral traction pin, often
only a minor reduction maneuver is
required to align the fracture for
passing the guide wire, and this
should be confirmed before “prepping” and draping. A curved guide
wire is generally required for pass
ing across the fracture site using
closed techniques. The curve has
two components. A long gentle
curve throughout the guide wire
will reliably place its tip at one
endosteal surface. A second, shorter
curve in the same direction as the
long curve is placed in the distal
few centimetres so that the guide
wire can be manipulated into a
slightly offset distal intramedullary
canal. Reaming and rod insertion
are technically similar in both open
and closed techniques.
Generally, if progress of the rod
is impeded for any reason during
insertion, continued driving of the
rod will likely cause iatrogenic frac
turing. The problem must be identi
fied and corrected. Many of the
locked intramedullary devices are
stiffer than nonlocking devices and
often require a full millimetre of
over-reaming to accommodate a
mismatch between the shape of the
femur and that of the rod. The
insertion of locking screws involves
CJS, VOL. 33. NO. 4. AUGUST 1990
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other technical considerations. In
short, the proximal siting devices
are generally reliable. The distal
locking screws can be reliably ins
erted using the free-hand technique.
Closed intramedullary rod inser
tion techniques are the method of
choice. The superior results docu
mented in the literature are achiev
able, even during the learning peri
od. The necessary equipment is
widely available and the technique
is well described. An effort to learn
the closed technique is justified by
the results.
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When choosing an antibiotic for nosocomial infections,

LOOKBEYOND
THEPRICETOG.
Look at the
safety profile
and total cost
of treatment.

Significant biliary excretion of antibiotics can have a very disruptive effect on
intestinal flora, which may promote the emergence of resistant strains of bacteria and
cause diarrhea.1’ This can add substantially to the cost of treatment.3
CLAFORAN (cefotaxime sodium) has an excellent safety profile. With only 5% biliary
excretion, Claforan has little effect on intestinal flora, thus reducing the risk of
diarrhea and bacterial resistance.14 And Claforan provides excellent coverage of
major nosocomial pathogens.
Over a complete course of therapy, if one looks at the average cost per patient,
Claforan makes good sense.3
1. Guggenbichler JP et at. J Antimicrob Chemother 1984;14 (Suppl B) :pg. 67-70.
2. Hooker KD, Dipiro JT. Clin Pharm 1988;Vol 7:pg. 878-888.
3. Giaden HE et at. Infect Surg 1986;5(10):559-572.
4. Alcock SR, Update in Intensive Care and Emergency Medicine 1989;7:102-108.
5. Bivens BA et at. Diag Microbiol Infect Dis 1989;12:113-118,
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Claforan;
P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action ol Claforan (cefotaxime sodium) a semi synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
T reatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus
aureus (penicillinase and non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
U rinary tra ct infections: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B acte re m ia /S e p tice m ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal infections: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological infections: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis] anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
a ntib iotics); therefore, it is im portant to consider its diagnosis in patients w ho develop diarrhea during
the adm inistration of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. G astrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. H em ic and Lymphatic System ( < 1%): Mild, reversible leukopenia, granulocytopenia and thrombo
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with
Claforan. G en itourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGPT,

serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)

Type of Infection

Daily Dose
(g)

Frequency and Route

Uncomplicated Gonorrhea

1

1 g IM (single dose)

Uncomplicated infections

2

1 g every 12 hours IM or IV

Moderately severe to severe infections

3-6

1-2 g every 8 hours IM or IV

Very severe infections (e.g. septicemia, CNS)

6-8

2g every 6-8 hours IV

Life-threatening infections

up to 12

2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
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Multiple Small-Bowel Carcinoids
Presenting With Gastrointestinal
Hemorrhage: a Case Report
C.J. McNamee, MD, FRCSC;* C. Macarthur, MB, ChB;t L.D. Jewell, MD, FRCPC;t
N.M. Kneteman, MD, FRCSC*
Gastrointestinal hemorrhage from a small-bowel lesion can be a problem
diagnostically and therapeutically. The authors present a case of multiple
small-bowel carcinoids, which were the cause of multiple upper gastrointestinal
hemorrhages over a 15-year period. Despite advances in endoscopy and diagnostic
imaging, accurate localization and definitive diagnosis remain elusive in such cases.
Optimal treatment depends on careful clinical evaluation and timely laparotomy.

Une hemorragie digestive originant d’une lesion du grele peut poser un probleme, a
la fois, diagnostique et clinique. Les auteurs decrivent le cas d’une femme de 63 ans,
chez qui de multiples lesions carcinoldes du grele avaient ete la cause d’hemorragies
digestives recidivantes au cours d’une periode de 15 ans. Malgre les progres de
l’endoscopie et des techniques d’imagerie diagnostique, la localisation precise du
foyer hemorragique et le diagnostic definitif demeurent difficiles a etablir dans de
tels cas. Le traitement optimal depend d’une evaluation clinique soigneuse et d’une
laparotomie pratiquee au bon moment.

rimary neoplasms of the small
intestine, both benign and ma
lignant, are rare entities. One au
topsy series of approximately
17 000 cases identified only 93
(0.5%) primary tumours.1 In clinical
series malignant tumours predomi
nate, with adenocarcinomas,2 endo
crine (carcinoid) tumours3-5 and ma
lignant lymphomas6 being the most
frequent histologic types encoun
tered. Small-bowel malignant tu
mours account for less than 2% of
all gastrointestinal carcinomas, with
an annual incidence in Canada of
1.6/100 000.7 Endocrine cell (car
cinoid) tumours are classified as

P

malignant because of their invasive,
albeit slow, and metastatic poten
tial.8 Carcinoids may arise in diverse
sites including breast, liver, lung
and thymus. Most, however, are
primary in the gastrointestinal
tract, anywhere from mouth to
anus. The tumours arise from enterochromaffin (Kulchitsky) cells,
normally present in the gastrointes
tinal mucosa. Small-bowel car
cinoids may be asymptomatic and
discovered incidentally at laparoto
my or autopsy. Eventually, howev
er, they are likely to produce clini
cal symptoms because of local inva
sive growth or by releasing secreto
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ry products. Abdominal pain or in
termittent or partial intestinal ob
struction are common.5 Elaboration
of secretory products may give rise
to the carcinoid syndrome.910 We
report a case of multiple small-bow
el carcinoids causing frequent mas
sive gastrointestinal hemorrhages.

Case Report

A 63-year-old white woman pre
sented with hypotension as a result
of 6 hours of hematochezia. The
hypotension responded to infusion
of crystalloid and 2 units of packed
red blood cells. Her medical history
revealed seven admissions over 15
years for management of gastroin
testinal hemorrhage. Laparotomy
for hemorrhage in 1971 had re
vealed multiple small-bowel ectasias
and a few scattered, mucosal nod
ules (for which biopsies were not
done). Subsequent hemorrhages
had been attributed to these vascu
lar malformations and managed
conservatively. Subsequent colonos
copy, gastroscopy and duodenoscopy with inspection of the upper
small bowel had not revealed any
obvious abnormalities. A previous
technetium-labelled autologous red
blood cell scan had demonstrated
some extravasation into a distal
ileal loop (Fig. 1), and selective
mesenteric angiography during the
current admission demonstrated
pooling of blood from a distal jeju
nal lesion (Fig. 2). No history conCJS, VOL. 33, NO. 4, A U G U S T 1990
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sistent with the carcinoid syndrome
was elicited.
At laparotomy, multiple upper je
junal ectasias were identified but no
associated luminal blood. Examina
tion of the proximal and mid-ileum
revealed multiple mucosal nodules 1
to 2 cm in dimension with associat
ed luminal blood and palpable mes
enteric nodes. Palpation of the liver
revealed no obvious masses. Exami
nation of a frozen section of a
mucosal nodule revealed a car
cinoid. A segmental resection of
ileum (61 cm) with a generous
portion of mesentery (including all
palpable nodes) was removed and
primary anastomosis performed.
Gross examination of the excised
segment of ileum revealed 32 firm,
yellow, submucosal nodules rang
ing in size from 0.3 cm to 2 X 2 X
1 cm. The mucosa overlying the
lesions was thin but intact. Fibrosis
of the underlying muscularis
propria deep to the lesions was
noted. Microscopic examination of
the nodules showed multiple car
cinoids composed of solid nests of
monotonous cells with small oval
nuclei and inconspicuous cyto
plasm; they were situated predomi
nantly in the mucosa and sub
mucosa (Figs. 3 and 4). Several of
the larger tumours penetrated
through the muscularis propria into
the mesenteric fat. Lymphatic inva
sion was clearly identified, and 11
of 16 mesenteric nodes contained
metastatic carcinoid. Electron mi
croscopy showed the presence of
neuroendocrine granules in tumour
cells, confirmed by positive immunocytochemical staining tech
niques for neuron-specific enolase
and chromgranin.
The patient had no further gas
trointestinal hemorrhage over 20
months of follow-up. Computed to
mography of the liver showed no
abnormality and serum and urine
were negative for 5-hydroxyindoleacetic acid (5-H1AA).
292
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Discussion
Small-bowel carcinoids are only
rarely associated with hemorrh
age.11 Invasive carcinoids tend to
grow outward and produce a local
fibroblastic reaction in the serosa
and mesentery, often resulting in
angulation or kinking of the bowel
wall in these areas.9 In part as a
result of this typical growth pat-

FIG. 1. Technetium-labelled autolo
gous red blood cell scan demonstrating
hemorrhage into distal loop of small
bowel.

FIG. 2. Selective superior mesenteric
arteriogram demonstrating pooling of
blood from distal jejunal lesion, corre
lating well with autologous red blood
cell scan in Fig. 1.

tern, mucosal erosion with ulcer
ation is uncommon, as is tumour
necrosis.5 In addition to ulceration
due to a mass effect, hemorrhage
may also result because tumour
paracrine vasoconstricting products
cause local ischemia. Patients who
present with hemorrhage associated
with gastrointestinal carcinoids

FIG. 3. Low-power view of small intes
tinal wall shows predominantly sub
mucosal growth of carcinoid with in
volvement of crypt zone of mucosa
(arrow) (hematoxylin and eosin, origi
nal magnification X 100).

FIG. 4. Detail of tumour. It grows in
insular pattern with occasional cribri
form spaces. Nuclear character is uni
form with bland appearance (hematox
ylin and eosin, original magnification
X 160).

CARCINOIDS AND GI HEMORRHAGE

often undergo multiple investiga
tions before the correct diagnosis is
made.1213
Diagnosis of small-bowel car
cinoids requires clinical and labora
tory correlation. Gastrointestinal
symptoms and signs usually pre
dominate. Abdominal pain or symp
toms and signs of intermittent or
partial intestinal obstruction are
common with intussusception or
volvulus occurring less frequently.
The average duration of symptoms
before the correct diagnosis is made
is 4 years.4 Carcinoid syndrome
with vasomotor disturbances, intes
tinal hypermotility, bronchial con
strictive episodes and right-sided
cardiac involvement may be present,
due to the elaboration of secretory
products.910 For most small-bowel
carcinoids, production of clinical
symptoms is synonymous with
spread beyond the primary site.
Measurement of urinary 5-HIAA
aids in the diagnosis of the car
cinoid syndrome. This metabolite of
serotonin is produced after passage
through the pulmonary circulation.
However, a positive finding implies
extensive hepatic metastases, as the
liver usually degrades the secretory
products of small-bowel carcinoids.
In the absence of hepatic metasta
ses, selective venous serotonin sam
pling may reliably determine the
presence of a carcinoid.14
Laparotomy is the definitive
means of demonstrating a smallbowel carcinoid. At the time of
laparotomy, exploration of the re
mainder of the gastrointestinal tract
should be undertaken, because 30%
of small-bowel carcinoids exist con

currently with other malignant neo
plasms.45-7 Surgical excision re
mains the only method of cure. The
5-year survival rate for mid-gut le
sions is approximately 59%, even
with distant metastases.15 This com
pares favourably with adenocarcino
ma (approximately 23% 5-year sur
vival), indicating the less aggressive
nature of the carcinoid.7
Our case demonstrates the diffi
culty of identifying with accuracy
the source of recurrent small-bowel
hemorrhage. Past laparotomy re
vealed that multiple jejunal vascular
ectasias and subsequent hemorrh
age had been attributed to these
malformations; each episode was
managed conservatively. The find
ings at laparotomy 15 years later
suggested that the previously noted
mucosal nodules may have been
involved in these recurrent episodes
of bleeding. Although no precise
bleeding point was identified on
pathological examination, luminal
blood was associated only with the
carcinoids (and not the vascular
malformations), and hemorrhaging
ceased when this portion of the
small bowel was resected. Smallbowel carcinoids are rare and he
morrhage associated with such le
sions is rarer still, but such tu
mours may be considered in the
absence of a definitive diagnosis for
recurrent small-bowel hemorrhage.
Despite advances in endoscopy and
diagnostic imaging, accurate local
ization and definitive diagnosis of
small intestinal hemorrhage remain
elusive. In such cases, optimal
treatment depends on careful clini
cal evaluation and close follow-up.
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Popliteal Artery Injury After Tibial
Osteotomy: Report of Two Cases
F. Rubens, MD; J.L. Wellington, MD, FRCSC; A.G. Bouchard, MD, FRCSC
Operative injury to the popliteal artery after meniscal surgery on the knee has been
described previously, but its occurrence after tibial osteotomy has not been reported.
The authors describe two cases of the latter condition, both involving the formation
of a false aneurysm at the site of injury. The pathogenesis of this condition, its
clinical sequelae and its subsequent repair are discussed.

On a deja decrit des lesions peroperatoires de l’artere poplitee consecutives une
chirurgie du menisque, mais sa survenue lors d’une osteotomie tibiale n’avait pas
encore ete signalee. Les auteurs en decrivent deux cas, les deux impliquant la
formation d’un faux anevrisme au siege de la lesion. On commente la pathogenese
de cette affection, ses consequences cliniques et sa reparation subsequente.

possible due to the small size of the
vessel and the large size of the
defect. The injured segment was
resected and replaced with an inter
position saphenous vein graft.
The postoperative course was un
complicated. The pedal pulses re
turned, with complete resolution of
the patient’s popliteal pain and the
numbness of her foot.
Case 2

rauma to the knee is associated
with vascular complications in
about 2% of cases,1 the majority of
which, in North America, arise from
motor vehicle accidents. Operative
trauma to the popliteal artery has
also been seen with meniscal re
pairs2 and arthroscopy.3-4 The inci
dence after meniscal surgery has
been reported to be 2.4%,2 but its
occurrence may be underreported
because of the fear of litigation. We
present two cases of popliteal artery
trauma and false aneurysm forma
tion arising after tibial osteotomy.

T

Case Reports
Case 1

A 17-year-old girl was transferred
to our hospital 3.5 weeks after she
underwent a right high-tibial oste
otomy and placement of a table
staple for a knee deformity.
One day after the initial surgery,

she had complained of increasing
pain and swelling in the region of
the popliteal fossa. Examination
showed evidence of impaired circu
lation; no pulses were felt in her
right foot, which was pale and cool.
The patient also complained of
numbness on the right side of that
foot. She could not fully extend her
knee. A firm, pulsatile mass was
palpable in the popliteal fossa.
Angiography on the day of ad
mission to our hospital revealed a
large false aneurysm, measuring 9
X 5 cm, arising from the anterolat
eral aspect of the distal third of the
popliteal artery. The artery was
splayed over the mass. The distal
vessels were patent (Fig. 1). At
surgery the following day, proximal
control was obtained, and an Sshaped incision was made posterior
ly over the popliteal fossa. The false
aneurysm was exposed. A 1-cm de
fect in the anterior aspect of the
lower third of the popliteal artery
was found. Primary repair was im-
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A 56-year-old man underwent a
left tibial osteotomy for osteoarthri
tis. In the immediate postoperative
period he complained of pain and a
“lump” in his cast, with increasing
discomfort in his leg. His pain per
sisted, and 6 months later he under
went venography, which revealed a
chronic deep-venous thrombosis.
During reassessment in the clinic
11 months after the initial surgery,
the patient was still complaining of
persistent pain in his calf when he
walked. A bruit was discovered over

FIG. 1. Case 1. Lateral arteriogram
showing large false aneurysm in popli
teal space. Table staple is evident in
proximal tibia. Popliteal artery is dis
placed posteriorly; knee could not be
extended completely.

POPLITEAL INJURY AFTER TIBIAL OSTEOTOMY
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his calf and a widened popliteal
pulse was noted.
He was admitted to hospital. A
left femoral angiogram obtained the
same day revealed a tear-drop
shaped aneurysm originating from
the popliteal artery, extending down
the calf. This false aneurysm dis
placed the popliteal artery posteri
orly and laterally. There was good
runoff in the lower leg, except in
the mid-anterior tibial artery, where
there was a severe focal stenosis
(Fig. 2).
In the operating room, the pa
tient was placed in a prone position
and proximal control was obtained.
The false aneurysm was then deliv
ered through an S-shaped incision
overlying the popliteal fossa. Unfor
tunately, the tissue was quite friable
and direct repair of the injury was
not possible. Bypass grafts, from
the popliteal artery to the tibioperoneal trunk and to the anterior
tibial artery, were constructed,
using reversed greater saphenous
vein.

The patient did well postoperatively. He had complete resolution
of his ambulatory pain, with return
of his pedal pulses. At followup 6
months later he was asymptomatic.

Discussion
Popliteal artery injury with for
mation of a false aneurysm was first
described in the medical literature
in a series of battlefield casualties
compiled by DeBakey and Simeone.5 It has also been reported after
some types of knee surgery,2' 4 but
there have been no reports of injury
after tibial osteotomy.
The popliteal artery enters the
superior and medial part of the
popliteal space through the tendi
nous arch in the adductor magnus
muscle. It then passes parallel to
the semitendinosus until it reaches
the middle of the limb. At that
point, it descends to the distal bor
der of the popliteus muscle, passing
through the annulus of the soleus

* (

V -

FIG. 2. Case 2. (Left) Lateral arteriogram showing large tear-drop shaped false
aneurysm with posterior displacement of popliteal artery. (Right) Femoral arterio
gram, anteroposterior view, reveals aneurysm situated medially in popliteal fossa;
popliteal artery is displaced laterally. Arrow indicates level of osteotomy.

muscle, then terminating by divid
ing into the tibioperoneal trunk and
the anterior tibial artery. It is initial
ly lateral to the midline, up to the
level of the intercondylar notch of
the femur. There are extensive col
lateral branches about the knee,
with superior, middle and inferior
genicular arteries. Theoretically,
these should be sufficient to main
tain blood flow to the lower extrem
ity in the event of interruption of
the popliteal artery, but ischemic
lesions of the foot and toes may
result in up to 45% of cases.1
Injury to the popliteal artery with
knee trauma usually results from
the generation of bony fragments.
These can produce direct injury to
the arterial trunk, or a displaced
piece can cause compression in
knee-displacement injury. Indirect
compression due to tension hemato
ma in the fibular groove may add to
the effect of the direct trauma on
the vessels. The usual injury in
operative arterial trauma is stretch
ing of the anterior tibial artery at
the interosseous membrane with
varus correction. Compression of
the artery also occurs with valgus
compression.
During tibial osteotomy, the bone
is cut with a high-pressure oscillat
ing saw and the repaired fragments
may be stabilized with a nail-plate,
which is secured by screws in holes
bored with an operative drill. The
knee is flexed to 90°, which should
displace the artery away from the
operative site, but injury from a saw
or drill must be suspected in these
cases.
The aneurysm enlarges rapidly
because of its location in the midst
of loose tissue and because of the
absence of the muscle support com
mon to the other vascular trunks of
the extremity. The presence of a
bifurcation means that tension is
already increased in the main trunk.
Most false aneurysms are found in
the superficial aspect of the calf
CJS, VOL. 33, NO. 4, AVG U ST 1990
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space, as they expand rapidly, meet
ing little resistance.
A false aneurysm is often associ
ated with a stiffness of the knee
similar to arthritis, and the leg may
be maintained in a semiflexed posi
tion. A bruit overlying the artery is
important in diagnosis.6 Distally,
the foot is often pulseless; pulses
were present in only 8 of 28 pati

ents with popliteal artery injury
reported by Krige and Spence.6
The posterior approach to the
popliteal artery was introduced by
Seeley and colleagues in 1953.7
With this incision, up to 2.5 cm of
the vessel can be excised and the
ends brought together for a primary
anastomosis, after freeing the artery
for 5 to 7 cm in each direction.

The classically-accepted proce
dure for popliteal artery injury after
removal of the false aneurysm is
excision of the damaged segment
with subsequent vein grafting,
using reversed saphenous vein, par
ticularly if the defect is greater than
1.5 cm.
Orthopedic and vascular sur
geons should be aware that poplite-
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al artery injuries can occur after
tibial osteotomy. Awareness would
encourage them to investigate im
m ediately w ith arteriographic
studies, particularly if, in the post
operative period, the patient com
plains of symptoms referable to the
popliteal fossa. We believe that
early recognition of arterial injury is
essential for effective management.
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Laser Fulguration for Palliation of Rectal
Tumours
Peter L. Birnbaum, MD, MSc; C. Dale Mercer, MD, FRCSC, FACS
Palliative therapy for rectal carcinoma includes control of bleeding, tenesmus,
mucous discharge, obstruction and pain. These local symptoms can cause serious
morbidity for patients with locally advanced or metastatic rectal cancer. As an
alternative to surgical resection for palliation, the authors applied endoscopic laser
fulguration in 15 patients with rectal tumours; 14 experienced immediate relief of
symptoms. At 6.4 months’ follow-up, two patients had recurrent tenesmus and two
required a colostomy.
A high degree of patient acceptance makes laser fulguration for rectal tumours an
important modality for palliation; however, control of tenesmus may be temporary.
Le traitement palliatif du cancer du rectum comprend la suppression des saignements, des tenesmes et de l’ecoulement muqueux, la reduction de 1’obstruction et le
soulagement de la douleur. Ces symptomes locaux peuvent etre la cause d’une
serieuse morbidite pour les patients souffrant d’un cancer rectal avance ou
metastatique. Comme alternative a la resection chirurgicale a visees palliatives, les
auteurs ont utilise la fulguration endoscopique au laser chez 15 patients porteurs
d’un cancer rectal; 14 ont eu un soulagement immediat des symptomes. Apres 6.4
mois de surveillance des suites therapeutiques, deux patients avaient eu une recidive
des tenesmes et deux autres avaient necessity une colostomie.
La fulguration au laser des tumeurs rectales est bien acceptee des patients, d’ou
son importance comme moyen palliatif; toutefois, le controle des tenesmes peut
n’etre que temporaire.

ectal cancer is the second lead
ing cause of cancer deaths.
Patients who present early have an
opportunity for curative resection.
However, up to 20% of patients
with rectal carcinoma present with
advanced disease not amenable to
curative resection.1 In such cases
surgical resection of the primary
tumour is often required to control
local tumour symptoms of tenes
mus, bleeding and intestinal ob
struction. Operative options include
sphincter-sparing procedures such
as low anterior resection2 (made
possible with stapling devices) and

R

local transanal or trans-sacral resec
tion.3 Very low rectal tumours re
quire abdominoperineal resection
for palliation.1 Patient acceptance of
a permanent colostomy is low, par
ticularly in elderly patients whose
debility from arthritis and loss of
visual acuity make management of
the colostomy difficult. It may be
impossible to excise the primary
rectal tumour in up to 5% of cases
due to extensive abdominal disease
with a frozen pelvis or advanced
medical illness of the heart and
lungs.1 Radical radiotherapy can be
utilized for cure and for palliation
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of local symptoms.4 Recently neo
dymium : yttrium-aluminum-garnet
(Nd-YAG) laser vaporization for rec
tal tumours has become a therapeu
tic option for palliation. This report
presents our experience with sigmoidoscopic fulguration of rectal
cancers with the Nd-YAG laser for
palliation.

Patients and Methods
From 1986 to 1989 we used
Nd-YAG laser fulguration for pallia
tion of rectal tumours in 15 pa
tients (7 women and 8 men); their
average age was 75 ± 3 years
(range from 67 to 93 years). Laser
treatment was indicated for pallia
tion in nine patients with diffuse
metastases, for refusal of operation
in four and because two patients
were judged to be medically unfit
for surgery. Presenting symptoms
included bleeding and tenesmus in
10 patients and large-bowel ob
structive symptoms in 3; 2 were
asymptomatic. The asymptomatic
patients also underwent therapy be
cause of the circumferential extent
of the tumours and the likelihood
of obstruction. Three patients had
previously undergone bowel resec
tion, one had had electrocautery
treatment and two had received
maximum radiotherapy.
On average the tumours were
located 8 ± 1 cm from the anal
verge. Adenocarcinoma was present
in 14 patients and villous adenoma
in 1. One or two cleansing enemas
were given before treatment.
The Cooper Laser Sonics Molectron 8000 Nd-YAG, continuous
wave, 1064 nm laser (Sigmacon
CJS, VOL. 33, NO. 4, A U G U S T 1990
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Corp., Downsview, Ont.) was used
with 50 to 80 W, pulse duration of
0.5 seconds in the non-contact mo
dality. The laser wave guide was
inserted in the biopsy channel of
the Olympus CFPIOS flexible sig
moidoscope (Carsen Medical & Sci
entific Co. Ltd., Markham, Ont.).
Electrocautery snare removal of
the bulk of the exophytic tumour
was done in one patient before
Nd-YAG laser vaporization.

Results
Fourteen patients gained immedi
ate relief of symptoms after laser
treatment. One patient who did not
improve had a large extraluminal
tumour component encroaching on
the bowel lumen. Energy utilization
ranged from 1000 to 11 000 J
(mean 5525 J) per session. Eight
patients required general anesthesia
and seven received neuroleptic seda
tion. The mean hospital stay after
laser therapy was 5 days. Four
patients received their therapy on
an outpatient basis. Seven patients
underwent laser fulguration an av
erage of 145 ± 75 days (range from
3 to 485 days) after the initial
procedure. Three patients requiring
early repeat laser fulguration (with
in 7 days) had large tumours neces
sitating several sessions for ade
quate debulking. Four patients who
required late repeat laser fulgura
tion had recurrent local tumour
symptoms. There were no perfora
tions and no excessive bleeding.
Postoperative discomfort was mini
mal and was related to the build-up
of colonic gas from the coaxial
stream of air through the fibre.
Of 13 patients followed up from
3 to 19 months (mean 6 months)
after initial laser fulguration, 3 died
of carcinomatosis but had good
palliation of local symptoms, 6 were
completely free of local tumour
symptoms, 2 suffered recurrent te
nesmus and 2 required a colostomy.
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Discussion
Endoscopic application of the NdYAG laser to vaporize upper and
lower gastrointestinal tumours has
provided an important nonoperative
tool for palliation in patients with
advanced local tumour. Our initial
experience with this technique was
using Nd-YAG laser vaporization
for palliation in 18 patients with
obstructing esophageal carcinoma;
dysphagia was relieved in 16 of
them.5
In this paper we used similar
techniques and principles for pallia
tion of rectal carcinomas. Standard
palliative measures for these tu
mours may subject elderly patients
with concomitant medical illness to
major surgical procedures. Surgical
resections will provide excellent
control of local tumour symptoms;
however, they may leave the patient
with a permanent colostomy. De
spite the best efforts of physicians
and stomal therapists, many pa
tients do not want a permanent
colostomy. Also, the ability to care
for the colostomy may exceed the
capabilities of many elderly patients,
who choose to die from aggressive
local or metastatic tumour rather
than have a colostomy.
Other operative techniques are
available for controlling local rectal
tumour symptoms. Very low anteri
or resections, which are made possi
ble by the circular stapling device,6
abdominosacral resection,7 and abdominoanal pull-through resection,8
permit sphincter-sparing excision of
low rectal carcinomas. A high de
gree of technical expertise and the
magnitude of the operative proce
dure remain as obstacles to these
therapeutic options in elderly frail
patients.
Radiotherapy provides a nonoper
ative modality for palliation of rec
tal tumours. Small doses (20 to 30
Gy) may provide effective control of
symptoms. Larger doses (up to 50

Gy) are required to effect tumour
regression.9 Endocavitary radiation
was used in 57 patients for pallia
tion of rectal carcinoma with a good
local response, as judged by control
of tenesmus and bleeding in 84%.4
However, several difficulties with
this technique restrict patient selec
tion. Radiation to lesions adjacent
to the transitional mucosa of the
anal verge may cause severe procti
tis. Lesions above the peritoneal
reflection are inaccessible to in
tracavitary radiotherapy. A circum
ferential, bulky lesion may prevent
proper placement of the procto
scope required for delivery of radia
tion.10
Electrocoagulation, first intro
duced in 1935, has been applied for
curative therapy of low-lying rectal
carcinomas displaying favourable
morphologic and pathologic fea
tures." As a palliative tool, Hughes
and colleagues12 found elec
trocoagulation ineffective in con
trolling tenesmus, bleeding and mu
cous discharge. Electrocautery
snare debridement of broad-based
tumours of the rectum before NdYAG laser vaporization of the base
of the polyp can provide tissue for
accurate diagnosis and reduces the
volume of tumour requiring laser
treatment.13 One of our patients had
electrocautery snare removal before
laser fulguration of the base.
Endoscopic Nd-YAG laser fulgu
ration is becoming an important
modality for effective palliation of
rectal carcinoma. Ideally, palliation
should relieve obstruction and te
nesmus and prevent bleeding and
mucous discharge. Minimal risk,
widespread patient applicability and
reduced hospital stay are also im
portant. The Nd-YAG laser utilizes
a fiberoptic delivery system with
tissue penetration of the beam to a
depth of up to 4 mm. These physi
cal characteristics make the NdYAG laser particularly well suited
for rapid coagulation of a large
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tumour mass.14 The argon laser
with a wavelength of 10.6 g m, a
fiberoptic delivery system and pene
tration depth of 1 mm has also been
used for colorectal tumours. Bow
ers15 found that the argon laser was
satisfactory for benign colonic pol
yps but had insufficient penetration
depth for malignant tumours of the
rectum. They now use the Nd-YAG
laser for treatment of all rectal
cancers. Although the likelihood of
perforation is greater with the NdYAG laser, none occurred in their
series of 14 rectal tumours, and in
our series of 15 patients there were
no perforations. Air insufflation
during laser fulguration to cool the
fibre tip will thin the bowel wall and
potentially increase the possibility
of perforation. Newer water-cooled
fibres result in less colonic disten
sion and thereby reduce the likeli
hood of perforation. Cautious ful
guration restricted to the tumour
mass, taking care to avoid normal
bowel, will also reduce this risk. In
a series of 115 patients who under
went photoablative Nd-YAG therapy
for colorectal tumours, Low and
colleagues16 demonstrated similar
therapeutic response rates of tu
mours treated above and below the
peritoneal reflection. The complica
tion rate was not increased even
though 45% of the colonic lesions
were located in the thin-walled ce
cum.
Effective palliation must provide
the patient with a subjective im
provement. McGowan, Barr and
Krasner17 demonstrated the effec
tiveness of laser therapy in improv
ing the quality of life in 14 patients
with inoperable colorectal cancer.
Their prospective study showed
that patients with diarrhea, rectal
bleeding, mucous discharge or pain
secondary to the tumour mass ben
efited most from laser vaporization.
In contrast, pain due to tumour
invasion of the sacral plexus, a
tumour mass in the anal canal with

sphincter dysfunction and malig
nant cachexia were relative con
traindications to laser therapy. In
our study 14 patients (93%)
achieved immediate relief of symp
toms. In seven patients (50%) a
second laser fulguration was re
quired to control local tumour
symptoms, providing an average du
ration of improvement of 4.8
months. Rectal tumours with ob
struction from an extraluminal
component are a relative contraindi
cation to laser fulguration. We were
unable to provide relief to one pa
tient who presented with predomi
nantly extrinsic mass. We also
found that patients with tenesmus
were not palliated as well as those
with bleeding or obstructive symp
toms. Our results compare favoura
bly with those of Brunetaud and
associates18 who achieved a 90%
immediate success rate with an av
erage duration of improvement of
9.3 months in 142 patients with
rectosigmoid cancer.
A cost-benefit study19 showed
that the cost of endoscopic laser
therapy is significantly less than
other methods of palliation and that
hospital stay, intensive care time
and complications are significantly
greater in patients who undergo
palliative surgery for rectal cancer.
This cost advantage more than off
sets the initial capital cost of the
laser and its ancillary equipment.
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D exon Plus Versus Maxon Fascial
Closure in Morbid Obesity: a Prospective
Randomized Comparison
Mervyn Deitel, MD, FRCSC; Ritha Alhindawi, MD, PhD; Mohamed Yamen, MD; Toan B. To, MD;
Claude J. Burul, MD, FRCSC

A monofilament polyglyconate suture (Maxon) was developed as a longer-lasting
suture associated with less potential for infection than braided polyglycolic acid
suture (Dexon). The authors compared Dexon Plus and Maxon in a prospective
randomized study of 84 consecutive morbidly obese patients who underwent vertical
banded gastroplasty. Linea alba was closed with continuous running suture,
reinforced with a few interrupted, sutures. After more than 2 years’ follow-up, one
seroma (2.4%), one wound infection (2.4%) and no hernias were found in the Dexon
group. In contrast in the Maxon group there were three seromas (7.1%), four wound
infections (9.5%) and four incisional hernias (9.5%, p < 0.05). The hernias were
noted between 2 and 10 V2 months after the operation in two patients who had had
wound infections and in two who had had seromas. When Maxon was used, the
needle occasionally pulled off the suture and the ends beyond the knot projected
rigidly. Dexon Plus was easier to handle in very fatty wounds.
Le fil en monofilament de polygluconate (Maxon) a ete mis au point pour offrir une
suture de plus longue duree et moins susceptible aux infections que le fil tresse
d’acide polyglycolique (Dexon). Les auteurs ont compare les sutures Dexon Plus et
Maxon dans une etude prospective et randomisee, chez 84 patients souffrant
d’obesite pathologique qui on subi une gastroplastie par bande verticale. La ligne
blanche a ete refermee a l’aide d’une suture a points continus renforcee de quelques
points non continus. Apres une periode de surveillance d’au moins 2 ans, un serome
(2.4%), une infection de plaie (2.4%) et aucune hernie ont ete observes dans le
groupe Dexon Plus. Par opposition, dans le groupe Maxon, on avait enregistre trois
seromes (7.1%), quatre infections de plaies (9.5%) et quatre hernies dues a l’incision
chirurgicale (9.5%, p < 0.05). Les hernies ont ete observees de 2 a 10 mois apres
l’operation, chez deux patients qui avaient eu une infection de plaie et chez deux
autres qui avaient eu un serome. Avec la suture Maxon, Taiguille a, occasionnellement, tire la suture et les extremites au-dela du noeud rigide. La suture Dexon Plus
etait plus facile d’utilisation dans les tissus tres adipeux.
From the Department o f Surgery and Department o f Nutritional Sciences, University o f Toronto
and St. Joseph's Health Centre, Toronto, Ont.
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orbid obesity is a risk factor
for postoperative wound com
plications.1 General surgeons, and
those doing surgery for morbid obe
sity in particular, are interested in
finding an ideal suture material for
abdominal wound closure. McNeil
and Sugerman2 found no advantage
of nonabsorbable suture over
Dexon Plus (braided polyglycolic
acid coated with poloxamer 188)
closure in morbid obesity. Dexon
Plus lasts 90 days in tissues and is
absorbed by hydrolysis. It retains
good tensile strength for about 18
days (4 days longer than Vicryl
[polyglactin-910]),3 which is longer
than the critical period (15 days) of
tissue healing.4 The hydrolysis of
Dexon is delayed in acidic pH such
as in ischemia and infection;5 more
over, the degradation products of
Dexon have a bactericidal action.6
Davis & Geek developed Maxon
(monofilament polyglyconate) as a
longer-lasting (180 days, having
good tensile strength for 4 to 6
weeks) absorbable suture with less
potential for infection than Dexon.7
In a prospective randomized study
we compared the efficacy of Dexon
Plus and Maxon for the fascial
closure in morbidly obese patients.

M

CLOSURE IN MORBID OBESITY

Patients and Methods

Results

The study comprised a consecu
tive series of 84 morbidly obese
patients (at least 45 kg over their
ideal weight) who underwent verti
cal banded gastroplasty (VBG)
(clean-contaminated surgery). All
were operated on by one surgeon
(M.D.) in our hospital between Au
gust 1986 and April 1987. The
patients were allocated for closure
with No. 1 Dexon Plus or with No.
1 Maxon by drawing a randomized
card. Patients with previous upper
abdominal incisions were not in
cluded in the study. All patients
received antibiotic prophylaxis (2 g
cefazolin) preoperatively, repeated
once postoperatively. An upper mid
line incision ending above the um
bilicus was used. The fascia was
closed in a single layer of continu
ous running suture, reinforced with
a few interrupted sutures, by a
senior resident supervised always by
the same surgeon (M.D.). No subcu
taneous sutures were inserted. Skin
incisions were closed with staples.
All patients were followed up for
more than 2 years by two surgeons
(R.A. and T.B.T.) who were blinded
to the closure material used, and
wound complications (seroma, in
fection and incisional hernia) were
recorded (Table I). A collection was
considered to be a seroma when it
contained a clear yellow watery flu
id, and a wound infection when the
content was pus, usually associated
with fever and increased leukocyte
count.
The results were analysed by the
X 2 test with Yates’ correction.

An analysis of age, sex and
weight in both groups did not show
any difference. We noted with No. 1
Maxon that the needle not infre
quently pulled off the suture, and
the ends beyond the knot projected
rigidly. The mean skin-to-skin oper
ative time was 37 minutes.
The overall incidence of immedi
ate postoperative complications (se
roma or infection) was 10.7%.
Wound complications occurred in 2
(4.8%) of 42 patients in the Dexon
Plus group compared with 7
(16.7%) of 42 patients in the Maxon
group. Deep subcutaneous wound
infection occurred in one patient of
the Dexon Plus group and in three
of the Maxon group. One other
patient in the Maxon group had a
superficial wound infection. Two
wound infections were due to ahemolytic streptococcus, in one,
culture grew Staphylococcus au
reus, and in another Klebsiella and
one was a mixed aerobic-anaerobic
infection. All seromas were cul
tured; one showed a light growth of
Staphylococcus epidermidis, the
rest were negative. The wound in
fections were treated with drainage
and healed within 3 weeks. The
seromas were treated after release
with a dry dressing or light com
presses and healed within 2 weeks.
In the four patients in the Maxon
group who had ventral hernia, two
had had deep wound infections and
two had had seromas. Hernias in
these patients were noted at 2, 3, 5
and 10.5 months after VBG. One
hernia was discovered during ab

T a b le 1.

No. of patients
Age, yr
Female-male ratio
Wound infection, no. (%)
Seroma, no. (%)
Hernia, no. (%)
Dehiscence

Wound Complications in Dexon Plus and Maxon Groups
D exon P lu s

M axon

42
34 ± 9
36.6
1 (2.4)
1 (2.4)
0
0

42
36 ±8
39.3
4 (9.5)
3(7.1)
4 (9.5)
0

dominal lipectomy. All hernias were
repaired electively or at the time of
lipectomy.
The differences in seromas and
wound infections were not signifi
cant. However, the occurrence of
incisional hernia was higher in the
Maxon group (p < 0.05) than in the
Dexon group.

Discussion
Morbid obesity is known to be
associated with wound complica
tions and incisional hernias. Bucknail, Cox and Ellis8 found that
35.7% of patients in their series of
1129 patients who underwent
major laparotomy and subsequently
had a ventral hernia were obese. In
our study the overall incidence of
incisional hernia was 4.7%, which is
comparable to that reported in the
literature.9 All four hernias oc
curred in the Maxon group, in
which we had found more postoper
ative seromas and wound infections.
These hernias occurred in two pa
tients who had had seromas and in
two who had had wound infections,
reinforcing the tenet that wound
complications are associated with
later hernias. The total incidence of
wound infection and seroma in both
groups was 5.9% and 4.7% respec
tively, rates comparable to those
reported in the literature for surgi
cal procedures performed on obese
patients.9 The higher rate of the
complications in the Maxon group
may be due to the rigid ends pro
jecting beyond the knot, which,
with the movement of the abdomi
nal wall, could create a dead space
leading to fluid collection. The stiff
ness of Maxon has been confirmed
by Chu and Kizil.10
It can be difficult to recognize a
fascial defect in adipose patients,
and in one patient the hernia was
discovered and repaired at the time
of lipectomy. Dexon Plus was assoCJS, VOL. 33, NO. 4. AUGUST 1990
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Nursing Mothers
Studies performed in lactating rats have shown that
PEPCID® is secreted in breast milk. It is not known
whether this drug is secreted in human milk.
Nursing mothers should either stop this drug or
should stop nursing.

D EITEL E T AL

Pediatric Use
Safety and effectiveness in children have not been
established.

ciated with fewer incisional hernias
and was easier to handle in very
fatty wounds.

Use in Elderly Patients
No dosage adjustment is required based on age (see
HUMAN PHARMACOLOGY, Pharmacokinetics).

ADVERSE REACTIONS

We are indebted to Sigmund Krajden,
MD, FRCPC (Microbiology) and Max
well Patterson, MD, FRCPC (Chief of
Laboratories) for assistance.
Histamine H2 Receptor Antagonist
ACTIONS AND
CLINICAL PHARMACOLOGY
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PEPCID® (famotidine) is a competitive inhibitor of
histamine H2-receptors. The prim ary clinically
important pharmacologic activity of PEPCID® is
inhibition of gastric ju ice secretion. PEPCID®
reduces the acid and pepsin content, as well as the
volume, of basal, nocturnal, and stimulated gastric
secretion.

INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment
of the following conditions where a controlled
reduction of gastric secretion is required for ulcer
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory
conditions (e.g., Zollinger-Ellison syndrome).
PEPCID® I.V. is indicated in some hospitalized
patients with pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage forms for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
H y p e rs e n s itiv ity to any c o m p o n e n t of this
medication.

PEPCID® (famotidine) is usually well tolerated;
most adverse reactions have been mild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.
The following adverse reactions have been reported
at a rate of greater than 1% in patients on therapy
with PEPCID® in controlled clinical trials, and may
be causally related to the drug: headache (4.6%),
dizziness (1.2%), constipation (1.2%) and diarrhea
( 1. 6% ) .
Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.
Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychlatric

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory

4.4%

Bronchospasm
Body as a Whole

3.0%

Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in
patients w ith advanced renal in s u ffic ie n c y
(creatinine clearance <10 mL/min.) to adjust for the
longer elim ination half-life of famotidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION.)

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1.7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Skin

1.7%

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Cardiovascular

1.0%

Use in Gastric Ulcer
Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.
Use In Pregnancy
Reproductive studies have been performed in rats
and rabbits at oral doses o f up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of impaired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or wellcontrolled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema
Urogenital

Jk /**

~A i

A *

<0.1%

PRECAUTIONS

Drug Interactions
Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e g., cytochrome
P450 system. Compounds tested in man have
included w a rfa rin , th e o p h y llin e , phenytoin,
diazepam, am inopyrine and antipyrine. Indo
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.
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0.1%
0.1%
<0.1%
0.9%

The adverse reactions reported for PEPCID®
Tablets may also occur with PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
Laboratory Abnormalities
Laboratory parameters may be affected during
treatment with PEPCID®, but the changes are
usu ally not co n sid e re d serious. Among the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.
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Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

Parenteral Products

The oral LD50 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy

The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for
4-8 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy

For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtime, fo r a duration of up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy

Other effects

Dilution of PEPCID® I.V.
for Infusion

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 640 mg/day have been
employed in patients with pathological hyper
secretory conditions with no serious adverse
effects. In the event of overdosage, treatment
should be sym ptom atic and supportive. Un
absorbed material should be removed from the
ga strointestina l tra ct, the pa tie n t should be
monitored, and supportive therapy should be
employed.

emptying and exocrine pancreatic function are not
affected by PEPCID®.

RECONSTITUTION

V o L ...a of
P E P C ID ® I.V .

C o m p a tib le

F in a l

F in a l

R a te of

S o lu tio n

I.V . S o lu tio n

V o lu m e

C o n c e n tra tio n

In fu s io n

2m L

3 mL

5 mL

4 m g /m L

N o t le s s th a n

2 mL

8m L

10 m L

2 m g /m L

N o t le s s th a n

2 m in u t e s

2 m in u t e s
2 mL

100 m L

102 m L

0 . 1 9 6 m g /m L

1 5 - 3 0 m in u t e s

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer's Injection
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution

Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
a llo w s u ffic ie n t tim e to s o lu b iliz e a ll th e
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: P arenteral d rug p ro d u c ts s h o u ld be
inspected visually for particulate matter and
disco lo u ra tio n p rio r to a d m inistra tion
whenever solution and container permit.

DOSAGE FORMS AND AVAILABILITY

The recommended adult oral dosage for acute
benign gastric ulcer is 40 mg once a day at bedtime.
Treatment should be given for 4 to 8 weeks, but the
duration of treatment may be shortened if healing
can be documented.

T a b le ts PEPCID® (fa m o tid in e ta b le ts ) are
D-shaped, film-coated tablets supplied as follows:

P A T H O L O G IC A L H Y P E R S E C R E T O R Y C O N 
D IT IO N S (S U C H AS Z O L L IN G E R -E L L IS O N
SYNDROME)

No. Ca 8103 - 40 mg light brownish orange,
coded 964. Available in bottles of 100 tablets.

The do sage o f PEPCID® in p a tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose for pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required.
Doses should be adjusted to individual patient
needs and should continue as long as clinically
indicated. Doses up to 160 mg q6h have been
ad m inistered to some p a tie n ts w ith severe
Zollinger-Ellison syndrome
Intravenous Administration

In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids

Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal
Insufficiency

In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min.,
the elimination half-life of PEPCID® may exceed
12 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient’s clinical
response.

PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets

Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection

Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
in a c tiv e in g re d ie n ts : L -a s p a rtic acid 4 mg,
mannitol 20 mg, and Water for Injection, q.s., 1 mL.
The multidose injection also contains benzyl
alcohol 0.9% added as preservative.

No. Ca 8102 - 20 mg b e ig e c o lo u re d ,
coded 963. Available in bottles of 100 tablets.

No. Ca3539 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 10 x 2 mL vials.
No. Ca3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
preserved m u ltip le dose c o n ta in in g 4 mL of
injectable solution. Available in 4 mL vials.

HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the antisecretory effect occurred within one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of 10
and 20 mg inhibited basal nocturnal secretion fo ra
period of 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhibited basal nocturnal acid secretion in all
subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, for a period of at least
10 hours. Sim ilar doses given in the m orning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after drug, and of 25% and
30%, respectively, 8 to 10 hours a fte r drug;
however, in some subjects who received the 20 mg
dose, the antisecretory effect was dissipated earlier,
within 6-8 hours. There was no cumulative effect
with repeated doses. The basal nocturnal intragastric pH was raised by evening doses of 20 and
40 mg of PEPCID® to mean values of 5.0 and 6.4,
respectively. When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be s lig h tly elevated d u rin g periods o f drug
antisecretory effect, and with chronic therapy an
increase in gastric bacterial flora may occur. Gastric

Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory o r endocrine
systems have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics

PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may be
slightly increased by food, or slightly decreased by
acntacids; however, these effects are of no clinical
consequence. PEPCID® undergoes minimal firstpass metabolism. After oral doses, peak plasma
levels occur in 1-3 hours. Plasma levels after
multiple doses are sim ilar to those after single
doses Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3.5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 m L/m in., indicating some
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an
intravenous dose are recovered in the urine as
unchanged co m p o u n d . The o n ly m e tabolite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
with severe renal insufficie ncy, i.e., creatinine
clearance less than 10 mL/min., PEPCID® elim i
n a tio n h a lf - life m ay e xce e d 20 hours and
adjustment of dosing intervals may be necessary
(see PRECAUTIONS, DOSAGE AND ADMINIS
TR ATIO N ). In e ld e rly pa tients, the re are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.
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ORIGINAL ARTICLES

Nonparasitic Splenic Cysts: a Case Report
and Review
P. Ehrlich, BSc; C.G. Jamieson, MB, BS, FRCSC, FACS
Cysts of the spleen are rare but usually benign. The authors describe the case of a
young woman with a splenic cyst who underwent splenectomy.
Ultrasonography and computed tomography have helped improve the
preoperative diagnosis of nonparasitic splenic cysts, and as the use of
ultrasonography increases, so will the finding of incidental splenic cysts. Whether
all splenic cysts enlarge is unknown, and it is uncertain whether all small
asymptomatic cysts need treatment. The cysts may enlarge, become infected or
rupture. Total splenectomy has been the most common treatment in the past, but,
because of the risk of postsplenectomy sepsis, partial splenectomy may be preferred
when technically possible.

Les kystes de la rate sont rares mais habituellement benins. Les auteurs decrivent le
cas d’une jeune femme, porteuse d’un kyste de la rate, qui a subi une splenectomie.
L’echographie et la tomographie axiale ont contribue a ameliorer le diagnostic
preoperatoire des kystes spleniques non parasitaires et, avec l’utilisation croissante
de l’echographie, on peut s’attendre a voir augmenter la detection des kystes
spleniques fortuits. On ignore si tous les kystes spleniques augmentent de taille, et
on ne sait si tous les petits kystes asymptomatiques necessitent un traitement. Les
kystes peuvent croitre, s ’infecter ou se rupturer. Dans le passe, la splenectomie
totale a ete le traitement le plus courant. Toutefois, a cause du risque de sepsie
post-splenectomie, une splenectomie partielle peut etre preferable lorsqu’elle est
techniquement possible.

lthough nonparasitic splenic
cysts are uncommon, the first
case was reported in 1829 by Andral, and the first surgical treat
ment by Pean in 1 8 6 7 . We report
a case of a benign splenic cyst and
review the published reports of this
condition.

A

Case Report
A 25-year-old nulliparous woman
presented with splenomegaly. Her

medical history was unremarkable
as was her family history. She had
been taking an oral contraceptive
for 10 years.
The incidental finding of spleno
megaly was first noted by her family
doctor. She had complained of
crampy intermittent abdominal pain
in the left lower and right upper
quadrants for the previous 3
months and had also complained of
intermittent diarrhea and constipa
tion. There were no symptoms of
weight loss, fever, chills or night
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sweats. There was no history of
trauma or foreign travel.
On physical examination there
was a palpable mass 4 cm below the
left costal margin, but no other
abnormalities and no palpable lymphadenopathy. Hematologic indices
were all normal. Ultrasonography
suggested a splenic cyst.
At laparotomy a large hard
spleen was found adherent to the
diaphragm and containing multiple
cysts. The liver and other intra
abdominal organs appeared normal
and there was no retroperitoneal
lymphadenopathy. Splenectomy was
uncomplicated.
The spleen weighed 1585 g and
contained multiple unilocular cysts
with a large central cyst that mea
sured 15 cm and was filled with
clear yellow fluid. Culture of this
fluid failed to demonstrate any or
ganisms. The epithelial lining was
composed of a single layer of strati
fied squamous cells with one single
area of keratinization. There were
areas in the large cyst without
epithelial lining, and other areas
showed signs of previous hemorrh
age into the wall of the cyst. The
features were considered to be con
sistent with an epidermoid cyst.
There was no evidence of an infec
tious or traumatic process.
The patient made an uncompli
cated recovery.

Discussion
Primary cysts of the spleen are
uncommon. Worldwide, parasitic
(i.e., hydatid) cysts are more com-

NONPARASITIC SPLENIC CYSTS

mon than nonparasitic cysts,6 but
these are rare in North America.
Fowler’s original classification3 in
cluded subcategories of nonparasit
ic cysts such as epithelial, inflam
matory and neoplastic. A revised
and more practical grouping by
Martin7 includes congenital and
neoplastic cysts.
A classification of the types of
splenic cysts is shown in Fig. 1.
Splenic cysts can be divided into
“true” and “pseudo” cysts, the
difference being the presence or
absence of an epithelial lining.
True cysts comprise two large
categories, parasitic and nonparasit
ic cysts. The nonparasitic cysts in
clude neoplastic, congenital, vascu
lar and infectious varieties. Pseudo

FIG. 1. Classification of splenic cysts.

cysts are generally the result of
trauma. Congenital cysts constitute
25% of nonparasitic cysts6 and are
epithelial cysts, described as epider
moid, dermoid or simple cysts, of
which epidermoid is the most com
mon. The cysts may be single or
multiple, and may be uni- or multilocular. Ough, Nash and Wood in
1981® reported on studies in the
development of congenital splenic
cysts. After examining fetal and
adult spleens, they concluded that
most epithelial cysts (excluding der
moid cysts) are of the same entity.
They proposed that the spleen, like
other abdominal organs, is lined
with pluripotential mesothelium; a
cyst is formed when there is invagi
nation of the splenic capsule during

development. The cells, being pluri
potential, result in a variety of
epithelia, which may in turn result
in focal metaplasia. Thus, they sug
gested the term “mesothelial cysts
of the spleen with squamous meta
plasia”.
The cause of the progressive ex
pansion of cysts is unknown, al
though trauma may cause bleeding
in an already enlarged spleen. Pri
mary dermoid cysts of the spleen
are exceedingly rare and many are
thought to originate from other
sources.3
Pseudocysts (described as having
no epithelial lining) are generally a
result of trauma.3 Excluding para
sitic cysts they constitute 75% of all
splenic cysts. It is thought that
trauma results in bleeding which
leads to encapsulation, expansion
and persistence of a cavity. True
cysts also may undergo degenera
tion as a result of pressure from
hemorrhage secondary to trauma
and may lose their cellular lining.8
Splenic cysts are most common
in the second or third decade of life.
The symptoms of a splenic cyst are
related to the presence of a mass.
An asymptomatic painless mass is
the presenting feature in 30% to
45% of cases, sometimes as an
enlarging abdomen noticed by the
patient’s parents.5 The symptoms
are primarily gastrointestinal, and
the classic description is that of a
dragging sensation in the abdo
men,8 which may be a recurrent
intermittent dull pain unrelieved by
food or antacids. The pain is vague
and associated with early satiety.
Pulmonary symptoms including
pleuritic chest pain, shortness of
breath and left shoulder pain
are not uncommon9 and may result
from low-grade inflammation, re
sulting in adhesions of the spleen to
the diaphragm. The spleen may
compress the left kidney,1 leading
to renal colic and displacement.
Hypertension has been reported as
CJS, VOL. 33, NO. 4, AUGUST 1990
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secondary to renal artery compres
sion.10 Menstrual and bladder symp
toms may result from the enlarged
spleen,5 and a relationship to the
menstrual cycle and pregnancy has
been described.1
The major complications include
infection and rupture.11 The spleen
may rupture spontaneously or as a
result of trauma, and up to 25% of
splenic cysts may present in this
way.2 Trauma may be the primary
cause of the cyst or may complicate
a cyst already present and result in
further enlargement. The trauma
may be a recent or a remote event,1
with the average interval between
the trauma and splenomegaly being
approximately 18 months.12 A sple
nic cyst may bleed spontaneously,
resulting in either a slow or rapid
enlargement, or acute abdominal
pain.11
If a splenic cyst is suspected,
hydatid disease must be considered
before surgery. A history of resi
dence in an endemic area may raise
this possibility, and serologic inves
tigations are indicated.78 Hemato
logic investigations are usually nor
mal with a nonparasitic splenic cyst.
Although hypersplenism has been
reported, most authors feel this is
coincidental rather than causal.713
A chest film may show an elevated
left hemidiaphragm or a left pleural
effusion.179 Abdominal x-ray films
and barium studies may show dis
placement of the left kidney, stom
ach or splenic flexure of the colon.
Liver-spleen isotope scans are often
normal.1 Angiography may distin
guish a tumour from a cyst but is
rarely necessary. Typically it shows
intrasplenic vessels surrounding an
avascular space.13 The primary radi
ologic tools are ultrasonography
and computed tomography.113-15 On
ultrasonography, splenic cysts are
homogeneous echo-free lesions
with a smooth well-defined acoustic
wall, but ribs, bowel gas, fat and
multiple cysts may limit this tech
308
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nique. Computed tomography helps
define the mass and rule out other
disease; typically it shows a round
mass having the density of water
with no enhancement with contrast.
Even with modern imaging tech
niques the diagnosis of benign sple
nic cysts may be difficult to estab
lish.
Surgery is the treatment of
choice for nonparasitic splenic
cysts. Fowler’s review in 19403 rec
ommended total splenectomy rather
than puncture, incision and drain
age, or marsupialization. The un
derstanding and awareness of post
splenectomy sepsis has resulted in
revised methods of surgical treat
ment.16-19 The risk of postsplenec
tomy sepsis and young age of the
patients has resulted in alternative
surgical methods.20-27 Partial sple
nectomy (when technically possible)
and autotransplantation have been
reported as successful. If total sple
nectomy is anticipated, pneumococ
cal vaccine should be given preoperatively.
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T h e Inguinal Sarcoma: a Review of Five
Cases
R.S. Bell, MD, FRCSC;* B. O’Sullivan, MB, FRCPC;t J.L. Mahoney, MD, FRCSC;$
C. Nguyen, MD, FRCSC;§ F. Langer, MD, FRCSC;* C. Catton, MD, FRCPCt
A review of five patients who presented during a 3-year period with sarcoma arising
in the inguinal canal demonstrated that the lesion is frequently mistaken for a
hernia. In three of the patients incomplete excision of the inguinal mass resulted in
spread of the lesion beyond the inguinal canal. The authors suggest that neoplastic
lesions discovered in the inguinal canal should be evaluated by a small incisional
biopsy followed by wide resection if sarcoma is confirmed on pathological
examination. Preoperative irradiation and re-excision should be considered if
widespread microscopic disease remains after excisional biopsy.

L’etude de cinq patients vus au cours d’une periode de 3 ans, alors qu’ils etaient
porteurs d’un sarcome originant du canal inguinal, demontre que cette lesion est
souvent prise pour une hernie. Chez trois de ces patients, l’excision incomplete de la
masse inguinale a entra ne une extension au dela du canal inguinal. Les auteurs
proposent que les lesions neoplasiques decouvertes dans le canal inguinal soient
evaluees par excision-biopsie suivie d’une resection large si un sarcome est confirme
a l’examen pathologique. Une irradiation preoperatoire et une deuxieme excision
doivent etre envisagees si un envahissement microscopique demeure apres l’excision-biopsie.

oft-tissue sarcomas are relative
ly rare (400 to 500 new cases
annually in Canada). Despite this,
the diagnosis is generally straight
forward to the knowledgeable sur
geon, since there are few diseases,
except for sarcoma, which present
as a subfascial mass in an extremi
ty. However, in certain anatomical
locations these sarcomas are diffi

S

cult to diagnose; sarcomas in the
inguinal canal are perhaps the best
example. In the past 3 years, we
have seen five such cases, each of
which was originally thought to be
an inguinal or femoral hernia. The
initial management of four of the
five patients markedly complicated
their definitive care and we there
fore present brief case histories for
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each patient as well as suggestions
for appropriate treatment.

Case Reports
Case 1

A 52-year-old woman presented
with a painless inguinal mass that
was diagnosed as a direct inguinal
hernia. Exploration through a stan
dard transverse hernia approach re
vealed a tumour, which was re
moved en bloc. Despite a diagnosis
of high-grade m: 'ignant fibrous his
tiocytoma, no further treatment or
follow-up was offered until the pa
tient presented 2 years later with a
recurrent mass. Computed tomog
raphy demonstrated a 4-cm lesion
adjacent to the pubic tubercle and
involving the femoral vessels (Fig.
1). Preoperative irradiation (50 Gy)
was given followed by wide resec
tion of the inguinal canal, femoral
vessels and abdominal wall. Vascu
lar reconstruction was with Gor-tex
(W.L. Gore & Associates, Flagstaff,
Ariz.), and the external oblique apo
neurosis was advanced to the thigh
fascia, following a generous relax
ing incision. Wound dehiscence oc
curred 3 weeks after surgery and a
contralateral myocutaneous abdom
inal rectus flap was required for
wound closure. Thirty-two months
later, the patient remained free of
local and systemic disease and had a
good functional result; her only
major complaint was swelling of the
thigh.
CJS, VOL. 33, NO. 4, A U G U S T 1990
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Case 2
A 28-year-old man underwent in
guinal exploration for a presumed
direct inguinal hernia. A high-grade
malignant fibrous histiocytoma was
found and removed; the margins of
the specimen were positive for ma
lignancy. Because of the obvious
microscopic tumour residuum in
the wound, he received radiothera
py (50 Gy) to the entire inguinal
wound, then underwent wide resec
tion of the inguinal canal and sper
matic cord. The abdominal wall was
closed by advancing the external
oblique aponeurosis to the deep
thigh fascia, following a relaxing
incision. Several foci of sarcoma
were found in the specimen, but the
resection margins were disease-free.
There were no complications postoperatively and the patient was well
28 months later.

Case 3
A 31-year-old man underwent
surgery for a presumed femoral
hernia. A tumour was found, but no
attempt was made to remove it.

Incisional biopsy demonstrated a
high-grade liposarcoma. Planning
of radiotherapy preoperatively and
of surgery was greatly assisted by
the presence of residual tumour
mass. Although the lesion approxi
mated the fascia of the femoral
canal, this plane was not violated at
the initial operation, and this fascia
was employed as a tumour margin
in performing a wide resection. A
contralateral rectus myocutaneous
flap was used in abdominal wall
closure. The patient was diseasefree at 18-month follow-up.

Case 4
A 59-year-old man underwent
marginal resection of a high-grade
epidermoid sarcoma discovered in
the inguinal canal at a planned
hernial repair. No further treatment
was offered until 3 months later
when the patient returned with a
6-cm fixed mass extending from the
pubic tubercle to the corpus cavernosum. Systemic staging studies
were negative for metastases and
the patient received radiotherapy
(50 Gy). Repeat staging studies be

fore surgery revealed two pulmo
nary lesions. Because of the prox
imity of the mass to the penis, wide
resection with orchiectomy, partial
resection of the corpus cavernosum
and reconstruction using a contra
lateral rectus abdominis flap was
performed. The patient’s postopera
tive course was uncomplicated. The
lung lesions progressed despite che
motherapy and he is currently alive
with evident disease.

Case 5
A 72-year-old man had partial
resection of a malignant fibrous
histiocytoma discovered at inguinal
herniorrhaphy. The tumour re
curred rapidly, and two more partial
resections, accompanied by adju
vant chemotherapy were performed.
The tumour grew to massive size,
with painful involvement of the
penis before the patient was re
ferred for palliative radiotherapy
(Fig. 2). Preoperative irradiation
was stopped at 40 Gy when the
lesion ulcerated through the skin.
Wide resection was then undertak
en with emasculation combined
with bilateral external iliac dissec
tion and bilateral inguinal canal and
abdominal wall resection. The ab
dominal wall was reconstructed
using a rectus femoris myocutane
ous flap in combination with scrotal
skin. A perineal urethrostomy was
used for bladder drainage. Patho
logical examination of the operative
specimen confirmed that the mar
gins of resection contained healthy
tissue. Six months after surgery the
patient died suddenly and no autop
sy was performed. Immediately be
fore his death, examination and
chest radiography showed him to be
disease-free.

Discussion
FIG. 1. Case 1. Recurrent lesion at pubic tubercle extending to femoral vessels.
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Although inguinal sarcomas have

INGUINAL SARCOMA

received little or no attention in the
literature, our experience with five
cases in 3 years suggests that this
subject should be familiar to sur
geons who perform inguinal herni
orrhaphies.1' 3 We suggest that the
presence of a firm, irreducible mass
in the inguinal canal should be
considered as a tumour rather than
a hernia and that a more limited
approach to the lesion be undertak
en until the surgeon is sure that the
mass is not a neoplasm. This is
especially important because most
tumours arising in the inguinal
canal are sarcomas.13
If a tumour is encountered in the
inguinal or femoral canal, an inci
sional biopsy should be performed
through as small an incision as
possible, and the wound should be
closed. Excision of the lesion
should not be undertaken through
the same wound used to biopsy the
lesion.1 We have shown, in a retro
spective review of 100 patients with
soft-tissue sarcoma, that excision
accompanied by histologically posi

tive resection margins results in
local recurrence of the sarcoma in
50% of patients, despite the provi
sion of postoperative adjuvant ra
diotherapy.4 Excision of a sarcoma
after exposure of the lesion will
inevitably result in contamination of
the wound by microscopic disease.
Since the dissection necessary to
perform a marginal resection is
often extensive, microscopic disease
may well be spread beyond the
fascial limits of the inguinal canal.
This extension of tumour outside
the inguinal canal was seen in three
of our patients. Tumour extension
in case 1 encompassed the femoral
vessels, and in cases 4 and 5 recur
rent tumour was found medially at
the pubic tubercle and even extend
ed to the contralateral inguinal
canal and base of the penis. The
value of limited exposure in per
forming a biopsy is demonstrated in
case 3. If the surgeon had attempt
ed to excise the lesion arising in the
femoral canal, the femoral vessels
would likely have been contaminat

FIG. 2. Case 5. Massive recurrent sarcoma extending to both inguinal canals and
surrounding penis and testicles.

ed, requiring a much more complex
definitive resection.
The presence of the tumour in
situ after incisional biopsy assists
the radiation oncologist in planning
preoperative radiotherapy and facili
tates the planning of the definitive
surgical resection on the basis of
computed tomography and magnet
ic resonance imaging. Because ade
quately wide resection of the ingui
nal region requires extensive dissec
tion of the retroperitoneal iliac and
femoral vessels and the femoral
nerve to free these structures from
the site o f tumour origin, we prefer
to irradiate the site of tumour ori
gin before resection. If postopera
tive irradiation is used, it is neces
sary to include the entire surgical
field that may be contaminated by
microscopic disease. In the case of
lesions arising in the inguinal canal,
a treatment field would be much
larger postoperatively. Preoperative
irradiation not only decreases the
volume o f normal tissue exposed to
irradiation but also avoids irradia
tion of th e peritoneal contents. Al
though our early experience with
preoperative irradiation in difficult
tumours was associated with a sub
stantial incidence of wound dehis
cence and infection,5 our recent use
of vascularized tissue transfer from
outside th e irradiated field has re
duced our incidence of wound com
plications markedly.6
The use of vascularized tissue
transfers necessitates that histologi
cally tum our-free margins be
achieved at resection to prevent
contamination of the donor site.
Accordingly, detailed pathological
assessment of the lesion according
to a rigorous protocol is undertak
en in the surgical pathology suite
before th e donor muscle is har
vested. For lesions of the inguinal
canal, we prefer to use a contralat
eral rectus abdominis myocutaneous transfer (since the ipsilateral
inferior epigastric vessel is usually
CJS, VOL. 33. NO. 4. AUGUST 1990
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sacrificed at resection). For massive
lesions, such as in case 5, which
require resection of both inguinal
canals and both inferior epigastric
arteries, a rectus femoris myocutaneous flap is preferred.
In summary, optimal manage
ment of inguinal canal sarcomas is
exemplified by our case 3. A pre
sumed femoral hernia was explored
through a limited incision which
revealed a tumour. A small incision
al biopsy was performed and the
patient referred to a multidiscipli
nary centre for management. Preop
erative staging studies demonstrat
ed the femoral triangle fascia to be
intact, permitting a wide resection
with tumour-free margins and pres
ervation of the femoral vessels after
preoperative irradiation.
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In vitro stud ies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7a position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fe ctio n s caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the suscepti
b ilit y of the causative o rg a n ism (s) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus inlluenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m ethicillinr e s is ta n t s ta p h y lo c o c c i and L is te ria
monocytogenes
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.

Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the incidence of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.
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CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS

*

Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillinsorotherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous co litis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.
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PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100£ig/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if w ith
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m in is tra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should betaken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.
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Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
to pregnant patients is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g /kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a c u lo p a p u la r rash, u rtic a ria , p ru ritu s,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after a n tibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDFI, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating conditions as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g o r 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by
severity of infection, s u sce p tib ility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.

Usual Adult Dosage
Type of
Infection

Dally
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

'Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
fo r at least 10 days to guard against the risk of
rheum atic fever or g lom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients w ith
reduced renal function but a reduced dosage
should be employed and it is advisable to
m onitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:

A t p re s e n t th e re is in s u ffic ie n t data to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recom m endations fo r adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdom inal hysterectom y and
abdominal surgery
2 g adm in iste re d in tra m u scu la rly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
adm inistered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intramus
cularly four hours and eight hours after the first
dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored
b e lo w 30°C . The d ry m aterial as well as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

(332-a,4,89)
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION

CREATININE
CLEARANCE
mL/min

Mild
impairment
Moderate
impairment
Severe
impairment
Essentially
no function

DOSE

MERCK

FREQUENCY

| PAAB
50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

In patients un d erg o in g hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADM INISTRATIO N in the com plete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

MSP

3386

20-40 mg/kg every 12 h I.V.

Neonates

01 week of age 20-40 mg/kg every 12 h I.V.
1- 4 weeks of age
20-40 mg/kg every 8 h I.V.
Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and ch ild ren may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.
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Prospective and Retrospective Analysis
of Colonoscopy Findings in Patients With
a History of Colorectal Carcinoma
in First-Degree Relatives
Wojciech Brzezinski, MD;* W.J. Orrom, MD, MSc, FRCSC;t E. Wiens, MD, FRCSCJ
The frequency of colorectal neoplasia was assessed by colonoscopy in 48 patients
with a history of colorectal cancer in a first-degree relative. Twelve of these patients
were found to have polyps in the colon, including 1 who had invasive cancer.
Patients with multiple first-degree relatives who have a history of colorectal cancer
were found to be at increased risk, 56% having colonoscopic findings positive for
polyps. Of the 12 patients with positive colonoscopic findings, 5 (42%) had multiple
lesions. These findings are similar to those reported in recent pedigree studies and
further support a genetic basis for common colorectal cancer. First-degree relatives
of patients with colorectal cancer should be considered a high-risk group for
colorectal neoplasia. Screening with colonoscopy is recommended.

La frequence des neoplasies du colon et du rectum a ete evaluee par colonoscopie
chez 48 sujets dont un parent du premier degre avait souffert d’un cancer colorectal.
Des polypes du colon ont ete decouverts chez 12 personnes; dans 1 cas, il y avait
presence d’un cancer invasif, alors que 5 sujets etaient porteurs de polypes
multiples. Ceux qui avaient plusieurs parents du premier degre victimes de cancers
colorectaux, avaient eux-meme un risque accru; des polypes ont ete observes chez
56% d’entre-eux. Ces resultats sont similaires a ceux qui ont ete rapportes lors
d’etudes genealogiquts recentes et apportent des arguments supplementaires a
l’appui d’une base genetique au cancer colorectal. Les auteurs croient que les
personnes qui ont un parent du premier degre avec des antecedents de cancer
colorectal doivent etre consideres a risque eleve, et ils proposent des directives pour
l’utilisation de la colonoscopie comme moyen de depistage dans de tels cas.

H

eredity plays an important role
in the development of colorec
tal cancers. An association of the
polyposis syndromes with colorectal
cancer has been known for over two
decades. In the last decade other
hereditary forms of colorectal can
cer have been well documented

from detailed pedigree studies.
Lynch and colleagues1 described he
reditary nonpolyposis colorectal
cancer, which includes a large num
ber of hereditary syndromes (e.g.,
cancer family syndrome). These en
tities characteristically show an in
creased number of cases of right
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sided colonic malignant disease,
young age of the affected patients
and often multiple primary tumours
(colonic and noncolonic).1-5 It seems
that an autosomal dominant pattern
of transmission is responsible in
these syndromes.67 In all cases of
colorectal cancer, hereditary cancer
syndromes are responsible for ap
proximately 5% to 6%.48 In compar
ison, familial polyposis syndrome is
responsible for less than 1% of all
cases.8
The problem of increased risk of
colorectal cancer in first-degree rel
atives of patients with this disease
was assessed as early as 1958,
when it was found to be three times
greater than in the general popula
tion.9 In 1976, Lovett10 reported a
family history of colonic cancer in
26% of patients with this disease.
Studies by Burt and colleagues11
published in 1985 implicated an
inherited autosomal dominant sus
ceptibility in a large kindred, with
numerous cases of colorectal can
cer. A similar result was obtained
when another 33 family members
were studied in a similar way.12
The goal of this study was to
determine the prevalence of neo
plastic changes in the first-degree
relatives of patients who had colo
rectal malignant disease and to out
line a surveillance program for this
group of patients.

Patients and Methods
Between

January

1988

and

COLONOSCOPY IN RELATIVES OF COLORECTAL CANCER PATIENTS

March 1989, patients with a history
of colorectal cancer in a first-degree
relative were studied. The patients
were over 25 years of age because
adenomatous polyps rarely occur in
younger patients.13 There were 48
patients (28 women, 20 men) with a
mean age of 53 years (range from
31 to 86 years).
A complete history was obtained
from each patient. All were asymp
tomatic for colorectal disease. No
formal documentation of their fami
ly history of colorectal cancer was
sought.
A complete examination of the
colon was performed using an 01mypus CF-1T20L 168-cm colonoscope (Olympus Corp., Lake Suc
cess, NY) after a 2-day preparation
of the colon. The entire mucosa was
systematically examined, and all
polyps found, their location and
size were recorded. In patients with
multiple lesions, every attempt was
made to remove or at least biopsy
all lesions. In 3 of the 48 examina
tions the right colon was not
reached. All three had no positive
findings.
The histologic slides were exam
ined independently.

Results
The type of family relationships
is shown on Table I. Twelve pa
tients (25%) had positive findings
on colonoscopy; 2 of them had a
hyperplastic polyp only, 9 had tubu
lar adenomas and 1 invasive carci
noma. In 5 of the 12 patients
polyps were multiple, including the
patient with carcinoma, who also
had multiple adenomatous polyps
(42% of positive colonoscopies).
The majority of adenomas were 1
cm in dimension or larger (Table II)
and most were found on the left
side of the colon (Table III).
Nine of the 48 patients in the
study had multiple first-degree rela

tives with colorectal cancer. Five of
them (56%) had positive findings on
colonoscopy (4 with adenoma and 1
with hyperplasia) and are included
with the 12 patients who had posi
tive colonoscopies.

Discussion
Inherited susceptibility to colo
rectal cancer is perhaps one of the
most important factors in the
pathogenesis of this disease. Rou
tine screening of the general popu
lation for colorectal neoplasia is not
cost-effective. It is clear that pre
vention rather than treatment of the
fully developed disease, would be
more beneficial for the patients, as
well as for cost-conscious govern
ments. Efforts concentrated on
screening the high-risk groups
could improve patient survival and
cost-effectiveness.
Our analysis of unrelated patients
with a history of colorectal cancer
in a first-degree relative revealed a
frequency of colorectal neoplasms
of 25%, more than twice the in
crease over the controls reported by
Burt and colleagues11 (9%) and Cannon-Albright and associates12 (12%),
as well as the prevalence in the
general population reported by Ujszaszy and associates13 (8.9%). The
patients with multiple first-degree
relatives involved appear at even
greater risk (56% positive colono
scopies in our study). These obser
vations support a genetic basis for
common colorectal cancer. A simi
lar result was obtained when a
larger, prospective, communitybased study was undertaken and
analysed.14 There is growing evi
dence in the literature that hyper
plastic polyps may represent an
early stage of colonic neoplasia.15
Therefore, we elected to classify
patients with hyperplastic polyps as
having colonoscopy positive for
neoplasia.

We propose the following guide
lines for screening and follow-up of
patients with a history of colorectal
cancer in first-degree relatives.
• Patients should be pursued
for entry into a surveillance pro
gram.
• Initial colonoscopy should be
done at the age of 40 years. Earlier
examination should not be discour
aged especially if a particularly
strong family history exists.
• After a positive examination,
repeat colonoscopy every 1 to 2
years is recommended until nega
tive.
• After a negative colonoscopy,
examination should be repeated in 5
years (polyp cancer transformation
does not occur in less that 5
years.16
• Careful follow-up is important
since the increased risk of colorec
tal neoplasia is life-long.
We thank the Medical Records Depart
ment, Royal Alexandra Hospital, Ed
monton, for help in preparing the data
and Ms. Dorothy Olson for preparation
of the manuscript.

Table 1. Family Relationships (48 Patients)
Relationship

No. (%)

Father
Mother
Brother
Sister

19(40)
21 (44)
7(15)
9(19)

Table II. Polyp Size
Tubular
adenomas

Hyperplastic
polyps

3
1

1
1

> 1

5

0

Totals

9

2

Size, cm

< 0.5
0.5 - 0.9

Table III. Location of Lesions
Location

Rectum
Left colon
Transverse colon
Right colon

No.

2
8
2
3
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This book is intended to provide an
overview of the vestibular system and
its disorders. I think the authors have
done a credible job. The text is divided
into three sections: the vestibular sys
tem (anatomy and physiology), evalua
tion of the dizzy patient and manage
ment of common neurotologic disor
ders.
The section on the vestibular system
is easy to read and, I thought, quite
complete without getting too deeply
into detailed neurophysiology and los
ing me in the process. It clearly outlines
vestibular function and all the vestibu
lar reflexes that must be understood in
order to sort out vestibular disorders
and the tests available to assist in their
diagnoses.
The section on assessment of the
dizzy patient appropriately focuses on
the clinical features. As is the case in
clinical practice, the focus is on accu
rate history-taking followed by otoneurologic examination. Numerous condi
tions associated with (and frequently
confused with) vestibular disease are
discussed. Nystagmus and its many
forms are clearly described. The type of
neurologic examination required in the
dizzy patient is defined.
The principles of electronystagmog
raphy (ENG) and the standard test
procedure are helpful in outlining the
role and limitations of ENG. A clear
advantage of ENG is its superior ability
to elicit and document pathologic nys
tagmus or vestibulocular dysfunction. A
separate chapter is dedicated to new
techniques of rotational testing and
mention is made of posturography and
vestibular-evoked potentials.
I was pleased to see auditory func
tion included in the assessment of the
dizzy patient. The chapter correctly
focuses on the role of routine pure-tone
audiometry and the newer, more accu

rate, techniques of brainstem evoked
response audiometry (BERA). Little
mention is made of older, outdated
special auditory tests.
The final section on dizziness and
management of common disorders cov
ers most pathologic conditions of the
vestibular system. More detail could
have been provided in certain areas,
particularly in those common disorders
of benign postural vertigo and Me
niere’s disease. There could have been
more discussion about the various med
ical and surgical techniques available
for managing Meniere’s disease and
some of the controversies surrounding
them. The book, however, is more of an
overview than a definitive text on each
subject. Therefore the authors have a
difficult task in avoiding excessive de
tail.
I enjoyed reading this book. My
practice in otolaryngology includes, but
does not focus on, otoneurology. I
found the book to be informative, and it
restored some long-forgotten features
of vestibular physiology and testing.
The text would be most useful to
trainees in otolaryngology and neurolo
gy and informative to generalists who
also manage dizzy patients. It should be
included in any general hospital library
and the departmental libraries of oto
laryngology and neurology. It will be
a good reference text for all practition
ers of otolaryngology and neurology. It
is moderately expensive but of good
value.
Paul F. Odell. MD, FRCSC
Chairman,
Department o f Otolaryngology,
University o f Ottawa,
Ottawa, Ont.

CURRENT CRITICAL PROBLEMS IN
VASCULAR SURGERY. Edited by
Frank J. Veith. 587 pp. Illust. Quality
Medical Publishing Inc., St. Louis, Mo.
1989. $69.95 (US). ISBN 0 -9 4 2 2 1 9 01-5

Vascular surgery is still a relatively
young specialty, and it has evolved so
quickly that it is difficult for a busy

vascular surgeon to keep up with all
the advances. This book presents a
good update on trends in many vascular
topics. It covers the complete practice
of a vascular surgeon from manpower
issues to the use of lasers and comput
ers.
This is not a textbook. It is not a
book for the junior trainee looking for
basic knowledge in the vascular field
but is an excellent reference book for
the fellow or vascular surgeon who
wants to reach his own conclusions
about controversial topics. Most of the
difficult topics are discussed by authors
with a specific interest in the area. The
majority are from North America. Even
though answers to every question
raised are not supplied, controversial
issues are discussed, supporting data
are supplied for each side of the argu
ment and the author’s own preference
is given. Previous and ongoing studies
used in solving the controversial issues
are also presented and discussed.
This is a well-organized book with
109 concise chapters focused on the
different aspects of vascular surgery.
The writing is lucid and the liberal use
of diagrams, tables and figures, with
high-quality photographs, greatly en
riches the text.
The strength of this book is the
highlighting of potential new horizons
or areas into which vascular surgeons
might expand their activity. The present
edition admirably fulfils the goal out
lined by the author: addressing the
technical progress, innovations, impor
tant precautions and new horizons in
vascular surgery. As mentioned in the
preface, the information presented in
this book is essential knowledge for
vascular surgeons and others who want
to keep pace with all that is new and
important in the treatment of vascular
diseases.
I highly recommend this book to any
senior trainee or vascular surgeon. It is
well worth the price.
J-F. Morin, MD, FRCSC
Cardiovascular surgery,
The M o n tre al General Hospital,
Montreal. H Q
H 3 G 1A4
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FIBROLAMELLAR HEPATOCELLULAR CARCINOMA: AGGRES
SIVE SURGERY RESULTS IN LONG-TERM SURVIVAL. P. Sheiner,
B. Langer, B.R. Taylor, P. Greig. Department of Surgery, University
of Toronto, Toronto General Hospital, Toronto, Ont.
Fibrolamellar carcinoma is an unusual variant of hepatocellular carcino
ma, occurring in younger patients, unassociated with hepatitis B virus
infection or underlying cirrhosis and with distinct pathological features.
Between 1982 and 1989, nine patients underwent resection for
fibrolamellar carcinoma. The average age was 32 years (19 to 57 years).
All were hepatitis-B negative. Operations included right liver resection
(five), left lobectomy (two), left lateral segmentectomy (one), extended
resection with lymph-node dissection (one). Three patients are free of
disease 26, 54 and 84 months postoperatively. One patient had a formal
re-resection 8 months after segmentectomy because of positive margins
and has been disease-free for 72 months. Four patients had recurrence
at 13, 15, 41 and 72 months after the first resection. Two had further
resections (one formal right lobectomy, one radical nephrectomy) and
have been disease-free for another 42 and 42 months. One patient with
massive recurrence in the liver had a liver transplant and is disease-free
at 7 months. One patient with extensive disease at initial operation
expired at 14 months. Seven out of nine patients (77.8%) are alive and
disease-free at 26 to 84 months since diagnosis (average 69 months).
Fibrolamellar carcinoma has a natural history that lends itself to
radical surgical therapy. Our experience suggests an aggressive ap
proach is worthwhile, including (a) radical surgical resection even with
extensive disease, (b) re-resection for recurrent disease and (c) liver
transplantation when necessary for complete removal of all tumour.
246

THE PREOPERATIVE APACHE II SCORE IN RIGHT HEPATECTOMIES FOR LIVER TUMOURS. M. Gagner, C. Vons, D. Franco,
J.W. Braasch. Department of Surgery, Hotel-Dieu de Montreal,
Montreal, Hopital Paul-Brousse, Villejuif, France and Lahey Clinic,
Burlington, Mass.
The APACHE II score, a severity of disease classification comprises the
sum of points given for age (A), physiological assessment (PA) and
chronic health evaluation (CHE) and has been shown to predict
mortality in intensive care unit patients. The objective was to evaluate
the ability of the APACHE II score to predict morbidity and mortality in
major surgery for liver tumours. We reviewed the charts of 65 patients
who had right hepatectomy for liver tumours between January 1980
and September 1989. The patients were divided into three groups
according to the preoperative APACHE II score; low (0 to 3), mid (4 to
7) and high (8 or more). The postoperative morbidity and operative
mortality increases as the preoperative APACHE II score increases.
Patients in the low-score group had a morbidity of 37% and no
mortality: those in the mid-score group had a morbidity of 55% and a
3% mortality and those in the high-score group had a morbidity of 83%
and a 17% mortality. We also looked at the APACHE II score minus the
age points (APACHE II —A) to look at the effect of only PA and CHE.
The patients with no points for PA and CHE (age being the only risk)
have a much lower morbidity (20%) and no mortality as opposed to
those who have points for PA or/and CHE, who have a threefold risk (p
< 0.01 Fisher’s exact test). We conclude that the preoperative APACHE
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II score correlates with postoperative morbidity and mortality in major
surgery for liver tumours. The effect of chronic health evaluation points
and physiologic assessment points on morbidity and mortality are
greater than the effect of age points alone. It may be used by clinicians
to predict morbidity and mortality and may identify a high-risk group of
patients who perhaps should be considered for therapeutic alternatives.
247

THE ROLE OF LOCAL EXCISION FOR ADENOCARCINOMA (CA)
OF THE AMPULLA OF VATER. B.S. Papsin, M. Abecassis, B.
Langer, B.R. Taylor, P.D. Greig. Department of Surgery, University
of Toronto, Toronto General Hospital, Toronto, Ont.
The standard operation for adenocarcinoma (CA) of the ampulla has
been pancreatoduodenectomy. Radical local excision is a useful tech
nique for treating benign ampullary lesions and has been suggested as
an alternative to pancreatoduodenectomy for ampullary CA, especially
in small lesions discovered early by endoscopic retrograde cholangiopan
creatography. Reported 5-year survival with this technique is from 17%
to 50%. From 1962 to 1989. 22 patients underwent local resection of
small ampullary lesions suspected of being carcinoma. Seven of these
lesions were invasive adenocarcinoma, nine adenoma, one adenoma with
carcinoma-in-situ, two neuroendocrine tumours, two papillitis, one
hamartoma. One patient with CA was converted to a pan
creatoduodenectomy because of positive margins found after local
excision. Two patients developed postoperative pancreatitis. There was
no operative mortality. Two patients having "palliative" local excisions
for CA died of recurrent disease at 6 and 37 months. Two of four
patients having “curative" local excisions for CA have died of recurrent
disease at 1 and 12 years. One has recurrent carcinoma at 10 years, and
one is alive and well at 12 years. During the same period 48 patients
had pancreatoduodenectomy for ampullary CA with an operative
mortality of 4%, and 5-year survival of 26%.
We conclude that local excision is appropriate treatment for benign
tumours of the ampulla and for CA in patients who cannot tolerate
pancreatoduodenectomy. Because of the high incidence of local recur
rence, pancreatoduodenectomy should remain the standard treatment
for proven ampullary carcinoma.
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NUCLEAR SHAPE AS A PROGNOSTIC DISCRIMINANT IN COLO
RECTAL CARCINOMA. B. Mitmaker, L.R. Begin, P.H. Gordon.
Department of Surgery and Department of Pathology, Sir Mortimer B.
Davis-Jewish General Hospital, McGill University, Montreal, PQ
In a search for a more reliable prognostic discriminant, a retrospective
analysis of 100 patients with colorectal carcinoma, having undergone
curative resection and followed for at least 5 years, was assessed by
nuclear morphometry. Each case was staged according to Dukes’
classification and graded histologically. For all patients in this series,
the perimeter, area and shape of 50 interphase nuclei were determined
for both the normal and transitional colonic mucosae as well as for the
carcinoma itself. The information was obtained through the use of an
image analysis system by tracing the nuclear profiles (magnification X
1000) as digitized on a video screen. The nuclear shape factor was
defined as the degree of circularity of the nucleus, a perfect circle
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recorded as 1.0. A nuclear shape greater than 0.84 was associated with
poor outcome. Multiple linear regression models showed that the single
parameter of nuclear shape was the most highly significant predictor of
survival (p < 0.0001). This variable remained highly significant even
when corrected for sex, age, histologic grade and Dukes’ classification.
These findings indicate that a nuclear shape factor > 0.84 as
determined by nuclear morphometry is an independent pathological
variable of great importance in the prognosis of large-bowel cancer.

borderline significance. Differences in swelling were less marked. After
adjustment for parity, previous breast biopsy, first-degree relative with
breast cancer, prior smoking and oral contraceptive use, the association
of cyclical breast pain with breast cancer was significant (p < 0.05). It is
concluded that cyclical mastopathy is associated with breast-cancer risk
in premenopausal women.
251
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MANAGEMENT OF BREAST CANCER IN THE ELDERLY: PREJU
DICE BASED ON AGE? M.C.K. Chan, E.E. Sterns. Department of
Surgery, Queen’s University, Kingston, Ont.

Pressure on the health care system, the increasing number of elderly
patients and the prevalence of breast cancer in this age group has raised
questions as to how these patients should be managed.
This study was undertaken to compare long-term results of treatment
of localized breast cancer in women over 70 years (n = 161) with those
between 55 and 70 years (n = 236). Nodal status, tumour size and
histology were the same in both groups. Surgical management was
similar except that axillary dissection was performed less frequently in
patients over 70 (p = 0.005). Radiotherapy reduced local recurrence
from 14% to 7% (p = 0.01), but fewer women over 70 were treated with
radiotherapy following local excision (“lumpectomy").
The overall (ov), disease-specific (ds) and disease-free (df) survival (%)
at 5 and 10 years is as follows:

Over 70 yr

55 to 70 yr
Time span, yr

OV

ds

df

OV

ds

df

5
10

81
60

87
72

76
62

70
39

81
75

81
75

NON-TERTIARY SURGERY IN MANITOBA: COMPARISON OF
PROVINCIAL WITH TEACHING HOSPITAL DATA. R.J. Blanchard.
Department of Surgery, University of Manitoba, Winnipeg, Man.

The objective of this study was to determine whether the surgical
experience available in Manitoba’s two teaching hospitals was relevant
to the nontertiary surgical needs in the province.
The following methods were employed: (a) Manitoba Health Services
Commission (MHSC) data for all operations in the province during 1985
and 1986 were downloaded into a PC computer: (b) all operations
performed in the two teaching hospitals were similarly downloaded and
separated into specialty sections (programs) prior to downloading; (c)
for both databases, the procedures were lumped into categories such as
"thyroid surgery” ; (d) provincial operations were separated into special
ty groups; (e) each operation was labelled either “ tertiary" or “ nonterti
ary’’.
In Manitoba there were 110 608 nontertiary operations performed in
the 2 years, approximately 5500 operations per 100 000 population per
year. Proportions in the four commonest surgical specialties were:
general surgery 44%, gynecology and operative obstetrics 29%, orthope
dics 17% and urology 10%. Of the 20 commonest operations in the
province. 10 are not usually included in general surgery training
programs. There were less than 10 procedures per resident for some
common operations.
The teaching hospitals had relatively even numbers of different
operations whereas the frequency spectrum in the province showed a
steep curve.
252

Evidence suggests that most women over 70 tolerate treatment for
breast cancer as well as those 55 to 70 and achieve comparable ds and
df survival. This suggests that women over 70 treated with local
excision should be offered adjuvant radiotherapy to reduce risk of local
recurrence on the same principles as women under 70, and alternative
methods of management must be judged against this background.
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THE ASSOCIATION OF CYCLICAL MASTOPATHY WITH PRE
MENOPAUSAL BREAST CANCER. P.J. Goodwin, G. DeBoer, R.M.
Clark, P. Catton, S. Redwood, N. Hood, N.F. Boyd. Mount Sinai
Hospital, University of Toronto, Toronto, Ont.

A case-control study was conducted to examine the association of
cyclical breast symptoms with breast-cancer risk in 192 premenopausal
women with axillary-node-negative breast cancer, diagnosed at least 6
months previously, and 192 healthy age-matched controls employed at
one of three large companies. Women with irregular menses, current
use of oral contraceptives or previous systemic therapy for breast cancer
were excluded. Subjects recorded breast pain and swelling in each
breast on a scale of 0 (absent) to 4 (severe) as well as the presence or
absence of menstrual flow on a daily basis during one menstrual cycle.
They also provided information on diet and risk factors for breast
cancer. Mean age, length of menstrual cycle and duration of menses
were similar in cases and controls. When the noncancerous (or matched)
breast was considered, cases and controls had similar scores for breast
pain on day 10 of the cycle. Cases had significantly greater pain scores
2 days prior to menses (p < 0.03). Cases also had larger premenstrual
increases in pain than controls, although this difference was of

THE ROLE OF GRADED COMPRESSION ULTRASOUND IN THE
PATIENT WITH SUSPECTED ACUTE APPENDICITIS. C. Barba, A.
Hreno, M. Atri. Montreal General Hospital, McGill University, Montre
al, PQ

A controlled prospective study was conducted to determine the role of
ultrasound (US), using graded compression technique in the manage
ment of a patient with suspected acute appendicitis who presented to
our institution over a period of 11 months.
Patients were divided into two groups. Forty-one patients did not
have US and the diagnosis relied on clinical judgement. The accuracy in
this group was 78% for the diagnosis of acute appendicitis. Forty-six
patients had US and the accuracy of the procedure was 91%. The
patients included in the latter group presented a more atypical
presentation when the presence of peritoneal signs was compared with
the former group (85.6% versus 21.7% for a p = 0.0001).
Our results revealed that US clearly affected the management of 54%
(n = 24) of the patients who had this procedure. Women constitute the
majority of this group (67%). Laparotomy was avoided in seven of these
patients. In five, surgery strongly relied on the US result. Appendecto
my was accelerated in two patients. Ultrasound helped to narrow the
diagnosis in 10 patients. Without the use of US the accuracy in the
diagnosis of appendicitis drops significantly from 84.8% to 69.6% (p =
0.0007).
We conclude that graded compression US is an important tool in the
management of a patient with suspected acute appendicitis. It should be
used in a patient with an atypical presentation, especially in high-risk
patients. Childbearing women are also a group for which this procedure
is indicated.
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SUBTOTAL COLECTOMY (STC) FOR ULCERATIVE COLITIS:
COMPLICATIONS RELATED TO THE RECTAL REMNANT. F.M.
Carter, Z. Cohen, R.S. McLeod. Department of Surgery, Toronto
General Hospital, University of Toronto, Toronto, Ont.

Complications related to the retained rectal remnant were reviewed in
136 patients undergoing subtotal colectomy (STC) for acute ulcerative
colitis. Fifty-five patients (group 1) had a closed rectal stump brought
up into the subcutaneous tissue and 30 (group 2) had an open mucous
fistula. These were compared with an intrapelvic Hartmann pouch
performed in 51 patients (group 3). All patients eventually had a pelvic
pouch procedure. Age. duration and activity of disease, and preoperative
steroid use were similar in all groups.
There was no mortality. Twenty group 1 patients (36%) spontaneous
ly opened and 8 (14%) developed local wound infections. One patient
(2%) had retraction below the fascia of an opened rectal remnant leading
to pelvic sepsis. Two group 2 patients (7%) and six group 3 patients
(12%) developed pelvic septic complications. Subsequent pelvic dissec
tion was difficult in 20% of group 3 patients versus 4% and 0% in
groups 1 and 2 patients (p < 0.05). Persistent rectal disease activity was
present in 41% of group 3 versus 27% in groups 1 and 2 (p < 0.05).
Our study suggests that exteriorization of the closed rectal stump
following STC is associated with fewer pelvic septic complications,
minimal local morbidity, and is not associated with increased disease
activity in the retained rectum.
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MULTIVISCERAL RESECTION FOR CARCINOMA OF THE COLON
AND RECTUM. M.J. Lopez. Washington University School of Medi
cine, Department of Surgery, Barnes Hospital and Ellis Fischel State
Cancer Center, St. Louis and Columbia, Mo.

Among 1042 patients explored for colorectal cancer between 1964 and
1980. 69 (6.6%) underwent curative multivisceral resection for contigu
ous invasion by the primary tumour. Follow-up was complete. There
were 47 women and 22 men. Surgical procedures included total pelvic
exenteration (11), abdominoperineal resection (31). low anterior resec
tion (7), sigmoid resection (9), left colectomy (6) and right colectomy
(5). En-bloc resection included 129 other viscera. The surgical morbidity
and mortality were 31.8% and 2.8% respectively. Surgical margins of
resection were positive in five patients. Clinical recurrence in this
subgroup was evident between 8 and 22 weeks postoperatively. and the
mean survival was 8.2 months. Tumour invasion of the contiguous
organ was demonstrated in 60 specimens and only adherence in 9. The
5-year survival rates for patients with and without lymph-node metastases were 7.6% and 78%, respectively. At 10 years, the overall survival
rate was 50.7% (35 of 69) and cancer-related mortality 36% (25 of 69).
It is concluded that survival in locally advanced colorectal carcinoma is
more dependent on lymph-node status than on the extent of local
invasion. Effective disease control and long-term survival can be
achieved by multivisceral resection.
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EXTRACORPOREAL BLOOD FLOW IN MICROGRAVITY. K.
McCuaig, C. Lloyd, J. Gosbee, W. Snyder. Department of Surgery,
University of Alberta and NASA Johnson Space Center, Houston, Tex.

Knowledge of venous, capillary and arterial blood flow in microgravity is
required to modify hemostatic techniques for bleeding control in case of
traumatic injuries or surgical procedures on Space Station Freedom and
a Mars mission. To stimulate human arterial, venous and capillary
bleeding, fresh whole bovine blood was injected by two operators at
calculated flow rates (3.5. 7 and 14 ml for venous and 2, 14 and 28 ml
for arterial) in 10 seconds with empirical controls in a lucent glove box
during zero gravity parabolic flights on a NASA KC-135 aircraft. A
pig's foot was used to mimic capillary bleeding. Hemostasis with
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sponges and laerdal suction was evaluated by video and still photogra
phy. Evaluation of the arterial and venous were conducted at the three
rates with three parabolas and capillary was evaluated with five
parabolas and two methods (pig’s foot and sponge).
Influenced by surface tension, the slow venous bleeding coated
syringe surfaces and formed a dome over the skin laceration bleeding
site. Arterial and venous bleeders broke into uniform spheres with
low-velocity spheres bouncing off absorbent pad and suction tip.
Conventional dabbing with gauze fragmented blood into small spheres.
Capillary oozing was better controlled by wicking up blood with gauze.
Repeated arterial bleeding opacified the glove box wall. This simulation
demonstrated unique characteristics of extracorporeal blood flow and
inadequacies of common methods of hemostasis in microgravity.
256
LASER DOPPLER ASSESSMENT OF BLOOD FLOW IN NORMAL
AND ISCHEMIC RAT BOWEL. P. Mitchell, J. Heine, R. Lafreniere,
W. Atherton, I. Jadusingh, S. Huchcroft, C. Jadik. Department of
Surgery, University of Calgary, Calgary, Alta.

Improved accuracy and objectivity in the evaluation of intestinal viabiity
has been reported by some investigators using laser Doppler. We
undertook to evaluate the role of the laser Doppler in predicting
ischemic changes in rat small bowel.
We found that the normal mean laser Doppler blood-flow reading for
rats was 31.3 ml/min-100 g - ' (95% Cl 28.2, 34.4). We devascularized
segments of small bowel ranging from 1 to 14 cm in length and
compared the pathologic grade of ischemia to the absolute laser
Doppler reading, laser Doppler Index (LDI). and to the LDI/Iength of
ischemic segment.
Using multiple linear regression analysis we found that the best
predictor of pathology (necrosis) was the LDI/length (R = 0.8, p <
0.0001), although each of the other factors was also significantly
correlated — absolute laser Doppler reading (R = 0.5, P = 0.0142) and
LDI (R = 0.6, P = 0.0023).
This study confirms that the laser Doppler flowmeter is a useful
method ot assessing bowel ischemia, particularly when the length of the
ischemic segment is accounted for.
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SPLENIC ABSCESS: 10-YEAR CLINICAL EXPERIENCE. A.R. Harrop, T.W. Theman. Department of Surgery, University of Alberta,
Edmonton, Alta.

Splenic abscess is a rare entity with fewer than 400 cases reported.
Prior to 1978 no reported cases had undergone CT scanning or
ultrasonography: this represents a watershed period with respect to
these diagnostic measures. This review examines the experience with
splenic abscess in five general hospitals since 1978.
There were 16 cases of splenic abscess (10 men, 6 women), occurring
in all age groups (age 22 to 83). Predisposing factors included
preceding pyogenic infection (11 patients), disease in contiguous organs
(2), immunocompromised state (2), preceding abdominal trauma (2) and
unknown (2) (includes combinations). Symptoms were generally nonspe
cific; however, the combination of fever and abdominal pain was present
in 12 patients. The most common combination of clinical signs was
fever and left upper quadrant tenderness (eight patients). Mean duration
of symptoms prior to diagnosis was 3 weeks.
CT scanning was the most specific method of diagnosis (7/7)
followed by ultrasound (6/9). There were two cases diagnosed at
laparotomy and three discovered at autopsy. Bacteriology was varied,
with representation by gram-positive (three), gram-negative (six) and
anaerobic organisms (four). There were three sterile abscesses. Blood
cultures corresponded to abscess cultures when both were positive
(nine).
Splenectomy was curative (nine) with no recurrence of sepsis or
mortality. Patients treated with antibiotics alone (four) all died of
ongoing sepsis. Percutaneous drainage (two) was followed by abscess
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recurrence in one patient (resolved after splenectomy) and freedom from
sepsis (more than 1 year) in the other. Splenotomy (one) was associated
with morbidity (chronic drainage) but not mortality.
Splenic abscess is a rare occurrence but the mortality is high if the
condition is not diagnosed or adequately treated. Suspicion should be
raised on the basis of clinical presentation in predisposed patients.
Confirmation of diagnosis is by CT scan or ultrasound. Definitive
treatment is splenectomy.

culture the septic complication rate rose to 71% and the mortality rose
to 47% (p < 0.05). The culture taken at operation identified organisms
present in subsequent septic complications 59% of the time but was of
no value 41% of the time. In addition, six patients with no growth in the
operative culture developed septic complications.
This study indicates that cultures taken from upper gastrointestinal
perforations are only marginally useful in identifying a high-risk group
of patients for septic complications and death.
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PLATELET ACTIVATING FACTOR (PAF) ENHANCES MACRO
PHAGE (MO) PROCOAGULANT ACTIVITY (PCA) INDUCTION BY
ENDOTOXIN (LPS). D.S. Kucey, O.D. Rotstein. Department of
Surgery, University of Toronto, Toronto, Ont.

ACUTE VENOUS INJURY: COMPARISON OF TOTAL VENOUS
AND ARTERIAL OCCLUSION. P. Wizman, C.L. Kerrigan. Microvascular Research Laboratories, Royal Victoria Hospital, McGill Universi
ty, Montreal, PQ

Fibrin deposition plays a critical role in the pathogenesis of abscess
formation. Several bacteria are known to stimulate MO-mediated fibrin
deposition (i.e., PCA). Since the lipid autocoid PAF is generated during
the inflammatory response, it was hypothesized that PAF might
modulate MO PCA induction in response to LPS. Thioglycolate-elicited
murine peritoneal MOs were incubated with LPS (10 jig/m l) for 2 to 6
hours following a 30-minute preincubation in PAF 10~7M or control
medium. The ability of treated MO to shorten clotting time (i.e., PCA)
was measured, and times were converted to PCA units using a
thromboplastin standard.

It has been postulated that venous injury is more deleterious to muscle
or skin survival than either arterial or global ischemia. Twenty-four
female white Landrace pigs each had bilateral buttock 10 X 18 cm and
latissimus dorsi 10 X 20 cm island flaps raised. All flaps were subjected
to 2 hours of complete pedicle occlusion. A 12-hour period of
reperfusion followed, after which the animals were randomized to
secondary ischemic intervals of 3, 5, 7 and 9 hours (n = 6). One side of
each animal received arterial clamping while the other was subjected to
venous clamping for the same ischemic interval. Skin and muscle
survival were determined 24 hours after the secondary ischemic injury.
Laser Doppler flowmetry (LDF) was documented at hourly intervals
during secondary ischemia, within 1 hour following reperfusion and 24
hours post-secondary ischemia. Skin survival was assessed using
intravenous fluorescein followed by Wood’s lamp illumination. Muscle
survival at 3 and 5 hours was measured using nitroblue tetrazolium salt
staining: however, this was difficult to interpret at longer intervals.
Histologic analysis was used, in these cases to confirm muscle death.
Cutaneous and myocutaneous flaps showed less necrosis in the arterial
versus the venous group (p < 0.05) at each interval. At 3 and 5 hours,
mean muscle mass survival in arterial versus venous was 98.2 ± 1.3%
versus 58.9 ± 12.9%, p = 0.02 and 57.5 ± 13.6% versus 4.2 ± 3.0%, p
= 0.006 respectively. The histologic sections showed total necrosis in
the venous flaps and greater than 90% necrosis in the arterial flaps
subjected to 7 and 9 hours of ischemia. Laser Doppler flowmetry
readings of viable flaps, expressed in arbitrary units during secondary
ischemia, were 0.69 ± 0.1, 1.35 ± 0.17 and 4.37 ± 0.32, on immediate
reperfusion were 5.82 ± 0.5, 1.68 ± 0.44 and 4.33 ± 0.38. and at 24
hours were 4.1 ± 0.31, 4.2 ± 0.5 and 5.26 ± 0.36 for arterial venous
and reference groups respectively. Venous injury was significantly more
detrimental to both skin and muscle survival. In viable venous flaps,
LDF shows that flow is markedly diminished on immediate reperfusion;
however, by 24 hours, flow in both arterial and venous groups
normalizes to 80% of control skin.

Procoagulant activity (mU/2 X 106 cells)
Duration of incubation, h
2

Group
Medium alone
LPS, 10 Mg/ml
PAF alone
PAF preinc.

52
193
68
355

±
±
±
±

4
12*
69
20
122t

41
380
71
658

±
±
±
±

6
9
78
16
144+

95
810
224
1252

±
±
±
±

13
100
41
159+

*Mean + SEM, n = 4.16. tp < 0.05 versus LPS alone. Jp < 0.01
versus LPS alone.
Medium alone did not induce PCA while PAF alone caused a small
stimulation. At all time points, preincubation with PAF enhanced MO
PCA induction by LPS. This priming effect was observed with PAF
I0 " 7 to 10"9M. Thus, PAF augments the ability of MO to mediate
fibrin deposition following stimulation with LPS. These data suggest
that local PAF generation may serve to modulate the magnitude of the
inflammatory response at the site of infection.
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VALUE OF CULTURES TAKEN AT OPERATION FOR UPPER
GASTROINTESTINAL PERFORATIONS. D. Katyal, O.G. Thurston.
University of Alberta, Edmonton, Alta.

The microbiologic flora encountered in perforations of the upper
gastrointestinal tract presents a bewildering variety of organisms,
including weak pathogens and yeasts. This study was undertaken to
determine the significance and predictive value of cultures taken at
operation for repair of upper gastrointestinal perforations.
Fifty-two adult patients treated between 1984 and 1989 met the
criteria of having a perforation of the esophagus (5), stomach (12),
duodenum (34) or proximal jejunum (1) and had a bacterial culture
taken from the perforation at the time of operation for repair. The
hospital courses of these patients were reviewed with particular
attention to septic complications and outcome.
Thirty-two patients had a positive culture from the perforation site.
Sixteen of these patients (50%) developed a septic complication(s) and
10 (31%) died. Twenty patients had no growth from the perforation site
and 6 (30%) developed a septic complication and there were no deaths (p
< 0.01). If Candida or yeast organisms were present in the positive
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CARDIAC COMPLIANCE AND EFFECTS OF HYPERTONIC SA
LINE. D. Croft, Y.M. Dion, M. Dumont, D. Langlois, S. Marcoux.
Department of Surgery, Hopital St-Francois d’Assise, Universite
Laval, Quebec, PQ

The purpose of this study is to verify the hypothesis that a 1.8%
hypertonic saline solution (HS) could allow a better cardiac performance
than the regular Ringer's lactate solution (RL) during and after major
abdominal surgery.
Twenty-eight patients were randomly allocated to one of two groups.
Patients in group I (n = 13) received RL and those in group II (n = 13)
HS. All patients were studied preoperatively, peroperatively and postoperatively for 72 hours.
The two groups were comparable for age. length of surgery and
length of aortic cross-clamping. Preoperatively, natremia. serum osmolarity. pulmonary capillary wedge pressure (PCWP) and ventricular
end-diastolic volume index (LDEDVI) were similar in both groups. A
significant difference was noted, during and after surgery, between the
CJS, VOL. 33, NO. 4. AVG U ST 1990
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sodium levels of the two groups (p = 0.1) which, however, remained
within normal limits. Serum osmolarity remained similar for the two
groups (p = 0.49). During and after surgery, PCWP (p = 0.01) and
CVP (p = 0.7) remained within 3 torr of the initial values with
non-significant difference between the two groups. Group II received
significantly less liquid than group I (p = 0.002). Cardiac compliance
decreased in both groups but significantly more in group I (p = 0.04).
No untoward effect was noted from HS infusion.
In conclusion, it appears that cardiac compliance is significantly less
altered when the hypertonic solution is administered. The hypertonic
solution could be particularly useful in patients with compromised
cardiac function who undergo major abdominal surgery.
262
ISLET BANKING: TRANSPLANTATION OF CRYOPRESERVED
CANINE ISLET AUTO- AND ALLOGRAFTS. F.A. Daudi, G.L.
Warnock, M.S. Cattral, M.G. Evans, R.V. Rajotte. Department of
Surgery and Department of Medicine, University of Alberta, Edmon
ton, Alta.

Clinical islet-cell transplantation would be facilitated by the ability to
cryopreserve allogeneic tissue. This study investigates two problems
that limit this approach: the quantity of frozen-thawed (FT) islets
needed and their function after alloimplantation. Purified FT islets were
autografted into the spleen of apancreatic recipients: group 1, untreated
dogs (n = 10); group 2, into cyclosporine A (CsA) treated dogs (n = 7).
Islets were frozen slowly, stored at - 196°C, then thawed rapidly.
Incremental islet volumes of 3 to 4, 4 to 5 and more than 5 *d/kg
resulted in corresponding plasma glucose (PG, m g/dl) levels of 130 ±
18, 191 ± 10, 163 ± 18 mg/dl in group 1 and 267 ± 22, 164 ± 19
and 166 ± 22 in group 2. At 30 days PG was less than 150 mg/dl in all
dogs that received more than 5.0 n \/k g . Frozen-thawed islets were then
allografted (6.6 ± 0.6 jd/kg) into outbred dogs treated with CsA at low
doses (group 3, 5 to 10 m g /k g --', n = 5) or high doses (group 4, 10 to
20 m g/kg-d-1, n = 7). Untreated controls failed at 5 ± 1 days. Four of
five (group 3) and 4 of 7 (group 4) dogs were initially normoglycemic
but PG rose to more than 150 after 4 days, requiring exogenous insulin.
One group 3 dog remained normoglycemic without insulin. All group 4
grafts secreted insulin after 30 days: basal splenic arteriovenous
gradient was 43.4 ± 1 6 mU/L and increased to 54.5 ± 20 mU/L after
intravenous glucagon. Mean CsA whole blood trough levels were 642 ±
32, 707 ± 43 and 1159 ± 45 n g /L for groups 2, 3 and 4 respectively.
These data demonstrate that FT islets induce normoglycemia after
autoimplantation but similar quantities of allogeneic islets have insuffi
cient function to induce normoglycemia.
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CHOLECYSTOCHOLEDOCHOJEJUNOSTOMY: A QUICK AND EF
FECTIVE METHOD OF BILIARY DECOMPRESSION FOR CARCI
NOMA OF THE PANCREAS. C.H. Scudamore, C.R. Shackleton, A.D.
Forward. Department of Surgery, University of British Columbia,
Vancouver, BC

The most appropriate method of biliary decompression for patients
presenting with obstructing nonresectable tumours of the pancreas
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remains controversial. Cholecystojejunostomy can reobstruct if the
cystic duct inserts distally. Choledochojejunostomy can be difficult with
a distended gallbladder in situ. We describe a technique of anastomos
ing Hartmann’s pouch of the gallbladder to the right hepatic duct,
followed by stapled Roux-en-Y jejunal anastomosis to the gallbladder in
10 patients. The procedure is significantly shorter (usually under 2
hours), technically easier and provides reliable long-term biliary drain
age.

Average age, yr
M/F
Follow-up, yr
Average hospital stay, d
Specific complications < 30 d
General complications:
atelectasis
prolonged ileus
gastrointestinal bleed
Long-term complications:
cholangitis

67
6 /4
> 2
11
nil
2
1
1
1

Despite the theoretical disadvantage of an additional anastomosis,
our pilot study has shown that this method is a quick, safe and reliable
method of biliary drainage for patients presenting with malignant
obstruction of the distal common bile duct.
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THYROID FOLLICULAR NEOPLASMS: FACTORS THAT PREDICT
THYROID FOLLICULAR CANCER. N.L. Davis, M. Gordon, G.L
McGregor, R.E. Robins. Department of Surgery, University of British
Columbia, Vancouver, BC

Needle aspiration biopsy is routinely used in the evaluation and
diagnosis of thyroid nodules. The cytologic diagnosis of “follicular
cytology” is considered an indication for thyroid exploration and
appropriate resection. In the case of a follicular adenoma, lobectomy is
considered adequate management; however, a total thyroidectomy is
preferred for treatment of follicular cancer. Unfortunately needle
aspiration biopsy usually does not discern these two neoplasms. This
study was designed to identify epidemiologic and clinical parameters
that could be applied preoperatively to identify patients at increased risk
of having a follicular carcinoma.
A retrospective review of 400 patients initially treated at Vancouver
General Hospital and the Cancer Control Agency of British Columbia
between the years 1965 and 1985 was completed. Patients with thyroid
follicular adenomas were compared to patients with follicular cancer. All
data obtained were analysed by univariate and multivariate methods.
Statistically significant factors (p < 0.05) distinguishing patients with
thyroid follicular cancer included age greater than 50 years, nodule size
greater than 3 cm and a history of neck radiation. Sex, family history of
goitre or thyroid cancer, alcohol and tobacco use and exogenous
estrogen intake all were not significant in distinguishing the two patient
populations. Preoperative identification of risk factors associated with
follicular thyroid cancer can be used to plan appropriate thyroid
resection.
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THE SURGICAL MANAGEMENT OF DISTAL (PEPTIC) ESOPHA
GEAL STRICTURE: A REPORT OF 75 CASES. A.A. Conlan, C.A.
Hammond, P.M. Marchand. University of Witwatersrand, Johannes
burg, SA and Queen’s University, Kingston, Ont.

A retrospective study was undertaken to assess the early and late results
of surgery for distal (peptic) esophageal stricture (DPOS). During the
period 1957 to 1989, 75 patients underwent surgical therapy for DPOS.
Thirty-six were men, 33 women and 6 children. Sixty-four patients had
prominent dysphagia, 32 had episodes of esophageal obstruction.
Sixteen had severe weight loss. Fifty-two demonstrated hiatus hernia on
x-ray study. Stricture was confirmed in all at endoscopy. Preoperative
dilation was completed in 33 but was difficult or incomplete in 39
others. It was abandoned in three. No perforations were recorded.
Surgical groups were: group 1 — dilation and antireflux operation
(48 patients); group 2 — dilation, esophagoplasty (Collis) and antireflux
procedure (16 patients), group 3 — stricture resection with visceral
interposition (11 patients) (colon 8, stomach 3). Two hospital deaths
occurred (myocardial infarction, mediastinitis). Hospital morbidity in
cluded esophageal leakage two. upper gastrointestinal bleeding one,
bolus obstruction one. Twenty-eight patients had significant postopera
tive dysphagia (one to three dilations in the first 6 weeks). Follow-up
evaluation criteria were: good — essentially symptom-free, satisfactory
— occasional symptoms or a dilation, poor — prominent symptoms of
dysphagia or reflux. Group 1, follow-up 1 to 300 months (mean 42.5)
— good 26. satisfactory 16, poor 6; group 2, follow-up 1 to 65 months
(mean 32) — good 10, satisfactory 5; group 3, follow-up 1 to 84
months (mean 22.5) — good 4, satisfactory 4, poor 2. The majority had
good results with dilation and antireflux procedure, alone or with
gastroplasty.
52
SELECTION OF PATIENTS FOR LUNG TRANSPLANTATION. M.
Scavuzzo, D. Morrison, Toronto Lung Transplant Group. University
of Toronto, Toronto, Ont.

Since 1983 we have performed 27 single lung transplantations (SLT)
and 18 double lung transplantations (DLT). Stringent recipient selection
criteria were used. We carried out a retrospective review of the 550
documented referrals from 1984 until August 1989. Fifty-six (10%) of
these patients died prior to assessment. One hundred and fifty-one
(27%) are currently awaiting or undergoing assessment. Two hundred
and sixty-six (48.4%) of the referrals were refused due to failure to meet
selection criteria. One hundred and fifty-five of 266 patients failed to
meet two or more of the criteria:

D iagnosis
R estrictive
O b structive
V ascular
B ro n chiectasis
C ystic tibrosis
M iscellaneous
T o tals

n

=

N o. of
p a tie n ts
98
89
35
13
16
15
266

T oo
old

D ebilitated

S v stem ic
d isease

2 3 (2 3 .5 )* 3 4 (3 4 .7 )
4 2 (4 7 .2 ) 2 8 (3 1 .5 )
3 (8.6)
1 (2.9)
4 (30.8)
0
0
1 (6.3)
3 (2 0 )
4 ( 2 6 .7 )

30 (30.6)
1 8 (2 0 .2 )
1 (2.9)
2 ( 1 5 .4 )
3 ( 1 8 .8 )
5 ( 3 3 .3 )

26 (2 6 .5 )
1 6 ( 1 8 .0 )
8 ( 2 2 .9 )
4 ( 3 0 .8 )
4 ( 2 5 .0 )
3 ( 2 0 .0 )

7 5 (2 8 .2 )

5 9 ( 2 2 .2 )

61 (2 2 .9 )

S teroids

6 8 ( 2 5 .6 )

%.

Of 73 patients accepted for SLT or DLT. 44 have been transplanted,
13 are waiting and 16 died prior to transplantation. These 16 patients

include: 8 with pulmonary fibrosis, 6 with cystic fibrosis; 1 with chronic
obstructive pulmonary disease and 1 with pulmonary hypertension.
Rigid selection criteria likely improve the results of SLT and DLT.
Patients with pulmonary fibrosis or cystic fibrosis should have greater
priority for available donors.
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PROLONGED PRESERVATION WITH UNIVERSITY OF WISCON
SIN SOLUTION. S.E. Fremes, Ren-Ke Li, R.D. Weisel, D.A.G.
Mickel, L.D. Tumiati, R.D. Furukawa. Center for Cardiovascular
Research, Toronto Hospital, Toronto, Ont.

Previous studies from this institution have suggested that University of
Wisconsin Solution (UWS) is preferred for prolonged cardiac preserva
tion. University of Wisconsin Solution contains adenosine (5 mmol/L)
which could maintain adenine nucleotides better than other storage
fluids. Human cardiomyocytes were isolated from left-ventricular biop
sies. Cells (five to six dishes/group) were rinsed of culture media and
placed in one of four solutions: Stanford cardioplegia (STA), phosphatebuffered saline (PBS), modified Euro-Collins (COL) and UWS. Metabo
lites were assessed using HPLC after 24 hours of storage at 0°C and
compared with the baseline (BASE).
Adenosine triphosphate (ATP) and diphosphate (ADP) decreased with
each solution compared with BASE, but were maintained best with
UWS. Adenosine monophosphate (AMP) increased with UWS but
decreased in all other groups. Adenosine (ADO) increased only with
UWS.

ATP
BA SE
STA
PBS
COL
UW S

0 .5 3 6
0 .0 0 7
0 .0 1 0
0 .0 0 4
0 .0 5 1

±
±
±
±
±

0 .2 0 4 t
0 .0 0 2 * +
0 .0 0 1 * +
0 .0 0 3 * +
0 .0 2 2 *

ADP
0 .1 6 1
0 .0 1 7
0 .0 0 8
0 .0 0 7
0 .0 4 4

±
±
±
±
±

0 .0 6 1 +
0 .0 0 2 * +
0 .0 0 5 * +
0 .0 0 3 * +
0 .0 2 1 *

AM P
0 .0 1 5
0 .0 0 1
0 .0 0 3
0 .0 0 2
0 .0 9 5

±
±
±
±
±

0 .0 1 5 +
0 .0 0 1 * +
0 .0 0 4 * +
0 .0 0 1 * +
0 .0 6 0 *

AD O
0 .0 2 2
0 .0 4 2
0 .0 2 3
0 .0 4 4
2 .9 6 3

±
±
±
±
±

0 .0 0 8 +
0 .0 4 2 +
0 .0 1 3 +
0 .0 2 0 +
1 .5 7 0 *

n m o l / Mg D N A . m e a n ± SD . *p < 0 . 0 5 v e r s u s B A S E , t p < 0 . 0 5 v e r s u s U W S .

Adenosine in the UWS cells was largely degraded to inosine (UWS:
1.78 ± 0.91; BASE; 0.029 ± 0.01, p < 0.01 and hypoxanthine (UWS:
1.71 ± 0.725: BASE: 0.003 ± 0.002, p < 0.01). Inosine (0.12 ± 0.045)
increased with COL while hypoxanthine was increased with PBS (0.054
± 0.027) and STA (0.51 ± 0.019) in comparison to BASE.
University of Wisconsin Solution maintains adenine nucleotides better
than other storage fluids and may improve the clinical results of cardiac
transplantation.
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HEMODILUTION REDUCES PULMONARY REPERFUSION INJU
RY. J.D. Puskas, T. Oka, E. Mayer, W. Wisser, G.A. Patterson.
Toronto General Hospital, University of Toronto, Toronto, Ont.

A reduction in ischemia-reperfusion (IR) injury after lung transplanta
tion would improve lung function and increase the supply of donor
organs by allowing longer preservation times. Two groups (n = 4) of
New Zealand White rabbits underwent extraction of heart-lung blocks
after pulmonary artery (PA) flush with Euro-Collins solution (50 m l/kg)
at 10°C. Prostaglandin (PGE-1, 30 #ig) was given prior to flush into the
PA and was added to the flush solution. Lungs were stored at 10°C for
18 hours before assessment in an ex-vivo ventilation/perfusion appara
tus. Left lungs alone were ventilated with room air and perfused (40
ml/min) with fresh venous rabbit blood at 37°C via a PA cannula.
CJS, VOL. 33, NO. 4, AUGUST 1990
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Blood gases of left ventricular effluent, PA pressure (PAP) and tracheal
airway pressure (AwP) during reperfusion and wet/dry weight ratios
were measured. In Group 1, lungs were reperfused with whole blood for
20 minutes (hematocrit 38%). In Group 2, lungs were reperfused with
blood diluted with Ringer's lactate (hematocrit 10%) for 10 minutes,
followed by whole blood for 10 minutes. Pa02 at the end of the
20-minute assessment period was significantly higher in the hemodiluted group (88.3 ± 14.3 versus 44.1 ± 20.8 mm Hg, mean ± STD: p =
0.006). While PAP, AwP, Paco2 and wet/dry weight ratios were lower
in the hemodiluted group, these differences did not reach statistical
significance. We conclude that an initial 10-minute period of hemodilut
ed reperfusion reduces IR injury associated with whole blood perfusion
in this 18-hour ex-vivo rabbit lung reperfusion model.
55
PHARMACOLOGICAL INTERVENTION IN THE PREVENTION OF
ISCHEMIA-REPERFUSION INJURY IN SWINE MODEL OF
HEART-LUNG TRANSPLANTATION. A.K. Qayumi, W.R.E. Jamie
son, A. Poostizadeh, H. Salari. Department of Surgery and Depart
ment of Medicine, University of British Columbia, Vancouver, BC

Preservation of heart-lung and lung for transplantation remains a major
concern. This experimental endeavour evaluated the role of pharmaco
logic interventions to improve the antioxidant status and functional
capacity of heart and lungs exposed to 6 hours of hypothermic ischemia
followed by reperfusion. Fifty-six swine were divided into four groups,
seven donors and seven recipients in each group. The initial protection
was Tyers iso-osmolar potassium cardioplegia for heart and modified
Collins-dextrose-magnesium solution for lung. The groups, according to
intervention, were as follows: Group A — control without intervention;
group B — lazaroid (a 21-aminosteroid analogue), 10 mg/kg; group C
— high molecular weight deferoxamine, 50 mg/kg and group D —
CV-3988 (antagonist of platelet-activating factor), 10 mg/kg. The
evaluations were performed at three time periods — T1 pretransplanta
tion (donor), and T2 30 minutes and T3 2 hours post-transplantation
(recipient) by functional, biochemical and pathomorphologic assess
ments. The CV-3988 group demonstrated superior heart and lung
function (p < 0.001), namely, Cl. SI, dp/dT, PVR. Po2. AaG and AaR,
as well as diminished extravascular lung water, consequently decreased
pulmonary edema. The deferoxamine group performed second to the
CV-3988 group. The lazaroid group did not show any protective effect,
and was not different from the control group. The study revealed that
platelet-activating factor plays an important role in ischemia-reperfusion
injury possibly by means of activation of polymorphonuclear neutrophils
and formation of oxygen free radicals. The antagonism of platelet
activating factor is a useful interventional therapy to prevent the
manifestations of ischemia-reperfusion in heart and lung following
transplantation.
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WARM BLOOD CARDIOPLEGIA IN A PORCINE MODEL. A. Panos,
S.J. Kingsley, A.P. Hong, T.A. Salerno, S.V. Lichtenstein. St.
Michael’s Hospital, Toronto, Ont.

Historically, hypothermia has been the fundamental component of
myocardial protection due to its reduction of cardiac oxygen (02)
demand. Yet it has detrimental side-effects. Since 90% of myocardial 02
consumption MV02 is due to electromechanical work, the major drop in
(MV02) occurs with potassium (K+) arrest alone without hypothermia.
Thus, continuous warm blood cardioplegia (CWBC) should protect
better than current methods of nonperfused hypothermic arrest.
An ex-vivo blood-perfused porcine heart model was used to assess
cardiac metabolism and function. MV02, tissue ATP and lactate levels,
left ventricular end-diastolic (Ed) and end-systolic (Es) elastance, and
coronary vascular resistance (CVR) were measured before and after a
324
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2-hour arrest period. Hearts were randomized into two groups. Group 1
received CWBC (1 mL/g-min_1, myocardial temperature = 37°C)
during the arrest period. Group 2 received intermittent cold blood
cardioplegia (ICBC) (500 mL every 30 minutes, temperature = 15°C).
The blood cardioplegia consisted of blood and Fremes solution (4:1)
with resulting K+ = 15 meq/L. Data is expressed as percentage change
from control.
C roup

N

ICBC
CW BC

7
7

Es

Ed

CVR

78 ± 8 127 ± 22 76 ± 16
86 ± 9* 143 ± 41 82 ± 13

mvo2

9 5 ± 52
114 ± 73

ATP

L actate

61 ± 23 115 ± 7 0
107 ± 22* 138 ± 9

The CWBC group had significantly better preservation of systolic
elastance and ATP than the ICBC group (* p 0.05 by f-test). The other
variables did not reach statistical significance. Continuous warm blood
cardioplegia may be useful for myocardial protection.
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NEONATAL MYOCARDIAL PROTECTION: COMPARISON OF DIF
FERENT COOLING RATES. T. Hosseinzadeh, R.C-J. Chiu, C.I.
Tchervenkov. The Montreal General Hospital, McGill University,
Montreal, PQ

It has been suggested that rapid-core cooling before circulatory arrest
may be harmful to the newborn myocardium. Our objective was to
determine whether rapid (R) cooling prior to ischemic arrest is indeed
detrimental to the immature heart. Isolated Langendorff hearts (n =
5/gp) from neonatal piglets, 5 to 6 days old, were perfused with
oxygenated Krebs buffer solution (38.5°C) for 20 minutes. This was
followed by either 20 minutes of slow (S) cooling or 5 minutes of R
cooling to 15°C, at which time global ischemia was induced and
maintained for 2 hours at 15°C. All hearts then underwent 30 minutes
of reperfusion at 38.5°C. Similar experiments were performed with the
addition of a single dose of cardioplegia (CPG = St. Thomas’ solution)
immediately after cessation of aortic flow to induce immediate cardiac
arrest. Post-ischemic recovery of cardiac function was measured as a
percent of pre-ischemic control levels (% mean ± SEM).
-dp/dT
Group
LVP
LVEDP
+dp/dT
Rapid cooling
84 ±4*
80 ± 3*
8 ± 5*
77 ±5*
63 ± 2
Slow cooling
61 ± 2
61 ± 4
33 ± 7
74 ± 4
Rapid + CPG
72 ± 3t
36 ± 12
71 ± 5t
Slow + CPG
57 ± 3
57 ± 4
62 ± 3
33 ± 18
*p < 0.05 versus S cooling gp, tp < 0.05 versus S cooling gp + CPG.
In all parameters, post-ischemic recovery was significantly better in
the R cooling group versus the S cooling group. This difference was
maintained in the presence of CPG, which did not improve post-ischemic
recovery versus hypothermia alone. Contrary to clinical impression, we
conclude that R cooling is not detrimental and may be desirable to S
cooling in better protecting the immature heart.
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SUCCESSFUL MANAGEMENT OF LIFE-THREATENING MEDIASTINITIS IN HEART AND HEART-LUNG TRANSPLANT RECIPI
ENTS. A.H. Menkis, K.R. Reid, R.J. Novick, P.W. Pflugfelder, W.J.
Kostuk, F.N. McKenzie. The University of Western Ontario, Universi
ty Hospital, London, Ont.

The incidence of mediastinitis after conventional cardiac surgery is 0.7%
to 1.4% with a mortality of 10% to 70%. One would expect greater
mortality from these infections in the immunosuppressed heart (HT) or
heart-lung (H/L) patient. We have successfully managed three HT and
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two H /L patients (of 220 HT and 15 H /L transplants) with mediastinitis in the last 2'/2 years. The patients presented 3 to 10 weeks
postoperatively with wound erythema, sternal instability, chest pain,
malaise, pyrexia and leukocytosis. Four had purulent mediastinitis; one
H /L patient presented with an infected false aneurysm arising from the
aortic stenosis. Operative management included sternal debridement,
high-pressure irrigation with an antibiotic solution and the use of a
closed irrigation system for 2 to 4 weeks. Omental pedicles were used in
two cases; in one H /L with a Dacron patch repair of the false aneurysm
and in one HT transplant (TX). Intravenous antibiotics were given for 2
to 4 weeks. Long-term oral antibiotics were maintained after discharge.
No deaths occurred due to sepsis in follow-up to 2t/2 years. One H /L
patient died of obliterative bronchiolitis 2 years after TX. We conclude
that mediastinal infections can be successfully managed in the immunosuppressed TX patient when a closed irrigation system is used in
conjunction with appropriate intravenous and oral antibiotics. Omental
pedicle grafts are used selectively, particularly when prosthetic materials
or a residual cavity is present.
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PHARMACOLOGICAL CONSIDERATION FOR CONTROL OF OXY
GEN CYTOTOXICITY IN PREVENTION OF PARAPLEGIA. A.K.
Oayumi, M.T. Janusz, W.R.E. Jamieson. Department of Surgery,
University of British Columbia, Vancouver, BC

The efficacy of pharmacologic agents for the prevention and control of
oxygen-free radical damage in ischemia-reperfusion injury of the spinal
cord was assessed in a swine model simulating surgery on the
thoracoabdominal aorta. The swine model of spinal cord ischemia was
induced by aortic cross-clamping for 30 minutes followed by 4 hours of
reperfusion. Proximal hypertension was controlled by afterload reduc
tion. The study groups were as follows: A — control (n = 7), B —
deferoxamine 50 m g/kg over 3 to 4 hours prior to ischemia (n = 7). C
— allopurinol 50 m g/kg daily pre-treatment for 3 days (n = 7) and D
— superoxide dismutase 50 000 units prior to removal of aortic
cross-clamp and 10 000 units/min for 10 minutes of reperfusion (n =
7). The assessment comprises neurologic criteria (0 to 4, 0 =
paraplegia, 4 = normal), spinal cord blood flow (microspheres) and
ulrastructure (electron microscopy).
Tarlov criteria
Control (A)
Deferoxamine (B)
Allopurinol (C)
Superoxide dismutase (SOD)

0

1

7

_ _ _

-

-

-

6

2
1
1
7

3
6
-

-

4

Mean

-

0
2.8
1.1
2.0

p value
<
<
<
<

0.05
0.05
0.05
0.05

exposed to prolonged hypothermia has been shown to develop changes
in relaxation properties during reperfusion. A state of contracture was
apparent at 4°C but to a lesser extent at 12°C which may be attributed
to altered calcium metabolism. To further elucidate the effect of
hypothermia on myocardial calcium homeostasis, human atrial append
ages were stored for 4 to 24 hours in saline at 0, 4, 12 and 22°C. They
were homogenized from a pool weighing 2.5 g, fractionated by
ultracentrifugation to obtain sarcoplasmic reticulum (SR) and mito
chondria (M) and assayed for Ca ATPase. The Ca ATPase was
concentrated more than 10-fold in the SR (11.2 fimo\ P./h-mg
protein-1) and less than 2 fold in the M (1.04) when fractionated from
the homogenate (0.64). Storage at 12°C preserved the Ca ATPase the
best, whereas at 22°C there was a decrease in the activity after only 4
hours of storage. The appendages which had not been stored were
fractionated as well. The fresh-frozen homogenate, SR and M were
assayed for Ca ATPase at 0, 4, 12, 22 and 37°C in order to determine
the temperature coefficient (Qio). Between 4°C and 12°C there was a
threefold change in the Qio when compared with 12°C and 22°C. These
results indicate that myocardial storage temperature affects recovery of
Ca ATPase. Excessively cold temperature led to poor recovery of Ca
ATPase function, which may be an explanation for abnormal relaxation
of stored myocardium.
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HYPOTHERMIA: DOES IT PROVIDE SIMILAR PROTECTION IN
ALL NEONATAL HEARTS? W. Vincenti, T.A. Salerno, C. Wittnich.
Division of Cardiovascular Surgery, St. Michael’s Hospital, Toronto,
Ont.

Despite the use of hypothermia, pediatric cardiac surgeons continue to
experience high mortality in newborn heart surgery. This study
examines the effects of hypothermia on neonatal heart metabolism and
tolerance to global ischemia measured by the time to onset of ischemic
contracture (TIC), an indicator of irreversible ischemic damage. After
control right ventricular biopsies, each neonatal (3-day, n = 36) heart
was excised and placed in one of three temperature-regulated baths
(37.5 ± 0.5°C, 19.0 ± 0.5°C, 12.0 ± 0.5°C). A compliant balloon was
inserted into the left ventricle and onset (2 mm rise in LV pressure) TIC
was recorded and sequential biopsies were taken. Data were analysed by
Student’s t-test or ANOVA. Hypothermia significantly prolonged TIC,
(29.5 ± 1.7, 37°C) decreased lactate build-up (22.1 ± 2.9 to 6.3 ±
0.7*. 5.8 ± 0.6) and slowed ATP decline (2.0 to 1.1, 0.5* p m o l/g -h -1).
A subgroup of hearts (n = 5 each) was identified with shorter TICs than
the group means and low ATP stores preischemia.
1 9 ° C (n =

Deferoxamine > SOD > allopurinol > control, p < 0.05.
T o ta l g ro u p
"A t ris k "

14)

1 2 ° C (n =

C o n tr o l A T P

T IC ( o n s e t)

C o n tr o l A T P

3 .8 6 ± 0 .3 3
2 .0 2 ± 0 .4 4 *

1 5 0 .0 ± 6 .4
6 5 .0 ± 8 .0 *

3 .9 7 ± 0 .2 4
2 .4 5 ± 0 .4 5 *

13)
T IC (o n s e t)
2 8 3 .0 ± 4 6 .4
1 6 7 .0 ±
4 .0 *

The spinal cord blood flow fell significantly in all groups during
ischemia and responded to hyperemic levels during reperfusion. The
blood flow patterns did not correlate with the neurologic findings. The
degree of ultrastructural damage correlated with neurologic findings.
The study demonstrated that modification of spinal cord injury induced
by ischemia is possible with pharmacologic intervention of oxygen
cytotoxic injury, deferoxamine, superoxide dismutase and allopurinol
provided varying degrees of neurologic recovery, deferoxamine was
superior to allopurinol and superoxide dismutase.

The protection offered by hypothermia in these hearts is therefore
not accurately portrayed by the mean TIC at 19°C and 12°C and
ischemic contracture developed rapidly. These at-risk hearts are identi
fied by low ATP stores even prior to ischemia. This may prove useful in
identifying those hearts which cannot tolerate a longer period of
ischemia.

60

62

M e a n ± S E M , A T P ( ^ m o l / g ) . T I C (m in ) . * p < 0 . 0 1 f r o m t o t a l g r o u p v a lu e .

TEMPERATURE AFFECTS HUMAN SARCOPLASMIC RETICULUM
CALCIUM ATPASE. R.S. Labow, E. Meek, P.J. Hendry, W.J. Keon.
Department of Cardiothoracic Surgery, University of Ottawa Heart
Institute, Ottawa Civic Hospital, Ottawa, Ont.

TEMPERATURE AND SOLUTION COMPOSITION AFFECT OUTCOME OF DONOR HEART PRESERVATION. P.J. Hendry, R.S.
Labow, D. Ayres, M. Watson, W.J. Keon. Department of Cardiothoracic Surgery, University of Ottawa Heart Institute, Ottawa, Ont.

In assessing methods of donor heart preservation, human myocardium

The optimal technique for donor heart preservation using hypothermic
CJS. VOL. 33, NO. 4, AUGUST 1990
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intra- or extracellular solutions remains controversial. The purpose of
this study was to assess six different crystalloid solutions at two
different temperatures (12°C and 4°C) using human right atrial
trabeculae contracting isometrically in vitro. Muscles were preserved in
either St. Thomas’ solution (ST), modified Krebs-Henseleit (MKH, K+ =
16 meq/L), Krebs-Henseleit (KH, K+ = 4.5 meq/L), saline, Euro
Collins (EC) or Belzer solution (B) for 24 hours, after which muscles
were restimulated and recovery of function was followed for 30 minutes.
Developed force (DF) was best preserved in ST (103.3 ± 6.2% of
control) compared with saline which had the worst DF (2.8 ± 1.3%) (p
< 0.0001). Recovery of muscles preserved in MKH, KH, EC and B all
demonstrated intermediate performance. Recovery of DF was not
affected by temperature (p = 0.13). While the solution did not affect
recovery of resting force (RF), those muscles cooled to 4°C had a high
RF compared with those at 12°C (220.0 ± 74.4 versus 142.4 ± 42.4%
of control, respectively) (p < 0.04). In conclusion, solution composition
is important for restoration of contractile function in preserved donor
myocardium, whereas temperature affects the preservation of relaxation
properties. St. Thomas' solution provided the best protection of atrial
myocardium while 4°C led to impaired relaxation.

patients with a preoperative myocardial infarction (MI) within 30 days of
surgery. There were 438 (74.5%) males and 150 (25.5%) females. The
mean age was 60.1 ± 10.2 years and 19.7% were more than 70 years.
Urgent surgery was performed in 452 patients (76.9%). Triple-vessel
disease was present in 402 patients (68.4%), and 197 patients (34.8%)
had diminished ventricular function (ejection fraction less than 40%).
Operative mortality was 11.1% in the entire group (65), 8.3% in patients
with a non-Q MI and 17.5% in patients with a transmural MI.
Stepwise logistic regression was performed to identify the independ
ent predictors of operative mortality. The following variables were
selected in order of decreasing importance: impaired left ventricular
function (p < 0.001), coronary reoperation (p < 0.01), nonuse of the
left internal mammary artery (p < 0.001), increasing age (p < 0.01),
transmural MI (p = 0.02) and left main stenosis (p = 0.05). Predicted
operative mortality varied between 0.4 ± 0.2% in patients with no risk
to 90.5 ± 8.4% in patients with every variable present.
Patients with recent myocardial infarction without other risk factors
can undergo coronary surgery with an anticipated operative mortality
approaching that of elective surgery. Alternative treatment strategies
are warranted for high-risk patients, particularly those with diminished
ventricular function.
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WARM CARDIOPLEGIA FOR CORONARY SURGERY. S.V. Lichten
stein, A. Panos, S.J. Kingsley, A.P. Hong, T.A. Salerno. St. Michael’s
Hospital, University of Toronto, Toronto, Ont.
Historically, hypothermia has been the most important component of
myocardial protection. It reduces myocardial oxygen requirements, but
has other unwanted side-effects. We have used continuous, cold, blood
cardioplegia (CCBC) since 1985. In the absence of ischemia, hypo
thermia may be unnecessary. Therefore, we developed a technique of
continuous warm oxygenated blood cardioplegia (CWBC). Consecutive
patients having coronary artery bypass (CABG) surgery in 1988 (N =
121, 95 male. 26 female, age 62 ± 10 years) were compared to a similar
cohort undergoing CABG using CCBC in 1987 (N = 133, 111 male, 22
female, age 61 ± 9 years). Ninety-five percent of patients were NYHA
class III or IV, and 60% had left ventricular grades 3 or 4. Thirty-five
percent of the CCBC and 36% of the CWBC group had urgent
operations. The number of grafts constructed was CWBC = 3.3 ± 1 .0
versus CCBC = 3.4 ± 0.9. Ninety-nine percent of CWBC patients had
spontaneous normal sinus rhythm (NSR) after aortic cross-clamp
removal. Pump time was CCBC = 84 ± 20 versus CWBC = 99 ± 29
min (p = 0.05), cross-clamp time was CCBC = 67 ± 19 versus CWBC
= 79 ± 25 min (p = 0.05).

Group

No.

Deaths

CCBC
CWBC

133
121

3(2.2)
1 (0.8)

NSR
14(10)
120 (99)*

IABP

MI

12(9)
1 (0.9)’

9(7)
2(2)

% in bracket * p = 0.01.
Continuous warm blood cardioplegia patients had spontaneous
recovery of NSR, a decreased need for IABP support and a reduced
perioperative infarction rate. Continuous warm blood cardioplegia has
become our method of choice for myocardial protection during cardiac
surgery.
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Acute traumatic injury of the thoracic aorta is relatively common
following deceleration accidents. Requirements for successful hospital
managment are early diagnosis and prompt treatment. Between 1969
and 1989, 120 patients (91 males and 29 females) were diagnosed by
aortography, surgery or autopsy. This includes the total hospital
experience with nonpenetrating or blunt injuries to the thoracic aorta.
The mean age was 36.5, range 11 to 82 years. Ninety-two percent of
the injuries resulted from motor vehicle accidents, and 8% from falls
from heights. The site of injury was the aortic isthmus in 110 patients
(92%), distal thoracic aorta in 7 patients (6.0%) and the aortic arch in 3
patients. Associated injuries were present in 110 patients (92%), isolated
aortic injuries in only 10 patients (8%). Initial chest roentgenograms
were available on 68 patients and widening of the mediastinum was the
predominant finding. Of this group, 32 patients had chest roentgeno
grams with a radiopaque nasogastric tube. Deviation of the tube to the
right contributed to the diagnosis in 80% of these cases. Only 47% (56
patients) had the opportunity for definitive surgical management. The
nonsurgical group (64 patients, 53%) died within 30 minutes of
emergency department arrival unsuspected, suspected or diagnosed but
without time for treatment. The group without definitive surgery
included 13 patients with unsuccessful, primary emergency department
thoractomies. There were 56 patients managed surgically for definitive
aortic repair. The surgical methods included: simple aortic clamping
(17), partial cardiopulmonary bypass (CPB) (34), full CPB (1) and
techniques of nonheparinized bypass (4). There were 11 intraoperative
deaths (19.6%) and 6 hospital deaths for a total early mortality of 26.7%
(15). The operative mortality during the first decade was 40% (8 of 20
patients) and for the second decade, 8.3% (3 of 36) (p < 0.05).
Paraplegia occurred only in the simple aortic clamping group, 24% (four
patients). Early diagnosis and prompt surgical management improved
patient survival.
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RISK ANALYSIS OF PREOPERATIVE MYOCARDAL INFARC
TION. S.E. Fremes, G.T. Christakis, R.D. Weisel, J. Ivanov, B.S.
Goldman, T.A. Salerno, T.E. David. University of Toronto, Toronto,
Ont.
Patients with postinfarction angina face an increased risk of operative
mortality. Between January 1982 and December 1987, clinical, angio
graphic and operative data were collected prospectively in 588 unstable
326

TRAUMATIC RUPTURE OF THE THORACIC AORTA: A 20-YEAR
REVIEW 1969-1989. S. Kodali, W.R.E. Jamieson, M. Leia-Stephens,
R.T. Miyagishima, M.T. Janusz, G.F.O. Tyers. University of British
Columbia, Vancouver, BC
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REDUCTION IN AUTOLOGOUS AND ARTIFICIAL VASCULAR
GRAFT THROMBOGENICITY: IMPLICATIONS IN CARDIOVASCU
LAR GRAFTING. T.A. Haas, M.C. Bertomeu, S.J. Brister, M.R.
Buchanan. Department of Pathology and Department of Surgery,
McMaster University, Hamilton, Ont.
Experimental studies, both in vitro and in vivo using human and rabbit
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vessel wall (VW) cells, indicate that there is an 1 / a between VW
13-hydroxyoctadecadienoic acid (13H0DE) synthesis and VW throm
bogenicity. To determine the potential clinical relevance of this
relationship, we examined (a) in intact VWs the correlation between VW
13H0DE levels and VW thrombogenicity using internal mammary
artery (IMA) segments obtained from 21 patients undergoing coronary
artery bypass grafting (CABG); and (b) whether coating artificial
vascular grafts (AVGs) with 13HODE also reduced their thrombogenici
ty. To do this, we measured: (a) IMA 13HODE levels determined by
HPLC, (b) IMA thrombogenicity, assessed as the number of 3H-platelets
adherent/mm2 surface area and (c) AVG thrombogenicity, using AVGs
(Hemashield vascular grafts) which were coated with increasing
amounts of I4C-13HODE.
The levels of 13H0DE in the IMA segments ranged from 1 to 267
pg/m m 2, and were inversely related to IMA thrombogenicity, r =
—0.932, p < 0.001. Furthermore, there was concentration-dependent
decrease in AVG thrombogenicity when the AVGs were coated with
increasing amounts of 13HODE. For example, when the AVGs were
coated with 21 ± 2 pg 13HODE/mm2, AVG thrombogenicity decreased
29 ± 5%. p < 0.005.
We conclude that (a) the thrombogenicity of autologous grafts (i.e.,
IMAs) is influenced by their 13HODE level and (b) artificial vascular
graft thrombogenicity can be reduced by coating the graft with
13HODE.
67

FUNCTIONAL AND METABOLIC CHARACTERIZATION OF THE
MARGINALLY PROTECTED VENTRICLE. T. Yau, R.D. Weisel, J.
Ivanov, M. Komeda, G.T. Christakis, W. Martin, D.A.G. Mickel,
Cardiovascular Surgery, The Toronto Hospital, University of Toronto,
Toronto, Ont.
Myocardial revascularization for patients with progressive ischemia has
a high perioperative morbidity and mortality. Improved methods of
intraoperative myocardial protection may improve the results in these
high-risk patients. We developed a canine model which simulates the
myocardial metabolic depletion and the ventricular functional depression
reported in patients after urgent revascularization for progessive
ischemia.

This canine model simulated clinical studies and provides an opportu
nity to evaluate new methods of protection.
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TUMOUR DORMANCY, INITIATION, MAINTENANCE AND TER
MINATION IN ANIMALS AND HUMANS. T.H.M. Stewart,* A.C.
Hollinshead, S.Raman.* ‘ University of Ottawa, Ottawa, Ont. and
George Washington University, Washington, DC
Tumour dormancy in man has long been noted by pathologists,
surgeons and radiotherapists. In animal models immunization can
induce tumour dormancy. Lymphocytes, macrophages and cytokine
production are essential for maintenance of this state: regrowth of
tumour follows immunosuppression. We describe five patients whose
histories suggest that dormancy was induced in micrometastases
present at the time of curative surgery, following specific immunothera
py of lung cancer. In three patients extrathoracic metastases of
adenocarcinoma appeared after 11, 12 and 14 years with no new
primary tumour found. In two patients regional recurrence occurred
after 8 and 9 years of clinical health: one adenocarcinoma, one
squamous-cell carcinoma. In each patient an immunosuppressive event
preceded the renewed tumour growth: three received steroids, one had
severe endogenous depression and one had acute myocardial infarction.
Each patient had shown a moderate to very strong delayed hypersensi
tivity reaction to soluble tumour antigen maintained up to 14 years
following surgery. The resurgence of growth of breast carcinoma
metastases 7 years after mastectomy was seen 8 months after treatment
with Cyclosporin A and steroids, following a renal transplant. This case
prompted a review of the effect of transplantation-associated im
munosuppression in patients with a previous history of curative surgery
for cancer. We conclude that cellular immune mechanisms play a crucial
role in maintenance of the tumour dormant state in man and that its
induction in some patients with lung cancer will improve their
prognosis.
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EMPYEMA FOLLOWING PNEUMONECTOMY FOR INFLAMMATO
RY LUNG DISEASE. A.A. Conlan, M. Scoccianti, C. Hammond.
Department of Surgery, University of Witwatersrand, Johannesburg,
SA

Eighteeen dogs were exposed to variable durations of normothermic
global ischemia (NTI) followed by 10 minutes of reperfusion, 1 hour of
cold blood cardioplegic arrest (BCP) and 30 minutes of reperfusion
(RP). Less than 50 minutes of NTI followed by BCP was well tolerated.
However, 50 minutes of NTI produced a severe depression in both
function and metabolism and only 50% of the dogs could be weaned
from bypass. One hour of NIT resulted in a stone heart.
Ventricular function was assessed by measuring intraventricular
pressures and cardiac output in response to volume loading at baseline
(PRE) and following bypass (POST). Myocardial performance was
severely depressed. Myocardial ATP content was only 35% of control
values after BCP (6.3 ± 1.1 mmol/g protein). AMP levels were
increased suggesting impaired mitochondrial function and inosine levels
rose and then fell with reperfusion limiting the recovery of ATP.

One hundred and sixty-three patients underwent pneumonectomy for
inflammatory lung disease and 30 developed post-pneumonectomy
empyema (PPE). This study was done to determine the value of the
treatment methods used. These were: (a) pleural drainage and irrigation
to sterility, followed by neomycin 0.25% instillation and closure
(Clagget) and (b) open thoracostoma drainage and later space closure.
Post-pneumonectomy empyema followed elective surgery in 18 and
emergency resection in 12. Eleven had preoperative empyema, 6 had
preoperative bronchopleural fistula (BPF). Twenty-four had intraopera
tive pleural spillage of infected material. Mixed aerobic and anaerobic
infection was common. Dominant pathogens were Staphylococcus
aureus 16. Klebsiella 9, Pseudomonas 7. Streptococcus faecalis 5.
Seven patients had major BPF with PPE. Fourteen patients had pleural
drainage and irrigation and 8 sterilized. Clagget closure was done, but
six recurred. Twenty had formal thoracostoma drainage (two ribs) and 6
patients had single rib resections. Four patients died (two early
postoperatively from systemic sepsis). Two late deaths were due to
pneumonia and aspiration. Five BPFs closed after thoracostoma drain
age. Clearance of sepsis and marked clinical improvement occurred in
all with space shrinkage. Space closure was completed by thoracoplasty
16, muscle transposition 2 or chronic shrinkage. Post-pneumonectomy
empyema was best managed by early open drainage and late space
closure.
CIS. VOL. 33. NO. 4. AUGUST 1990
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RESULTS OF LUNG TRANSPLANTATION, 1983-1990, IN
TORONTO LUNG TRANSPLANT PROGRAM. J.R. Maurer,
G.A. Patterson, R.F. Grossman, Toronto Lung Transplant Group.
University of Toronto, Toronto, Ont.

CARDIAC TRANSPLANTATION: THE TREATMENT FOR ENDSTAGE CARDIOGENIC SHOCK. S. Jackson, A.R.C. Dobell, A.
Guerraty, J.F. Symes. Cardiovascular Research Unit, Royal Victoria
Hospital, Montreal, PQ

Between Nov. 7. 1983 and March 1990, 36 single (SLT) and 21 double
lung transplants (DLT) were done by the Toronto Lung Transplant
Team. Underlying diseases of patients receiving SLTs included 24
pulmonary fibrosis. 4 pulmonary vascular disease, 6 emphysema. 1
lymphangiomyomatosis, 1 fibrosing mediastinitis. Underlying diseases
of DLTs included nine emphysema, five cystic fibrosis, four bronchiecta
sis and one each of eosinophilic granuloma, bronchiolitis obliterans and
primary pulmonary hypertension. Six SLTs (16.6%) died perioperatively
and seven (19%) died from 4 months to 6 years following transplant. Of
SLTs, 64.4% are alive, with survivals from 1 week to 5.5 years. Four
DLTs (19%) died perioperatively and one (5%) died late. Seventy-six
percent of DLTs are alive with survivals of 1 week to 3.5 years. Early
deaths have generally been due to airway dehiscence or infection and
late deaths to chronic rejection complicated by infection. One late death
was due to renal failure. Of surviving SLTs 4 of 23 are functionally
limited by chronic rejection/bronchiolitis obliterans. Two of 16 DLTs
have mild to moderate bronchiolitis obliterans but are not significantly
funtionally limited. Overall 39 patients (68.4%) have survived lung
transplantation and 90% of those have near-normal lifestyles.

Eighty-six patients received orthotopic cardiac transplants at the Royal
Victoria Hospital from 1985 to 1989. Of these, 16 were considered to
be mortally ill. being sustained in hospital by the use of intravenous
inotropes (15 patients. 94%) and/or intra-aortic balloon counterpulsa
tion (6. 38%). The average age of these 16 at the time of transplantation
was 47 years (range from 19 to 58 years). Eleven were suffering from
terminal coronary disease and 5 from cardiomyopathies. Nine (56%)
were mechanically ventilated and nine had active pulmonary infection.
Four patients (25%) had evidence of renal hypoperfusion (creatinine
more than 120 ^mol/L). and four (25%) had evidence of hepatic failure
(bilirubin more than 35 moioI/L). The average wait for a suitable donor
for these patients was 11 days (range 1 to 27 days). In addition to the
16 patients transplanted, there were 8 mortally ill patients who died
before a donor became available. There was one operative death (at 7
days) for a mortality of 6.3% (versus 8.6% for the 70 “elective”
transplants). Two others died of delayed infection, one of viral hepatitis
at 6 weeks and one of Pneumocystis pneumonia at 4 months
postoperatively. The other 13 patients are alive and well at 3 to 57
months postoperatively. Nine have resumed their preoperative work
status, two have decreased activity levels but are functioning well, one is
retired, and one is only 3 months postoperative and recuperating well.
As the salvage rate in this group of mortally-ill patients is so
promising, we believe that transplantation is the treatment of choice in
selected patients with end-stage cardiogenic shock.
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NEARING RETIREMENT?: - I am looking
for a rural general surgeon interested in work
ing half time, eg: 4 months on and 4 months
off, starting in 1 or 2 years. Located on the
beautiful Sunshine Coast. Contact: Dr. Eric
Paetkau. FRCS, Box 638, Sechelt, BC VON
3A0
-S90-29

gery with a full-time complement o f three
cardiovascular/thoracic surgeons. In addition
to active clinical practice, the position in
volves a strong commitment to undergradu
ate and postgraduate teaching and surgical
research. Applicants should have clinical ex
perience in cardiovascular and thoracic sur
gery with an interest in peripheral vascular
surgery, and should have a demonstrable
interest in surgical research. The successful
candidate will join the full-time faculty of the
College of Medicine with rank appropriate to
training and experience. The Department of
Surgery includes the divisions of cardiovascu
lar and thoracic surgery, critical care medi
cine, general surgery, neurosurgery, plastic
surgery, orthopedic surgery, otorhinolaryn
gology and urology. In accordance w ith Cana
dian immigration requirements, this advertise
ment is directed to Canadian citizens and
permanent residents. Letters of enquiry and
application including a curriculum vitae should
be sent to: Dr. E. W ayne Chappell, Profes

DOWNTOWN TORONTO - Medical office
available in Class " A " professional building,
600 sq. ft., recently decorated facility. Fully
furnished. Current practitioner retiring after 17
years at this location. Near hospitals. On
subway. Ample parking. For further details,
please contact, in confidence: ROI Corpora
tion, Mississauga, tel: (416) 8 2 0 -4145.
Ref. 315.
-S90-30
CARDIOVASCULAR AND THORACIC
SURGERY, ACADEMIC APPOINTMENT:
SK - The Department of Surgery, University
of Saskatchewan, Saskatoon, Saskatchewan
has a vacancy for a surgeon to join the
Division of Cardiovascular and Thoracic Sur

Central Hospital is an accredited, 176-bed community hospital,
located in the core of downtown Toronto. The Hospital is
currently expanding its community services to keep pace with
the evolving needs of its exciting, culturally diverse, downtown
community. To meet these needs, Central Hospital is expanding
its program of day surgery as an addition to the in-patient
services which utilize five O.R. theatres. To further the
development of this program , we are presently searching for a
new full-time Chief of Anaesthesia and an additional full-time
anaesthesiologist.
As Chief of Anaesthesia, you will head a departm ent of 4 to 5
anaesthesiologists and exert leadership in m aintaining
anaesthesia QA and staff educational programs. Also, while in
association with the Chief of Staff and Chief of Surgery, you wifi
help ensure the effective utilization of in-patient and day surgical
facilities.
Send Curriculum Vitae to the
M edical Director.

HOSPITALJ

333 Sherbourne Street, Toronto, Ontario M5A 2S5

The Best Care in Any Language

GENERAL SURGEON
P E R M A N E N T A N D /O R LO C U M
A general surgeon is required, either as a
summer locum and/or permanently, to
join a busy community practice in PEI. The
present medical centre has tw enty doc
tors, split evenly between GPs and spe
cialists. The practice requires three gener
al surgeons; as of July 1, 1990 it will have
only two. Experience in orthopedics and
urology would be an asset, but not a
necessity. LMCC and FRCSC required for
licensure.
Applications to:
W .L. W alker, M D, FRCSC
Sum m erside M edical Center
Sum m erside, PEI
C1N 3N 9
_s
________ Tel: (902) 4 3 6 -9 2 8 3
bMU 14

0SHAWA GENERAL HOSPITAL

CHIEF OF
ANAESTHESIA

CENTRAL

sor and A ctin g Head, D epa rtm e n t o f S ur
gery, University Hospital, Saskatoon, SK
S7N 0X0.
-S90-28

-S90-25 .

A 650-bed regional general hospital approximately
30 minutes east of metropolitan Toronto, requires
an additional

GENERAL SURGEON
The individual selected will function within the
framework of the Section of General Surgery in
the Department of Surgery. Preference will be
given to individuals with training in critical care
and trauma. Candidates must have FRCSC or
equivalent and be licensed to practise in
Ontario. Interested physicians should direct
enquiries to:

Dr. M. Pockey
Oshawa General Hospital
24 Alma Street
Oshawa, Ontario
L1G 2B9
Tel: (416) 576-8711
OSHAWA GENERAL HOSPITAL — AN EQUAL OPPORTUNITY EMPLOYER
— A SMOKE-FREE ENVIRONMENT
— S90-26
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TEXAS A&M UNIVERSITY
College of Medicine
TEMPLE CAMPUS

St. Clare’s Mercy Hospital, St. John’s,
Newfoundland, a 323-bed university-affiliated
(MUN) tertiary care facility, is looking for a
surgeon (FRCSC) with VASCULAR training to
join its Department of Surgery.
Applications and enquiries are invited and should
be directed to:

Dr. Sean Conroy, Medical Director
St. Clare’s Mercy Hospital
LeMarchant Road
St. John’s, Newfoundland
A1C 5B8
Tel: (709) 778-3437
Fax: (709) 738-0080

For further information, please send curriculum
vitae and references to:

The successful applicant will be jointly appointed
by St. Clare’s Mercy Hospital and Memorial
University of Newfoundland.
-sgo-27
ADVERTISERS’ INDEX

The Department o f Neurologic Surgery o f the Scott
and White Institutions and Texas A&M University
College o f Medicine is seeking applications for
senior staff physician faculty in the Sections o f
Pain/Stcrcotaxic Surgery or Neurosurgical Oncology.
Residency or post residency experience and a
defined interest in either subspecialty area together
with a broad capability and interest in general
neurosurgical disorders is desired. Basic and clinical
research opportunities are available commensurate
with previous experience. Medical student and
resident teaching/daily responsibilities are required.
The main campus is located in central Texas, north
o f Austin in the approximate center o f the Dallas/ Ft.
Worth, San Antonio, Houston triangle and benefits
from easy access to other surrounding universities
(Southwestern University, Georgetown; University o f
Mary Ilardin-Baylor, Belton; Baylor University,
Waco.)

M itchell S m igicl, M.D.
Chairman, N eu ro lo gic Surgery
Scott and W hite, Texas A&M University
C o llege o f M edicine
2401 South 31st Street
T em p le, TX 76508
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THE SURGEON’S CHOICE
SURGICAL SUTURES FROM SWITZERLAND
ASSUT® BRAND AND SUPERB QUALITY
HS-needles

HSRG-needles
1/2 circle, cutting-taper, heavy

n ^

3/8 circle, reverse cutting

IHS-171

VHS-19
-A

HSRG-38

1/2 circle, cutting-taper

TS-needles V

HS-12

HSRG-27

HSR-needles

P

1/2 circle, reverse cutting

HSR-18

TS-12

HSRG-45

V

TS-15
HS-2

TSR-needle ®
3/8 circle, cutting-taper

i

TS-17

h s -:

TSR-14
HS-38
HS-41

HSG-needle 1
1/2 circle, cutting, heavy

HS-45

HSG-24

TS-27
HS-52
TS-30

Introducing the finest quality of sterile double packed surgical
-•sutures from Switzerland. Available in Blue Nylon, Black Silk,
^Polypropylene. Also available in Linen, Surgical Steel, Astralen
as well as Tendon Sutures, Double-Armed Needles, Round
feodied and other type needles. A comprehensive catalogue
* will be furnished upon request with first order. Free suture
samples are available upon request.
SPECIAL

'-ISSsPEcwun
ASTRALEN
*

Green braided polyester with im
proved tensile strength and knot
“'security, siliconized. A modern
braiding technique gives the
strand a smooth and uniform sur
face that minimizes the trauma.

^

Black monofilament polyamide
with supersoft core, resulting in
r 'superior pliability and knot sec
urity. The uniform and smooth
surface permits effortless passage
through tissue with minimum
trauma. Supramid is extremely
well tolerated.

TS-45
I-60
TS-90

$16.95/doz.

REGULAR $23.95
nrv. v n n A n v i civic c D c n a i c iq q c / n n 7
POLYPROPYLENE - SPECIAL $ 1 8 .9 5 /D O Z .

N66dl6S 3T6 shown in 3ctu3l siz© for

shape and |ength_bu( nol for thickness.

LINEN

SUPRAMID WHITE

SURGICAL STEEL

Natural white twisted strand very
smooth and with high knot sec
urity. This well-known material has
been used in surgery for many
years and it is still very
appreciated.

White monofilament polyamide
with supersoft core, with the same
characteristics as Supramid.

Twisted stainless steel with very
high tensile strength and excellent
knot security. This strand causes
minimum tissue reaction.

POLYPROPYLENE

SILK

MONOFIL NYLON

Blue monofilament polypropylene
is flexible and ties securely. Ex
tremely well tolerated, its smooth
and uniform surface allows easy
passage through tissue with min
imum trauma.

Black braided surgical silk on
twisted core for greater tensile
strength. Silicone treatment and
new braiding technique render
the silk uniform and smooth and
facilitate its handling.

Blue monofilament polyamid with
high tensile strength. The uniform
and smooth surface permits effort
less passage through tissue with
minimum trauma. Extremely well
tolerated.

V-

SUPRAMID

TS-38

THE ABOVE INFORMATION IS PROVIDED TO ASCERTAIN YOUR BEST AND CORRECT CHOICES.

All our

MDICL INC.
175 TORYORK DRIVE, UNIT #6
WESTON, ONTARIO
M9L 2Y7

L
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products carry a one-year limited w arranty
Please call from anywhere in Canada

Toll Free - 1-800-387-7477

CALL 24 HRS A DAY
TEL: (416) 747-1125
FAX: 1416) 783-5795
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The best tip
for deep cavity surgery
VITAL VUE keeps control at your finger tips with superior
illumination, irrigation and suction...all in one compact unit.
•Superior visibility in dark cavities • Helps visualize elusive bleeders • May reduce the risk
of cross contamination • Minimizes inconvenience and delay of overhead light adjustments
• Reduces surgeon fatigue • Compact - easy to set up, easy to use, easy to store

VITAL'VUE
Irrigation, Suction and Illumination System

DAVIS+GECK
©Registered User Cyanamid Canada Inc.
TM Trade Mark of American Cyanamid Company

Cyanamid Canada Inc. 88 McNabb Street, Markham Ontario L3R 6E6

